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SYNOPSIS 
 One of the causative agents of meningitis is the gram-negative bacteria Neisseria 
meningitidis. This is a fairly common bacterium, which is present in the noses and throats 
of 10-15% of the population but rarely causes serious disease. The potentially fatal 
invasive disease occurs when the bacteria penetrates the mucous membrane of the nose 
and spreads to other parts of the body through the blood stream. In the region known as 
the meningitis belt, N. meningitidisserotype A is endemic in the population and is also 
known to cause large scale epidemics such as in 1996 when 250 thousand cases were 
reported leading to approximately 25 thousand deaths. An important virulence factor of 
this bacterium is the presence of a capsular polysaccharide, which also protects against 
phagocytosis. The capsular polysaccharide of serotype A is (1-6)-linked poly(2-
acetamido-2-deoxy-α-D-mannopyranosyl phosphate): 
 
 
 
 
 
 One of the issues with naturally derived carbohydrate polymers used in vaccine 
preparations is that they are heterogeneous mixtures that may include contaminants and 
unwanted impurities. Alternatively, through the use of synthetic carbohydrate structures, 
which can be chemically produced as single compounds, batch to batch variability can be 
eliminated and provide the desired CPS fragments in a more reproducible and robust 
manner. The chemical synthesis of CPS fragments also provides the opportunity to 
iv 
 
 
 
incorporate a linker moiety into the structure allowing for conjugation to an immunogenic 
carrier protein. 
 Therefore an efficient and reproducible method for the chemical synthesis of 
fragments of the capsular polysaccharide of N. meningitidis(serotype A) suitable for use in 
a potential glycoconjugate vaccine against this disease is highly desirable. To this end, we 
designed and chemically prepared N. meningitidisserogroup A synthetic phosphoglycans 
containing linkers, which allow further bioconjugation with a protein carrier. 
 Formation and elongation of the synthetic phosphoglycan chain proceeds through 
the condensation of a suitable anomeric H-phosphonate derivatives. In order to 
accommodate this all the monosaccharide synthetic precursors (compounds 56-59) allow 
for hydrolysis of the O-1 position to the hemiacetal. This is then converted to the H-
phosphonate before coupling to a monohydroxyl unit to form a phosphodiester linkage. 
Removal of the temporary protection at the O-6 position then gives the free hydroxyl 
needed for elongation to continue. To explore the optimal combination for the permanent 
O-4 protection and the temporary O-6 protection four different orthogonally protected 
monosaccharides 56-59 were designed. 
 
 
 
 
  
 
 
During the initial synthetic strategy a dec-9-en-1-yl linker was incorporated into the 
primary saccharide unit at the reducing end of the molecule. Chemical synthesis of the 
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‘decenylated’ phosphoglycans was attempted. They were synthesised as ‘protected’ 
derivatives. 
OHOHO
NHAc
O
AcO
P
O-
O
OHO
NHAc
O(CH2)8CH=CH2
AcO
O
n = 1-2  
 
Complications arising during final deprotection of the decenyl containing fragments 
however made it clear that this was not suitable for this approach. 
 A slightly different approach was then used which would allow the building of the 
phosphoglycan fragments to the required size before finally capping the structure with a 
suitable 6-aminohexyl linker via a phosphate group at the non-reducing end of the 
phosphoglycan chain. This incorporated another phosphate moiety into the CPS fragments 
while also providing an amino group for bioconjugation. 
 
 
 
 In addition, we synthesised a few N. meningitidisserogroup Aphosphoglycan 
molecules without a linker moiety. The chain elongation was successful in the 
integration of up to 3 intersaccharidic phosphates in the molecule (which is a record for 
N. meningitidisserogroup Aphosphoglycans so far). Also the introduction of a fourth 
intersaccharidic phosphate was in part successful, but the reaction did not go to 
completion and resulted in an inseparable mixture of the corresponding pentasaccharide 
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tetraphosphate and the tetrasaccharide triphosphate as the starting material. After the 
global deprotection a mixture of the phosphoglycans 103 (with 3 intersaccharidic 
phosphates) and 104 (with 4 intersaccharidic phosphates) was isolated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
CHAPTER 1 
1.  INTRODUCTION 
 
1.1  BIOLOGICAL INTRODUCTION 
 
1.1.1  Meningitis 
 
Meningitis is an acute life threatening disease brought on by swelling in the 
protective membranes lining the brain and spinal cord known as the meninges. The 
meninges are comprised of three membranes that, along with cerebrospinal fluid, 
enclose and provide protection for the brain and spinal cord, collectively called the 
central nervous system (see Figure 1). 
 
 
Figure 1: Meninges, protective membrane linings of the brain and spinal cord.1 
 
The first membrane is the pia mater, a thin and very delicate impermeable 
membrane that adheres firmly to the brain. The second is the arachnoid mater, a more 
loosely fitting membrane, and as the name suggests has a spider web like appearance. 
The space between the pia mater and the arachnoid mater is known as the subarachnoid 
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space which is occupied by cerebrospinal fluid. The third and outermost membrane is 
the dura mater, the thickest and most durable of the membranes attached to both the 
inside of the skull and the arachnoid mater. 
 
 The swelling can be caused by several microorganisms, including bacteria, 
viruses, parasites or fungi and requires prompt medical attention, and owing to the 
proximity to the central nervous system is classified as a medical emergency.2 Initial 
common symptoms of the disease in adults include severe headache, nausea, vomiting 
and the inability to flex the neck forward due to increased muscle tone and stiffness 
(known as nuchal rigidity).3 For diagnosis the classic triad of symptoms is sought, 
which are nuchal rigidity, sudden fever and an altered mental status. This is problematic 
however as all three features are only seen in 44-46% of bacterial meningitis cases.3,4If 
none of the three signs are seen then meningitis is extremely unlikely.4 Sensitivity to 
light (photophobia) and intolerance to loud noises (phonophobia) are other commonly 
associated symptoms. Unfortunately small children often do not display the 
aforementioned symptoms and may only appear irritable and unwell.5 Left untreated, 
bacterial meningitis is almost always fatal while viral meningitis on the other hand tends 
to resolve spontaneously and fatality occurs only on rare occasions. With treatment the 
fatality rates associated with the disease vary widely but can be as low as 2% in infants 
and children and as high as 20-30% in neonates and adults.6 Even with the successful 
treatment of children there may be lasting damage to the central nervous system, which 
is seen in approximately 15% of survivors. This may give rise to potential disabilities 
including sensorineural hearing loss, epilepsy, learning and behavioral difficulties along 
with a decrease of intelligence,5 although the hearing loss may in some cases be 
reversible.7 
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1.1.2  Neisseria meningitidis 
Neisseria meningitidis, commonly referred to as meningococcus, is a parasitic 
gram negative bacteria that was first described in 1884 by Marchiafava and Celli as an 
intracellular oval micrococci in a sample of cerebrospinal fluid (CSF).8 A few years 
later in 1887 Anton Weichselbaum isolated the bacteria and managed to distinguish 
Pneumococci from meningococci in a sample of CSF and named it as 
Diplococcusintracellularis meningitidis (see Figure 2).9 The first clinical descriptions 
of Neisseria meningitidis or meningococcus occurred a lot earlier following an outbreak 
of meningitis initially in 1805 in Geneva and soon after in New Bedford in 1806, 
although the causative agent was not known at the time.10,11 
 
 
Figure 2: Diplococcusintracellularis meningitidis(Neisseriameningitidis).12 
 
 
Interestingly, humans are the only known host of N. meningitidis. The most 
common natural habitat for the meningococcus is the epithelium of the naso- and 
posterior pharynx with 10-15% of the population being asymptomatic carriers of the 
bacteria which translates to hundreds of millions of carriers worldwide, with young 
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adolescents being the principal reservoir.13 The frequency and pattern of disease, 
however, varies significantly between different regions of the world. In temperate 
regions the pattern seen is usually that of endemic disease with an annual incidence of 
between 1 and 10 per 100,000 population.14,15 This is also subject to seasonal variation 
with most cases appearing in the winter months.16 There can also be hyperendemic 
periods, with disease incidence up to 20 per 100,000, usually brought about following 
the appearance of new virulent clones into non-immune populations.17,18,19 The story in 
developing nations however is quite different. Not only is there endemic disease but 
also regular outbreaks of epidemic meningococcal disease, where annual incidence rates 
erupt to 200 cases per 100,000 population. These epidemics occur in 5-10 year cycles 
and appear exclusively in the dry season. 
Colonisation of the mucosal surfaces in the upper respiratory tract by N. 
meningitidis is initiated largely through contact with respiratory droplets or secretions 
from an infected individual. After acquisition of N. meningitidis to the upper respiratory 
tract the infection may stay asymptomatic or may infrequently result in local 
inflammation, invasion of the mucosal surfaces, possible access to the blood stream 
leading to sepsis (meningococcal septicaemia) and meningitis.20 It should be noted 
though that internal infection is not part of the meningococcal transmission cycle and 
occurs more as an accident as crossing into the blood stream can be seen as a “one way 
ticket” for the bacteria. Once in the blood the meningococcus can no longer be 
transmitted through the usual route of respiratory droplets from coughing or sneezing 
and are in effect trapped in the host. In fact the relationship between virulence and 
transmissibility in the life cycles of many pathogenic organisms is still under debate.21 
The virulence of N. meningitidis is mediated by meningococcal structures and has been 
studied more intensively than transmissibility but the key event in both scenarios is the 
adhesion of the bacteria to the epithelial cells allowing the colonisation of the 
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nasopharynx. Pili and adhesins help facilitate adhesion and ultimately colonisation, 
while the bacterial capsule appears to prevent close contact with the membranes 
interfering with adhesion and will in effect reduce colonisation.22 In fact, during studies 
of nasopharyngeal colonisation by meningococcus the down-regulation of the capsule is 
selected or it may even be switched off completely.23,24 The capsule however must 
ultimately re-appear, which may assist the shedding of the bacteria from the epithelium, 
in order for the successful transmission to another host.25 
 
1.1.3  Bacterial capsule 
A principal component of most pathogenic bacteria, including N. meningitidis, is 
the presence of a capsule (see Figure 3). The structure of the capsule is in most cases a 
high molecular weight polysaccharide, although is some cases the capsule consists of a 
polypeptide. 
 
 
Figure 3: Diagram showing capsule surrounding cell surface.26 
 
The capsule surrounds the entire surface of the bacteria attached to the outer cell 
wall and provides several functions. The production of a capsule is a major virulence 
factor that helps the bacteria evade clearance from the site of infection by providing 
protection from the host’s immune response. The presence of the capsule also protects 
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the bacteria from phagocytosis, by hindering detection from opsonising antibodies, by 
the hosts defence cells. The capsule is in many cases hydrophilic giving the ability to 
retain water and prevent desiccation of the cell as well as providing anti-adhesive 
properties such as steric hindrance and repulsion through negative charge (e.g. sialic 
acid or phosphate).  
The invasive strains of meningococcus express a polysaccharide capsule with a 
range of chemical structures. The exact chemical composition of the capsule was used 
originally to distinguish between different strains giving rise to what are known as 
different serogroups.27 Currently there are thirteen structurally distinct serogroups that 
are known of which only six, designated A, B, C, Y, X and W-135, account for the 
majority of the invasive disease.20,28In fact, carriage strains are more widespread in 
nature than the disease causing strains hence N. meningitidis is considered an occasional 
pathogen. It is known that capsular polysaccharide expression is increased on clinical 
isolates derived from patients suffering invasive disease while the capsule is down-
regulated on meningococci sampled from the nasopharynx. This was seen clearly during 
the Stonehouse meningococcal outbreak in Gloucester where the strain B:15 was 
isolated which showed the same genotype and phenotype with the invasive isolates 
encapsulated and the carrier isolates non-encapsulated.29 
In the case of serogroups Y and W-135 the capsular polysaccharide structures 
are composed of alternating disaccharide repeat units of sialic acid and D-glucose or D-
galactose respectively. Serogroups B and C exist as a homopolymer of N-
acetylneuraminic acid with either anα2→8 or α2→9 linkagerespectively.The serogroup 
A capsule is composed of (1-6)-linked N-acetylmannosamine-1-phosphaterepeat units 
containing some 3-O-acetates, while serogroup X produces a phosphoglycan polymer of 
(1-4)-linked N-acetylmannosamine-1-phosphate (see Figure 4). 
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Figure 4: Repeat units of pathogenic N. meningitidis Capsules 
 
1.1.4  Neisseria meningitidis serogroup A 
 
The earliest studies of the capsule of N. meningitidis serogroup A showed that it 
contained both phosphorus and nitrogen but it was not until 1971 that it was shown that 
the polysaccharide was a polymer of partially O- and fully N-acetylated mannosamine 
phosphate.30Yet further study using 13C nuclear magnetic resonance (NMR) was 
required to resolve that there was a (1→6)-phosphodiester linkage between the α-(N-
acetyl-D-mannosamine) units, while also showing a 70% O-acetylation at the C-3 
position.31 Later detailed analysis, again using NMR, confirmed that the capsular 
polysaccharide of serogroup A was a homopolymer of (1-6)-linked poly(2-acetamido-2-
deoxy-α-D-mannopyranosyl phosphate)(see Figure 5) again with O-acetylation at 70-
95%.32,33 A small percentage of O-acetylation was also observed at the C-4 position, but 
it is possible this was due to acetyl migration from the C-3 position. 
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Figure 5: Repeating unit of N. meningitidisserogroup A capsule 
 
The degree of O-acetylation at the C-3 position of the purified polysaccharide 
does appear to vary depending on the strain used and the isolation and purification 
techniques used, however, it is still regarded as an important immunogenicity factor for 
the polysaccharide.34 
The ability of N. meningitidis serogroup A to cause large scale epidemics is still 
of major concern. Epidemic meningitis, usually caused by serogroup A, is greatly feared 
in sub-Saharan Africa as it causes death, disability and has been shown to be an 
important factor of poverty for the affected families.35In the region from Senegal to 
Ethiopia known as the meningitis belt(see Figure 6), N. meningitidis is endemic in the 
population and during epidemics up to 2% of the population can be affected.  
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Figure 6: The African meningitis belt.36 
 
The meningitis belt was first described by Lapeyssonnie in 1963, a vast area 
stretching almost 4 thousand miles, with a population of more than 300 million where 
major epidemics of meningococcal meningitis occur regularly.37 He showed that there is 
a distinct periodicity for meningitis epidemics, which usually start at the beginning of 
the dry season in late December and promptly cease following the first rains of May or 
June. This epidemic season is characterized by a hot dry wind that generates a great deal 
of dust known as the Harmattan.38 Other environmental factors that damage or weaken 
the integrity of the nasopharyngeal mucosa such as smoking, low humidity, cramped 
living conditions and even co-infections also increase the incidence of meningococcal 
disease.20,39,40 Most countries within the meningitis belt are subject to large outbreaks in 
cycles every 5-12 years since the 1940’s, however in recent years the intervals between 
epidemics has become irregular. One of the largestrecorded outbreaks was seen in 1996 
when 200 thousand cases were reported which lead to 20 thousand deaths.41 
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Similar cycles of epidemic meningococcal disease have also been described in 
Asia, mostly in China, during the past century.42 Studies carried out using strains 
available over the last 40 years have highlighted the origins of two meningococcal 
pandemics in China.43 The first meningococcal serogroup A pandemic occurred in the 
mid 1960’s and extended to Moscow and Norway in 1969, followed by Finland and 
Brazil in the early 1970’s. The second appeared in China and Nepal in the early 1980’s 
before spreading to Africa and the Middle East and most likely to India as well.43,44 
 
1.1.5  Meningococcal vaccines 
The first trial vaccines against N. meningitidis were developed over one hundred 
years ago in the early 1900’s.45 These early vaccines were composed of heat-killed 
whole cells, which were grown in culture, gently heated to around 60oC to kill but not 
lyse the cells, before dilution to the required concentration for injection into the patient. 
These initial vaccines were not very effective showing variable efficacy and an array of 
severe adverse reactions. The greatest efficacy observed was 87% in a study carried out 
on volunteers from Camp Funston, Kansas, following an epidemic outbreak of 
meningitis at the camp. The vaccine was prepared locally using fresh clinical isolates of 
N. meningitidis serogroup A taken from asymptomatic carriers at the camp.46 These 
types of studies were repeated but the level of efficacy seen in the Camp Funston trial 
was not reproducible.  
It was later in the 1930’s that a different approach was taken when Ferry and co-
workers along with Kuhns and co-workers investigated a possible meningococcal 
exotoxin.47,48,49,50 This was an attempt to repeat the success in the development of 
vaccines using tetanus toxoid and diphtheria toxoid, both utilising a detoxified exotoxin 
excreted by the bacteria. In these tests the supernatants derived from broth cultures of 
meningococci were investigated for their vaccine potential and they were able to show a 
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possible toxin-mediated immunological effect. Possibly, due to the presence of capsular 
polysaccharide among other agents in the supernatant cocktail. They were also able to 
show a reduction in meningococcal disease in young men who were vaccinated with 
this toxin but unfortunately were unable to prove either immunogenicity or efficacy and 
the exotoxin approach was abandoned.51 
A few years later, during the Second World War, there were multiple outbreaks 
of meningococcal disease caused by serogroup A and C amongst army recruits. This 
prompted the further investigation of purified capsular polysaccharide as a possible 
vaccine, which had been successfully isolated in 1935.52 Interest had grown around the 
potential of capsular polysaccharide as a vaccine candidate after it was demonstrated 
that anti-serogroup A meningococcal horse serum would prevent disease but only in 
proportion to the amount of anti-polysaccharide antibody it contained. The earliest of 
these immunological studies using purified serogroup A and C capsular polysaccharide 
however proved unsuccessful. This may have been due to the production techniques 
available at the time which could have allowed enzymatic degradation of the 
polysaccharides.53 
The first major breakthrough in meningococcal vaccinations came in the 1960’s 
when Gotschlich and co-workers were able to demonstrate the importance of the anti-
polysaccharide antibodies for both serogroup A and C in the human immune 
response.54,55Their success came after they were able to develop a novel method in 
which they employed the cationic detergent Cetavlon to precipitate the capsular 
polysaccharides from whole culture. This resulted in highly purified, high molecular 
weight (greater than 100,000) capsular polysaccharide.56 With this new method in hand 
they then went on to show that the capsular polysaccharide isolated in this way was 
immunogenic in adult volunteers.57 The success continued in subsequent clinical trials 
that were carried out during serogroup C outbreaks on army bases. These showed that 
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the army recruits that were vaccinated with the capsular polysaccharide demonstrated 
reduced acquisition rates compared with unvaccinated recruits along with an estimated 
90% efficacy for prevention of disease within the first 8 weeks of vaccination.58,59 
There are currently two polysaccharide vaccines that are in routine clinical use. 
They are a bivalent serogroup A and C vaccine or a tetravalent serogroup A, C, Y and 
W-135 vaccine. These vaccines are routinely used to combat meningococcal serogroup 
A and C outbreaks and epidemics as well as a preventative measure in high risk groups 
such as military recruits, patients with immunodeficiencies and travellers to high risk 
areas. That being said there are still a couple of major disadvantages to the use of these 
vaccines. The first being that the purified polysaccharide vaccine itself is poorly 
immunogenic when given to infants and young children, the exact group who are most 
vulnerable to the disease.60,61 Secondly, the duration of the immunity imparted by the 
vaccine is unfortunately quite limited and varies with age. In children 3 years of age or 
younger the vaccine provides almost no protection beyond 12 months following the 
vaccination.62 
The poor immunogenic response gained from all polysaccharide antigens can be 
attributed to the fact that the immune response they induce is of a T-cell independent 
nature. Without the recruitment of the T-cells there is a lack of induction of 
immunological memory. Another problem is that repeated doses of these polysaccharide 
antigens induces an abnormally low response, it has been suggested that a possible 
reason for this being that the pool of polysaccharide specific memory B-cells is 
depleted.63,64 
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1.1.6  Glycoconjugate vaccines 
 It is possible to induce a T-cell dependent response with a polysaccharide 
antigen as long as the polysaccharide is first chemically conjugated to a protein carrier. 
This conjugate is then able to recruit the help of T-cells in the immunologic response. 
The success attributed to this technique can be seen clearly in the production of the 
Haemophilus influenza type b vaccine. The use of which has almost eradicated the 
disease in countries which have chosen to add it to their infant vaccination schedule.65 
This conjugation approach works best when the polysaccharide is conjugated to a 
strongly immunogenic protein. In the case of the H. influenza b vaccines either tetanus 
toxoid or diphtheria toxoid has been used as a protein carrier which has been proven 
safe and immunogenic.66 These toxoids are exotoxins excreted by bacteria, which have 
been detoxified either by heat or chemical alteration but still elicit a potent 
immunological response. Meningococcal glycoconjugate vaccines are available and are 
produced from partially hydrolysed capsular polysaccharides that are size fractionated 
before chemically conjugating to a carrier protein. Vaccines produced this way have 
been subjected to immunogenicity studies and have proven successful at producing 
antibodies in infants and older children that are likely to be protective.64,67,68,69For 
example a Neisseria meningitidis group C (Men C) conjugate vaccine (Menjugate®) was 
introduced into the UK vaccination schedule for infants in 1999, along with a catch-up 
campaign with a single dose of vaccine given to 1 to 18 year olds. This resulted in a 
dramatic reduction in Men C meningitis and led to a major decrease in the circulation of 
Men C even in the unvaccinated population (herd immunity).70 This decrease 
demonstrated that as well as providing protection from the invasive disease, vaccinated 
individuals had decreased asymptomatic carriage of Men C resulting in an overall 
reduction in the prevalence of Men C meningitis in the population.  
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Three quadrivalent meningococcal serogroup A, C, Y and W-135 conjugate 
vaccines are also available internationally which differ only in the protein carrier used. 
The first conjugated to diphtheria toxoid (Menactra™)71, the second conjugated to 
CRM197(Menveo™)
72 while the third is conjugated to tetanus toxoid (Nimenrix™)73. 
Unfortunately all remain too expensive for a mass vaccination campaign in Africa 
where the cost per dose needs to be around 50 cents. 
I response to this the World Health Organisation (WHO) in partnership with the 
Program for Appropriate Technology in Health (PATH) set up the Meningitis Vaccine 
Project (MVP) in 2001. The aim of which was to eliminate epidemic group A 
meningitis by developing, testing and introducing a group A meningococcal conjugate 
vaccine which would be affordable in Africa.74This resulted in the release of 
MenAfriVac™ in 2010, a Men A – tetanus toxoid glycoconjugate vaccine,which can be 
produced for 44 cents per dose75, and since rolling out more than 217 million people in 
15 countries have received the vaccine. 
One of the remaining issues for the Men-A glycoconjugate vaccine however is 
its relative stability for shelf life and storage. This is not an issue in developed countries 
where access to fridges and freezers are readily available as meningococcal vaccines in 
a lyophilised state can be stored for two years if kept cold. Access to cold storage in the 
developing world however is much more difficult to guarantee, especially in remote 
areas where vaccination takes place.Meningococcal polysaccharides, especially Men-A 
polysaccharides, are unstable at ambient temperatures due to depolymerisation which 
severely reduces the vaccines efficacy. To date the degree of polymerisation required in 
the meningococcal polysaccharide to induce an acceptable immune response remains 
unknown. To address this we designed a synthetic strategy to produce a set of Men-A 
capsular polysaccharides of varying length with linkers suitable for bioconjugation. 
After bioconjugation these could potentially be used in immunological studies to assess 
15 
 
 
 
the immune response induced from relatively small synthetic fragments, and from this 
address whether a fully synthetic route to a Men-A glycoconjugate vaccine is 
theoretically possible. 
 
1.2  CHEMICAL INTRODUCTION 
 
1.2.1  The Hydrogenphosphonate (H-phosphonate) approach 
The H-phosphonate approach is a highly effective method for the formation of 
phosphodiester linkages. It was first explored as a synthetic route to oligonucleotides in 
the 1950s by Alexander Todd’s group.76 The technique was adapted almost thirty years 
later as a highly efficient method for the synthesis of oligonucleotides (including solid 
support synthesis) in the mid-eighties.77,78,79 This technique combined the benefits of 
excellent yields and a rapid reaction rate requiring only two simple steps in the 
elongation cycle consisting of protection group removal followed by nucleotide 
coupling.  
The success of this method led to its exploration as a means to synthesise 
disaccharide phosphates containing intersaccharidic phosphodiester linkages, which are 
inherently more hydrolytically labile due to a possible formation of a glycosyl cation 
upon cleavage of the glycosyl phosphate bond. It was first investigated in 1986 with a 
publication by van Boom and co-workers80 followed closely by another independent 
publication by Nikolaev and co-workers in 1987.81 In the van Boom synthesis a small 
fragment of the cell-wall polymerof Staphylococcus lactis was prepared(see Scheme 1). 
In this synthesis the glycosyl H-phosphonate 7 was combined in pyridine with the N-
acetyl-D-glucosamine derivative 8. Following the addition of the condensing agent 
pivaloyl chloride the H-phosphonate reacts rapidly with the primary hydroxyl of 9.After 
only 10 minutes, analysis with thin layer chromatography (TLC) revealed the 
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condensation had gone to completion. This was also confirmed with 31P-NMR which 
revealed only the characteristic signals of an H-phosphonic diester 9 (δP; 9.16 and 8.55 
ppm, JH,P 737 and 730 Hz). With the condensation complete a solution of iodine in 
pyridine-water was added to facilitate the insitu oxidation of the H-phosphonic diester 
to form the disaccharide phosphate 10 in 87% yield after purification. 
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Scheme 1:Initial van Boom glycosyl H-phosphonate condensation. 
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1.2.2  Synthesis of Neisseria meningitidis group Acapsular polysaccharide 
fragments 
Initial work on the synthesis of fragments of the capsular polysaccharide of N. 
meningitidis serogroup A was carried out in 1993 by Nikolaev and co-workers in 
Moscow.82 During this early work they were able to synthesise the disaccharide 
phosphate 13 through the condensation of the H-phosphonate 11 with the free primary 
hydroxyl of the N-acetyl-D-mannosamine derivative 12 (see Scheme 2). The 
condensation proceeded through the usual conditions with the addition of the 
condensing agent pivaloyl chloride in a solution of pyridine. The H-phosphonic diester 
was then oxidised, again with the addition of iodine solution in pyridine-water, to 
achieve the protected disaccharide phosphate 13 in 82% yield. After benzoate removal 
facilitated with sodium methoxidein MeOH,the desired disaccharide phosphate 14 was 
isolated by ion exchange chromatography in a high yield of 70%. 
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Scheme 2: First synthesis of N. meningitidis serogroup A capsule phosphoglycan fragment. 
 
 
Further progress in the synthesis of fragments of the capsular polysaccharide of 
N. meningitidis serogroup A was achieved by Pozsgay and co-workers as shown in 
Scheme 3.83 Their strategy employed the 2-azido-2-deoxy-D-mannosyl H-phosphonate 
derivative 15 and utilised benzyl ethers as permanent protection at the O-3 and O-4 
positions while a 6-O-acetyl was used as temporary protection. This was coupled in a 
condensation with the N-acetyl-D-mannosamine derivative 16 containing aN-
benzyloxycarbonyl (Cbz) protected ethanolamine linker at the anomeric position and a 
free hydroxyl at the C-6 position. Following condensation and oxidation the 
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disaccharide phosphate 17 was isolated in an excellent yield of 95%.The azide 
functionality of the disaccharide phosphate 17 then underwent reduction using sodium 
borohydride and nickel chloride to furnish a free amine, whichwas then acetylated in 
situ with the addition of acetic anhydride in methanol. The temporary protection of the 
O-6 position was removed using Zemplen conditions to give derivative 18, which was 
then ready for further chain elongation. The monohydroxyl derivative 18 was then 
combined with the H-phosphonate derivative 15 in pyridine and condensation was again 
initiated with pivaloyl chloride.Following oxidation the trisaccharide diphosphate 19 
was isolatedin a good yield of 74%. Although a good yield was achieved there is still a 
noticeable decrease in efficiency when the second intersaccharidic phosphate is 
introduced. This is in contrast with oligonucleotide synthesis where every condensation 
gives an excellent yield even after several chain elongations.  The azido group of 19 was 
then reduced and N-acetylated as above before the removal of the O-acetate, again using 
Zemplen conditions, to give derivative 20.Finally the trisaccharide diphosphate 20 was 
subjected to catalytic hydrogenolysis in order to remove the O-benzyl and N-
benzyloxycarbonyl protection to afford the phosphoglycan 21 containing a small linker 
region with a free amine functionality giving the ability to couple to a carrier protein. 
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Scheme 3: Pozsgay and co-workers synthesis. 
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Another synthetic route tocapsular polysaccharide fragments, including the same 
phosphoglycan 21 using a different synthetic strategy was carried out by the Oscarson 
group in Stockholm.84 Their method used a different protecting group arrangement with 
the use of O-acetates as permanent protecting groups and a tert-butyldimethylsilyl 
(TBS) as a temporary O-6 protection (see Scheme 4).In this synthesis the authors also 
opted to use azide functionalities throughout the process with reduction and N-
acetylation as a final step. Using this arrangement the authors were able to perform the 
first condensation of the 2-azido-2-deoxy-D-mannosyl H-phosphonate derivative 22 and 
the monohydroxyl containing azidomannose derivative 23 to give the disaccharide 
phosphate 24with an excellent yield of 96% after oxidation. The temporary silyl 
protection was then removed with a solution of triethylamine tri(hydrogen fluoride)to 
afford the disaccharide phosphate 25, again with an excellent yield of 91%, and with the 
free hydroxyl required at the terminal O-6 position ready for another step elongation. 
The introduction of the second intersaccharidic phosphate was achieved with the 
condensation of the disaccharide phosphate 25 and the same H-phosphonate 22 and, 
following oxidation, the trisaccharide diphosphate 26 was isolated in 62% yield. This 
second condensation also showed a similar drop in yield as was seen in the Pozsgay 
synthesis with the addition of a second intersaccharidic phosphate. The azide 
functionalities were then reduced to amines using sodium borohydride and nickel 
chloride before performing N-acetylation in situ.  
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Scheme 4: Oscarson group synthesis of trisaccharide diphosphate. 
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The N-benzyloxycarbonyl protecting group was then removed using hydrogenolysis to 
give the trisaccharide diphosphate 27 in a good yield of 83%. Finally the TBS 
protection was removed to give trisaccharide diphosphate 28 in a good yield of85% (see 
Scheme 5). 
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Scheme 5: Oscarson group trisaccharide diphosphate deprotection. 
 
With acetates at both the O-3 and O-4 position the trisaccharide diphosphate 28 better 
resembles the native polysaccharide, which only contains one acetate, usually at the O-3 
position but occasionally the O-4 position. These acetates were also cleaved off using 
sodium methoxide to furnish the trisaccharide diphosphate 21 replicating the fragment 
synthesised by the Pozsgay group. 
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The Stockholm researchers also developed a strategy allowing the synthesis of 
6’’-O-phosphorylated phosphoglycans (see Scheme 6). They achieved this by 
producing the 6-O-phosphorylated H-phosphonate derivative 29 and using this in the 
condensation (in standard conditions) with the previously synthesised monohydroxyl 
derivative 25. Following oxidation the trisaccharide triphosphate derivative 30 was 
achieved in a similar yield for second phosphate introduction of 59%. The azides of 30 
werethen reduced to amines again using sodium borohydride and nickel chloride before 
the addition of acetic anhydride to facilitate N-acetylation in situ to furnish the 
trisaccharide triphosphate derivative 31.Finally, the N-benzyloxycarbonyl protection 
was removed from the ethanolamine linker by hydrogenolysis to achieve the desired 
trisaccharide triphosphate 32, which again contained acetates at the O-3 and O-4 
position, in good yield. To achieve yet another derivative the acetates were first 
removed from derivative 31 with sodium methoxide before removal of the N-
benzyloxycarbonyl protecting group using hydrogenolysis to give the trisaccharide 
triphosphate 33again in good yield. 
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Scheme 6: Oscarson group synthesis of trisaccharide triphosphate compounds. 
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1.2.3  Synthetic glycoconjugate vaccines for Haemophilus influenza type b 
An alternative route for the production of glycoconjugate vaccines (see section 
1.1.6) is to chemically synthesise fragments of the capsular polysaccharide. One of the 
issues with naturally derived carbohydrate polymers is that they are heterogeneous 
mixtures that may include contaminants and unwanted impurities. Through the use of 
synthetic carbohydrate structures, which can be chemically produced as single 
compounds, batch to batch variability can be eliminated. For example, a fully synthetic 
hexasaccharide conjugated to keyhole limpet hemocyanin (KLH) has been shown to be 
an effective vaccine against prostate cancer.85 This methodology has also been used by 
Verez-Bencomo et al. with great success in manufacturing a fully synthetic vaccine 
against Haemophilus influenza type b (Hib).86Synthetic preparation of the glycan part of 
the glycoconjugate vaccines also allows for chemical modifications to the structure that 
may prove difficult or impossible to perform on the naturally derived material. 
With regard to the Hib vaccine the group had to first synthesise a fragment of the 
capsular polysaccharide of Hib, which is composed of ribosylribitol phosphate repeating 
units (see Figure 7). One alteration to this fragment was the addition of a linker region 
to the primary unit, which would allow the coupling of the fragment to a carrier protein. 
 
 
Figure 7: Repeat unit of Hib capsular polysaccharide. 
 
The aim of the researchers was to develop a synthetic methodology that would also 
allow the large scale good manufacturing practice (GMP) production of the fragments. 
With this in mind they set out to develop a strategy that would minimise the number of 
reaction and chromatography purification steps in order to simplify production. Their 
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approach utilised the reliable and efficient H-phosphonate chemistry (see Scheme 7) in 
their synthesis for the formation of the phosphodiester linkages.87 
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Scheme 7: Route to Cuban synthetic vaccine. 
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This has proven to be the method of choice for the efficient construction of various 
phosphodiester linkages which are characteristic of natural phosphoglycans.88 
Additionally, by the use of the H-phosphonic synthon 35,which also has a free hydroxyl 
group the reaction proceeded through a co-polycondensation process after the addition 
of the condensing reagent pivaloyl chloride.87Following the co-polycondensation of the 
H-phosphonate 35 with the linker-phosphate containing monohydroxyl unit 34 the H-
phosphonic diesters formed were oxidised readily to phosphodiesters with the addition 
of iodine in pyridine-water to furnish the protected phosphoglycan36. This allowed the 
production of long chain oligomers in a one-pot synthesis and enabled the researchers to 
reproducibly synthesise oligomers with an average size of 8 repeating units with an 
impressively high yield of 80% after being purified by size exclusion chromatography. 
After removal of the benzyl protecting groups and reduction of the azide with 
hydrogenolysis the desired oligomeric phosphoglycan37 was isolated with a primary 
amine functionality capable of conjugation to a carrier protein. The beauty and 
straightforwardness of this approach, which employed only five steps, allowed the 
whole process to be efficiently scaled up and proceed under Good Manufacturing 
Process (GMP) to provide 100 g per batch.The results of a clinical trial demonstrated 
that the synthetic glycovaccine is as effective as its natural counterpart. The vaccine was 
registered in Cuba in 2003 and is now part of the national immunization program.  
 
 
 
 
1.2.4  Synthetic neoglycoconjugates of Leishmania lipophosphoglycan 
Another nice exampleof using synthesised phosphoglycans containing a linker 
region to produce neoglycoconjugates as a potential vaccine was demonstrated in the 
synthesis of neoglycoconjugates ofLeishmania lipophosphoglycan. 
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A characteristic part of the Leishmania parasite is a complex glycoconjugate 
called the lipophosphoglycan (LPG).89,90 The most distinctive part of the Leishmania 
LPG is their variable phosphoglycan domain consisting of a β-D-Gal-(1→4)-α-
Man1→OPO3phosphosaccharide repeat. The synthesis of which is challenging due to 
the phosphoglycans being hydrolytically unstable under reaction conditions and further 
complicated by the need for the correct stereochemistry at the C1 position of the 
phosphodiester linkage. The first successful synthesis of the Leishmania 
phosphoglycans was achieved by the Dundee University group by again exploiting the 
H-phosphonate approach.91,92 All the phosphoglycans prepared contained a dec-9-enyl 
aglycone moiety which was purposely designed to both aid in the study of Leishmania 
biosynthetic enzymes and, after modification, allow for the preparation of 
neoglycoconjugates.93 An example of such a preparation is shown in Scheme 8. This 
approach employed the co-polycondensation technique by coupling the primary 
hydroxyl unit 39 with the monohydroxyl H-phosphonate derivative38. The H-
phosphonate 38 has a free primary hydroxyl group at the C-6 position, which allows for 
further condensation of the remaining H-phosphonate, which was present in a relatively 
high concentration of 1 M. Historically, this was the first phosphoglycan synthesised (in 
1995) using the H-phosphonate polycondensation technique,87and which was later 
followed (in 2004) by the Cuban researchers(see section 1.2.3).86_ENREF_76 
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Scheme 8: Synthesis of Leishmania LPG fragment. 
 
The phosphoglycan 40 was then debenzoylated with sodium methoxide and following 
purification through ion-exchange chromatography on Fractogel TSK DEAE-650 
(HCO3
-) the desired phosphoglycan 41 (n ~ 6)wasisolated in a yield of 60%. 
Phosphoglycans containing the dec-9-enyl moiety could then be used for the 
preparation of neoglycoconjugates via the oxidation of the double bond through the 
mild conditions of ozonolysis to afford an aldehyde moiety. Now with the linker region 
terminating in an aldehyde functionality, it was shown that the phosphoglycans could be 
coupled to a carrier protein through reductive amination technique with a free amino 
group of the carrier protein, an example of which is shown in Scheme 9.94,95,96 
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Scheme 9: Synthesis of neoglycoconjugatesby Dundee University group. 
 
This procedure was repeated with an array of synthesised LPG structures91,92,97,98,99,100to 
yield a range of neoglycoconjugates of progressively larger phosphoglycans and 
branching phosphoglycans shown in Figure 8. 
Although structurally unrelated to the capsular polysaccharide of Men-A the 
above synthesis does demonstrate two key points. The first being that the H-
phosphonate approach is the method of choice for the synthesis of natural 
phosphoglycans and secondly that the dec-9-enyl linker proved efficient and reliable in 
the preparation of neoglycoconjugates from structure containing intersaccharidic 
phosphate linkages. 
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Figure 8: Neoglycoconjugates of synthetic Leishmania phosphoglycans. 
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1.2.5  Phosphoramidite synthons 
An alternative method to the formation of phosphodiester bonds is the 
phosphoramidite approach. This has been used with great success in the chemical 
synthesis of oligonucleotides for many years.101,102 The preparation of suitably protected 
2-acetamido-3-O-acetyl-2-deoxy-D-mannose phosphoramidite derivatives was shown 
by Vann and Freese in 1996 (see Scheme 10).103Unfortunately the paper only describes 
the synthesis of synthons 47 and 48and does not mention any attempts to use them in 
the formation of a phosphodiester. 
 
 
Scheme 10: Phosphoramidite synthons related to N. meningitidis serogroup A capsulephosphoglycan. 
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CHAPTER 2 
2.  RESULTS AND DISCUSSION 
 
2.1  AIMS OF THE PROJECT 
 
2.1.1  Synthetic targets 
As mentioned earlier in section 1.1.4, the capsular polysaccharide(CPS) of 
Neisseria meningitidisserogroup A forms a dense protective layer of(1-6)-linked poly(2-
acetamido-2-deoxy-α-D-mannopyranosyl phosphate)around the cell and provides 
protection from the surrounding environment (Figure 5).Although successful, previous 
work on the synthesis of the CPS fragments stopped after the introduction of the second 
intersaccharidic phosphate and the fragments produced had either no acetate groups or 
acetates at both the O-3 and O-4 positions. The importance of this O-acetylation to the 
immunogenicity of the capsular fragments has been shown by Berry and co-workers to 
be of great significance.34 In their studies it was shown that antibodies against the native 
CPS of Neisseria meningitidesserogroup A had a reduced ability to bind capsular 
fragments that had been de-O-acetylated. Moreover the immunogenicity of de-O-
acetylated CPS fragments was markedly reduced, even when conjugated to a tetanus 
toxoid protein.34 
 
Therefore, to better replicate the native CPS structure, a synthetic strategy 
resulting in only 3-O acetates was proposed with the additional aim of producing larger 
fragments with more than two intersaccharidic phosphates (see Figure 8). 
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Figure 9: Proposed synthetic target phosphoglycans. 
 
As shown above, the original aim of this project was to synthesise fragments ranging in 
size from 1 to 4 intersaccharidic phosphates. All of the synthetic targets 52-55 also 
contain an integrated linker at the reducing end of the phosphoglycan chain allowing for 
conjugation of the capsular fragments to protein.  
 
2.1.2  Stability of the glycosyl phosphate bond in N-acetylmannosamine phosphate 
derivatives 
The chemical composition of this capsule however provides a particular challenge 
to any chemical synthesis due to the intersaccharidic phosphodiester linkage which is 
inherently unstable under reaction conditions. This is further destabilised by the 
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presence of the N-acetyl moiety of carbon 2 which can participate in the cleavage of the 
phosphodiester bond (see Figure 9). 
 
 
Figure 10: Instability of N-acetylmannosamine phosphate linkage. 
 
Like all intersaccharidic phosphodiester bonds, under reaction conditions, the ring 
oxygen of the carbohydrate can donate a pair of electrons to facilitate cleavage of the 
glycosyl phosphate bond. This is energetically favourable due to the resulting ManNAc 
6-phosphate being a good leaving group while the remaining glycosyl cation is also 
relatively stable entity. The most instability however comes from the oxygen of the 
acetamido group which in this structure sits in the axial configuration of carbon 2. This 
leads to the formation of a stable 1,2-oxazoline derivative and again ManNAc 6-
phosphate as the leaving group. 
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2.2  RETROSYNTHETIC ANALYSIS 
 
2.2.1  Retrosynthetic analysis of CPS synthesis 
In order to reduce the instability of the glycosyl phosphate potentiated by the 
acetamido group, during the synthesis an azido functionality was used at the 2 position. 
This proved successful during the synthesis of capsule fragments mentioned earlier 
(Scheme 3 and Scheme 4)by the Pozgay and Oscarson groups respectively. Although 
successful the synthesis stopped after the introduction of the second intersaccharidic 
phosphate and the fragments produced had either no acetates or acetates at both the O-3 
and O-4 positions. To better replicate the native CPS structure a synthetic strategy 
resulting in only 3-O acetates was proposed with the additional aim of producing larger 
fragments with more than two intersaccharidic phosphates (see Scheme 11). 
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Scheme 11: Retrosynthetic analysis of capsule fragments. 
 
Another important feature required for a potential vaccine is the ability to conjugate to a 
carrier protein. In this case it was thought that a 9-decen-1-yl moiety attached to the 
primary saccharide unit would make a good candidate. It has previously been used 
successfully by the Nikolaev group in the development of a potential anti-Leismania 
vaccine.94,96 Once installed the 9-decen-1-yl group is stable under a range of reaction 
conditions and the double bond can be readily oxidized to form an aldehyde 
functionality using ozonolysis. This aldehyde moiety can then facilitate conjugation 
through reductive amination.  
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The elongation of the fragments would proceed through the condensation of an 
orthogonally protected monomeric 2-azidomannose H-phosphonate derivative with the 
primary 2-azidomannose residue complete with decenyl spacer and the free hydroxyl 
required at the C-6 position. Following condensation of the H-phosphonate and 
subsequent oxidation to the phosphodiester the temporary protection at the O-6’ 
position can be selectively removed to provide the hydroxyl required for further chain 
elongation.   
 
2.2.2  Orthogonally protected monosaccharide synthons 
To explorethe optimal combination for the permanent O-4 protection and the 
temporaryO-6 protection four different orthogonally protected monosaccharides were 
designed (see Figure 9). 
 
 
Figure 11: Orthogonally protected monosaccharide synthons.  
 
Each compound comprises a selectively cleavable ether at the O-6 position to facilitate 
chain elongation and a permanent silyl or benzyl protecting group at the O-4 position, 
both of which can be removed while leaving the 3-O acetate intact. To prevent the 
aforementioned instability arising from the 2-acetamido group in the native ManNAc 
structure the N-acetyl group was ‘masked’ as a 2-azido group. This pseudo-protecting 
group can be readily reduced, followed by N-acetylation,in the final stages of the 
synthesis. The designed synthons also contain an ethanethiol group at the anomeric 
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position, which through hydrolysis can form the hemiacetal required for the formation 
of the desired H-phosphonates. Aside from being readily hydrolysed the thioglycosides 
also make efficient glycosyl donors, a property required for the glycosylation between 
the primary saccharide unit and the desired linker. 
 
2.3  SYNTHESIS OF MONOSACCHARIDE SYNTHONS 
 
2.3.1  Synthesis of 1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-α-D-mannopyranose 
A common precursor to all of the thioglycosides shown inFigure 9is 1,3,4,6-
tetra-O-acetyl-2-azido-2-deoxy-α-D-mannopyranose64 (see Scheme 12). The 
preparation of this tetra-acetate derivative found in literature was either low yielding or 
involved a complicated anhydrous work-up.104,105 
 
 
Scheme 12: Synthesis of 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-α-D-mannopyranose. 
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In order to avoid these complications a different synthetic route was developed. In this 
preparation, first the 4,6-benzylidene-protected methyl glucoside60 was selectively 
triflylated at the O-2 position using trifluoromethanesulfonic anhydride at -40ºC. The 
progress was monitored with TLC until no trace of the diol 60remained. The O-3 
position was then benzoylated with the addition of benzoyl chloride while the reaction 
was allowed to warm to room temperature. After work up the cude triflate derivative 61 
was obtained. Derivative 61 could then be used without the need for any purification in 
the triflate displacement with sodium azide. This resulted in an inversion of the 
configuration, which afforded the azido-mannose derivative 62in a good yield of 
96%.106 The next step was to convert to the peracetylated 2-azido-2-deoxy-manose. This 
was done by first removing the benzoyl ester at the O-3 position with transesterification 
using sodium methoxide in a solution of methanol and dichloromethane. After 
debenzoylation compound 63 was subjected to acetolysis in the presence of 1% (v/v) 
sulphuric acid in acetic anhydride, facilitating cleavage of both the anomeric O-methyl 
and the benzylidene acetal while fully acetylating all positions. This gave the target 
tetra-acetate 64 in a very respectable yield of 81%. 
 
2.3.2 Synthesis of the thioglycoside synthons 56-59 
The next stage in the synthesis required theinstallation of a thiol functionality at 
the anomeric position (see Scheme 13). This was achieved by reactingthe tetra acetate 
64 with ethanethiol in the presence of BF3●EtO2 and 4Å molecular sieves.
107 Once full 
conversion was observed by TLC the reaction was quenched with the addition of 
triethylamine and the reaction mixture applied directly onto a silica column. This was 
then flushed with toluene which served to both remove the remaining ethanethiol and 
additionally filter off the molecular sieves. The flushed toluene could then be safely 
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discarded with the organic waste eliminating the need for an aqueous workup. The 
thioglycoside 65was then acquired in 81% yield by eluting from the column with a 30% 
solution of ethyl acetate in toluene. 
 
 
Scheme 13: Synthesis of monosaccharide synthons 56 and 57. 
 
Following successful transformation to the thioglycoside the remaining acetate groups 
had to be cleaved to allow for further protection group manipulation. This was 
accomplished again using the standard conditions of sodium methoxide and methanol in 
a solution of dichloromethane. The solution was then de-ionised with the addition of 
DOWEX 50 (H+) resin and stripped of solvent to leave the triol 66. In order to 
selectively protect the 4,6-hydroxyls an isopropylidene ketal was formed. This was 
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installed using 2,2-dimethoxypropane with p-toluenesulphonic acid as a catalyst,while 
monitoring progress by TLC. Once all of the triol had been consumed the remaining O-
3 position was acetylated by adding acetic anhydride and pyridine to the reaction. This 
gave the required compound 67 in a respectable 77% yield. The ketal protection 
introduced in the previous step was then cleaved by hydrolysis in the presence of 
trifluoroacetic acid (TFA) to release the 4,6-diol. Selective protection of the C-6 
hydroxyl was then achieved by exploiting the increased reactivity of the primary 
hydroxyl in addition to the sterically hindered nature of the reagent dimethoxytrityl 
chloride (DMTrCl). Once complete the remaining O-4 position was then silylated with 
an injection of triethylsilyl trifluoromethanesulfonate (TESOTf) to furnish synthon56. 
The synthesis of synthon 57 proceeded in a similar manner with the cleavage of 
the ketal from 67again to give the 4,6-diol. This was then reacted with a slight excess 
(2.5 eq) of TESOTf in a solution of pyridine to give an 87% yield of 57. 
For the preparation of synthons 58 and 59 a slightly different approach was 
taken. This decision was taken to avoid the basic conditions used in the standard 
benzylation reaction which potentially could cause partial acetyl cleavage or migration. 
The triol 66 was first protected, again at C-4 and C-6 hydroxyls, using a benzylidene 
acetal. This was achieved with benzaldehyde dimethylacetal and the heterogeneous 
catalyst NaHSO4●SiO2 to yield 68 in 85% yield.
108 The remaining hydroxyl at the C-3 
was then acetylated, again using acetic anhydride in pyridine to give 69 in quantitative 
yield. The six membered ring of the benzylidene acetal could then be selectively opened 
to release the C-6 hydroxyl and following reduction provide the required benzyl 
protection at the O-4 position. This reductive cleavage was performed with 
dibutylboron triflate and borane in THF.109Thesteric hindrance around the O-4 position 
and the bulky nature of the Lewis acid dibutylboron triflate ensured that only the more 
available O-6 bond was cleaved.Subsequent reduction with borane gives derivative 70in 
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82% yield. The free primary hydroxyl group was then protected without difficulty using 
DMTrCl ortert-butyldimethylsilyl chloride(TBSCl) in pyridine to furnish compounds 
58 and 59 respectively. 
 
 
Scheme 14: Synthesis of monosaccharide synthons 58 and 59. 
 
2.3.3 Synthesis of a monohydoxylic 9-decen-1-yl glycoside derivative 
In order to produce the primary saccharide with linker attached a glycosylation 
was required. Initially it was thought that the thioglycosides could be used for the 
glycosyl donor in the glycosylation. A test reaction was carried out using synthon 57 as 
the donor and 9-decen-1-ol as the glycosyl acceptor (see Scheme 15).  
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Scheme 15: Attempted synthesis of decenyl glycoside using thioglycoside donor. 
 
The N-iodosuccinimide (NIS) promoted glycosylation was carried out in the usual 
manor with a catalytic amount of silver triflate (AgOTf) and the addition of freshly 
activated molecular sieves.78The progress of the reaction was monitored with TLC, 
which showed consumption of the reactants but unfortunately an array of products were 
formed. It was thought that one possible reasonfor this issue could have been the 
iodonium ion generated from the NIS causing migration of the double bond of 9-decen-
1-ol, however no products were isolated and no further analysis was performed.  
Instead a new approach was employed using the now plentiful tetra-acetate 64. 
Firstanomeric deprotection of 64 was carried out by treatment with dimethylamine, 
which reacted quickly and efficiently to generate the hemiacetal 71 (see Scheme 16).  
OAcO
AcO N3
OH
AcO
OAcO
AcO N3
OAc
AcO
Me2NH (2.5eq), THF, 97%
64 71
4:1 (a:ß)
Cl3CCN (3eq), DBU, DCM, 68%
OAcO
AcO N3
OC(NH)CCl3
AcO
72
OAcO
AcO N3
O(CH2)8CH=CH2
AcO
TMSOTf, 4Å MS, DCM, 93%
HO(CH2)8CH=CH2
73
+
 
Scheme 16: Synthesis of 9-decen-1-yl glycoside using trichloroacetimidate donor. 
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After purification the hemiacetal could then be converted to the trichloroacetimidate 
glycosyl donor 72through treatment with trichloroacetonitrile and 1,8-
Diazabicyclo[5.4.0]undec-7-ene (DBU).110 The trichloroacetimidate donor was then 
used in a glycosylation111,112 with 9-decen-1-ol as the acceptor and a catalytic amount of 
trimethylsilyl trifluoromethanesulfonate (TMSOTf). This proceeded very rapidly with 
complete consumption of the donor after only ten minutes leaving the 9-decen-1-yl 
glycoside 73 in 93% yield.  
With the glycosylation successful the next step was to install the correct 
protecting group arrangement. This was done following the same method as that used 
for the thioglycoside synthon 56 (Scheme 17).  
 
 
Scheme 17: Synthesis of decenyl glycoside 75. 
 
First the acetate groups were cleaved to release the triol before again using the 
isopropylidene ketal to temporarily protect the O-4 and O-6 positions. With this in place 
the required 3-O-acetyl group was installed to provide 74 in 78% yield. As before, after 
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acetylation, the ketal protection was cleaved with TFA releasing the 4,6-diol allowing 
the primary hydroxyl to be protected with a trityl ether followed by silylation of the O-4 
position. After purification the required decenyl glycoside 75 was obtained with a 78% 
yield. 
 
2.4  SYNTHESIS OF A GLYCOSYL H-PHOSPHONATE DERIVATIVE AND 
CONDENSATION REACTIONS 
 
2.4.1 Synthesis of the H-phosphonate 
The initial work in this preparation was carried out using the prepared 
monosaccharide 56. Hydrolysis of the ethyl thioglycoside 56 using NIS and AgOTf in a 
solution of wet dichloromethane78 gave the desired hemiacetal 76 in a disappointing 
40% yield and an α:β ratio of 3.5:1 (Scheme 18).  
 
 
Scheme 18: Synthesis of DMTr protected H-phosphonate 77. 
 
Subsequent phosphonylation with phosphorus trichloride (PCl3) and imidazole followed 
by aqueous work-up generated the H-phosphonate 77 efficiently in 88% yield. The H-
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phosphonate formed however had, as expected, the same α:β ratio (3.5:1) as that of the 
previous hemiacetal. Before any coupling could proceed, this ratio had to be improved. 
This was achieved by the degradation of primarily the β-anomer with silver triflate 
(AgOTf) in a solution of toluene and methanol (Scheme 19). After purification the pure 
α-H-phosphonate 77 was isolated in 37% yield. 
 
 
Scheme 19: Degradation of the β-H-phosphonate. 
 
2.4.2 Condensation of H-phosphonate. The chain elongation up to a trisaccharide 
diphosphate derivative. 
 
Following the successful synthesis of the H-phosphonate the first condensation 
was attempted. Prior to the coupling though the monohydroxylic acceptor 78 had to be 
generated (Scheme 20). This was achieved by mild acid hydrolysis of the trityl ether 
from 75 using 1% (v/v) TFA in dichloromethane at 0 oC followed by aqueous work-up. 
This generated 78 (96%) with the required free hydroxyl at C-6 position. 
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Scheme 20: Synthesis of disaccharide phosphate 79. 
 
The H-phosphonate 77 and the newly formed monohydroxylic derivative 78 were 
combined in pyridine and using standard H-phosphonate chemistry conditions the 
condensation was initiated with the addition of pivaloyl chloride.80,88 Following 
complete consumption of the acceptor 78, monitored by TLC, the reaction mixture was 
cooled to -40 oC before the formed H-phosphonic diester was oxidised with the addition 
of iodine in a solution of pyridine/water. The protected disaccharide phosphate 79 was 
then isolated in 75% yield. 
To facilitate further chain elongation the trityl ether of the newly formed 
disaccharide phosphate 79 was cleaved using an ice-cold 1% (v/v) TFA-
dichloromethane solution (Scheme 21).This led to the monohydroxylic derivative 80 in 
a 96% yield with no signs of degradation to the fragile phosphodiester linkage. After the 
successful deprotection the H-phosphonate 77 and the newly formed monohydroxylic 
disaccharide phosphate derivative 80 were combined in pyridine. The condensing 
50 
 
 
 
reagent pivaloyl chloride was then added to initiate the reaction. Following complete 
consumption of the acceptor 80, again monitored by TLC, the mixture was cooled to -
40 oC prior the addition of iodine in a solution of pyridine/water to facilitate further 
oxidation of the newly formed H-phosphonic diester. The trisaccharide diphosphate 81 
was then isolated in 50% yield, showing a notable drop in efficiency for the introduction 
of the second intersaccharidic phosphate.  
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Scheme 21: Introduction of the second intersaccharidic phosphate. 
 
With the formation of the disaccharide phosphate 79 and trisaccharide diphosphate 81 a 
success it deemed prudent to assess the suitability of the planned reduction and 
deprotection strategy. This involved initially the reduction of the azido functionality to 
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the required amine followed by in situ N-acetylation (Scheme 22). This was carried out 
on the disaccharide phosphate 79 using sodium borohydride and nickel chloride 
hexahydrate as a catalyst in a solution of THF and methanol. 
 
 
Scheme 22: Trial deprotection strategy. 
 
Following the complete reduction of the azido groups, monitored by TLC, acetic 
anhydride was injected to accomplish N-acetylation. The trityl ether was then cleaved 
with a solution of TFA, as described earlier, before the removal of the triethylsilyl 
ethers using the Et3N
.3HF reagent in THF. This unfortunately led to the n-decanol 
derivative 82 (40%) after the unexpected reduction of the double bond, thus rendering 
the chosen 9-decen-yl linker ineffective. 
To avoid this unwanted double bond reduction another method of reduction would have 
to be used. However, at this point only a small amount of material had been synthesised 
which had all been used in the initial deprotection attempt.It was therefore thought that 
this would be a good time to assess the synthetic strategy used to optimise the synthesis 
using the experience gained so far. As the double bond in the decenyl linker had been 
problematic in the first glycosylation attempt and also in the final deprotection, a 
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change in the nature of the linker was decided to avoid any further complications. It was 
also thought that the incorporation of the linker early in the synthesis complicated 
characterisation by adding a lot of additional signals into NMR spectra. This could 
easily be avoided for most of the synthesis by adding the linker onto the non-reducing 
end of the phosphoglycan in the final steps of the synthesis.  
 
2.5  RE-DESIGNED SYNTHETIC STRATEGY 
 
2.5.1  Revised synthetic targets 
Due to the unforeseen issues encountered in the previous route a revised 
synthetic strategy was developed. Through this new strategy a revised set of synthetic 
targets was proposed. 
 
 
Figure 10: Revised synthetic targets. 
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As shown above, all of the synthetic targets 83-85 also contain an integrated 6-
aminohexyl linker at the non-reducing end of the phosphoglycan chain allowing for 
conjugation of the synthetic CPS fragments to protein. 
 
2.5.2 Revised retrosynthetic analysis 
The new synthetic strategy focused on the use of synthons 58 and 59 and in 
place of the primary linker unit a simpler methyl glycoside 87 was proposed (Scheme 
23). This would allow the building of the fragments to the required size before finally 
capping the structure with a suitable 6-aminohexyl linker via a phosphate group at the 
non-reducing end of the phosphoglycan chain. 
 
Scheme 23: Re-designed synthetic strategy. 
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2.5.3Synthesis of the methyl glycoside synthon 87 
The first task for this revised strategy was the formation of the primary methyl 
mannoside unit 87 (Scheme 24). This was accomplishedby the reductive cleavage109 of 
the benzylidene derivative 62, selectively opening the acetal ring at the O-6 position to 
give the monohydroxylic derivative 86.  
 
Scheme 24: Synthesis of primary saccharide synthon. 
 
This was then treated with sodium methoxide and methanol to remove the benzoyl 
protection at the O-3position. The diol was then selectively tritylated at the O-6 position 
again using DMTrCl in pyridine after which the remaining O-3 hydroxyl was acetylated 
with the addition of acetic anhydride. The DMTr ether was then removed by treatment 
with an ice-cold solution of TFA in dichloromethane to furnish the desired methyl 
mannoside 87 in an overall yield of 78% over three steps. 
 
 
2.6  IMPROVED SYNTHESIS OF THE GLYCOSYL H-PHOSPHONATES AND 
CONDENSATION REACTIONS 
 
2.6.1 Synthesis of the H-phosphonates 89 and 91 
During the assessment of the synthetic strategy it was noted that the hydrolysis 
of the thioglycoside 56to form the hemiacetal76 using NIS and AgOTf (Scheme 18) 
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was low yielding and unreliable. For this reason, in the new strategy, the hydrolysis was 
carried out by first reactingthe thioglycoside derivative 58 with bromine in dry 
dichloromethane to form a glycosyl bromide which was then hydrolysed to the 
hemiacetal88in situ with the addition of Ag2CO3 and acetone-water (10:1)(Scheme 25). 
This greatly improved the yield (to 89% from 58 to 88) and proved a much more 
reliable route. 
 
 
Scheme 25: Synthesis of the DMTr protected H-phosphonate 89. 
 
It was also thought at this point that the phosphonylation of the hemiacetal to the H-
phosphonate using PCl3 and imidazole was somewhat inefficient. Although the 
conversion to the H-phosphonate itself is a high yielding and effective reaction the 
stereo chemistry of the hemiacetal remains the same. In this case the α:βratio is 4.5:1 
which leaves a high proportion of β-anomer which must be degraded, as seen in the 
previous synthetic route (Scheme 19). In order to avoid this issue a different 
phosphonylating reagent was utilised. By using salicylchlorophosphite80,113in a solution 
of dioxane-Et3N,followed by aqueous work-up,the conversion of the hemiacetal 88to 
the 6-O-DMTr protected H-phosphonate 89proceeded with a very respectable yield of 
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88%, but most notably resulted an α:βratio of which only traces of the β-anomer were 
observed. This was an acceptable ratio to use without any further treatment. 
The preparation of the TBS containing H-phosphonate derivative 91 also 
proceeded smoothly through the same route(Scheme 26). The thioglycoside 59 was 
treated with bromine in a solution of dichloromethane to facilitate the formation of a 
glycosyl bromide. Subsequentaddition of Ag2CO3 and acetone/water (10:1) enabled the 
in situhydrolysis providing the hemiacetal90 in an excellent 95% yield.  
 
 
Scheme 26: Synthesis of the TBS protected H-phosphonate 91. 
 
Treatment of the hemiacetal 90 with salicylchlorophosphite in a solution of dioxane-
Et3N enabled the conversion to the6-O-TBSprotected H-phosphonate 91 with an 88% 
yield. 
2.6.2 Condensation of the H-phosphonates. Synthesis of disaccharide phosphate 
derivatives. 
 
The newly prepared primary methyl mannoside unit 87 was then combined with 
6-O-DMTr protected H-phosphonate 89 in a solution of pyridine (Scheme 27). The 
condensation was initiated as before with the addition of pivaloyl chloride to the 
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reaction mixture. Again the coupling was monitored by TLC to ensure the reactants 
were consumed and the condensation was complete. 
 
 
Scheme 27: First condensation using DMTr protected H-phosphonate 89. 
 
In order to minimise potential cleavage of the fragile H-phosphonic diester bond during 
further oxidation83,114 the reaction was cooled to -40 oC prior to a solution of 
pyridine/water and Et3N being added. The oxidation was then initiated with the addition 
of solid iodine, which takes some 30 minutes to dissolve, giving slightly milder reaction 
conditions. The trityl ether was then removed using mild acid hydrolysis as described 
before again with a 1% (v/v) TFA/dichloromethane solution but to minimise risk to the 
newly formed phosphodiester the temperature was dropped to -10 oC. The disaccharide 
phosphate 92 was then isolated in 88% yield. 
Following the successful high yielding synthesis of disaccharide phosphate 92 usingthe 
dimethoxytrityl protected H-phosphonate 89the condensation was repeated this time 
with the silyl protected H-phosphonate 91 (Scheme 28). 
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Scheme 28: First condensation using TBS protected H-phosphonate 91. 
 
The primary methyl mannoside unit 87 was combined this time with the TBS protected 
H-phosphonate 91 in a solution of pyridine. Pivaloyl chloride was added to the reaction 
mixture as before to initiate the condensation. Coupling was monitored by TLC until all 
of derivative 87 was consumed.Again to prevent any potential cleavage of the fragile H-
phosphonic diester bond during the oxidation, the reaction was cooled to -40 oC before a 
solution of pyridine/water and Et3N was added. The oxidation was then initiated with 
the addition of solid iodine which again took some 30 minutes to fully dissolve at the 
reduced temperature. The disaccharide phosphate 93 was then isolated in 75% yield but 
still contained the TBS protecting group at the O-6’ position. In order for the TBS 
protection to be cleaved derivative 93 was first dissolved in a solution of 
tetrahydrofuran (THF) before addition of triethylamine tri(hydrogen fluoride)  
(Et3N●3HF). This facilitated cleavage of the silyl protection to reproduce the previously 
synthesised disaccharide phosphate 92 in a 95% yield. 
Although successful, the synthesis of the disaccharide phosphate 92 through the 
use of the TBS protected H-phosphonate 91 was slightly less efficient. The 
condensation itself was somewhat lower yielding, 75% using the TBS H-phosphonate 
59 
 
 
 
91compared with the 88% (after consecutive condensation, oxidation and detritylation 
steps) for the DMTr protected H-phosphonate 89. The O-6’ desilylation step also 
required a lot longer reaction time and used more hazardous reagents compared with the 
detritylation step. For these reasons it was decided that the DMTr protected H-
phosphonate 89 was the best candidate to proceed with all further chain elongations. 
 
2.6.3 Synthesis of a trisaccharide diphosphate derivative. 
After the successful synthesis of the disaccharide phosphate 92,which already 
contained the required C-6’ hydroxyl it was possible to proceed straight to the 
introduction of a second intersaccharidic phosphate. The monohydroxylic disaccharide 
phosphate 92 was combined with the DMTr protected H-phosphonate derivative 89 
(Scheme 29)in pyridine and condensation was again initiated with pivaloyl chloride.The 
reaction was cooled to -40 oC prior to a solution of pyridine/water and Et3N was added. 
The oxidation was then initiated with the addition of solid iodine. The trityl ether was 
then removed using mild acid hydrolysis with a 1% (v/v) TFA/dichloromethane solution 
at a reduced temperature of -10 oC. The trisaccharide diphosphate 94 was then isolatedin 
a very good yield of 74%. It should be mentioned that through this strategy only a slight 
decrease in yield was observed when the second intersaccharidic phosphate is 
introduced. 
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Scheme 29: Introduction of the second intersaccharidic phosphate. 
 
2.6.3Synthesis of a tetrasaccharide triphosphate derivative. 
Now with the trisaccharide diphosphate 94in hand it was possible to attempt the 
introduction of the third intersaccharidic phosphate (Scheme 30). The trisaccharide 
diphosphate 94 andthe H-phosphonate 89 were combined in pyridine prior to the 
addition of pivaloyl chloride to begin the condensation. The oxidation was again 
performed at -40 oC, initiated with the addition of solid iodine, in a solution of 
pyridine/water. As this was the first attempt at the introduction of a third 
intersaccharidic phosphate, in order to avoid any potential phosphodiester cleavage the 
acidic conditions required for detritylation were avoided (at this stage of the project) 
and the DMTr protected tetrasaccharide triphosphate 95 was isolated in a very 
impressive yield of 73%. So, the first synthesis of a linear ManNAc phosphate oligomer 
containing three intersaccharidic phosphates (see Figure 12) was performed 
successfully. 
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Scheme 30: Introduction of the third intersaccharidic phosphate. 
 
 
Figure 12: 31P NMR of DMTr protected tetrasaccharide triphosphate 95. 
Now, having shown the condensation and oxidation had progressed without 
issue for the introduction of a third intersaccharidic phosphate, it was time to assess the 
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stability during detritylation now that the phosphoglycan contained 3 fragile 
phosphodiester linkages (Scheme 31). 
 
 
Scheme 31: Detritylation of the tetrasaccharide triphosphate 95 
 
This was achieved by mild acid hydrolysis of the trityl ether from 95 using 1% (v/v) 
TFA in dichloromethane at -10 oC followed by aqueous work-up. This generated 96 
(96%) with the required free hydroxyl at C-6’’’ position, causing a characteristic change 
to the 31P chemical shift (see Figure 13), necessary for integration of the linker and 
possibly further chain elongation. 
 
 
Figure 13: 31P NMR of tetrasaccharide triphosphate 96. 
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It was now known that the condensation followed by oxidationto form 
thetetrasaccharide triphosphate 95worked well with no obvious signs of degradation. 
Further, detritylationunder mild acidic conditions was also shown to proceed with no 
signs of cleavage of the fragile phosphodiester linkage. With this in mind the 
preparation was repeated using the same 3 step process as that used for the preparation 
of the disaccharide phosphate 92 and the trisaccharide diphosphate 94 (Scheme 32). 
 
 
Scheme 32: Introduction of a third intersaccharidic phosphate with 6’’’-O-deprotection. 
The monohydroxylic disaccharide phosphate 94 was combined with the DMTr 
protected H-phosphonate derivative 89 in pyridine and condensation was again initiated 
with pivaloyl chloride.The reaction was cooled to -40 oC before a solution of 
pyridine/water and Et3N was added. The oxidation was then initiated with the addition 
of solid iodine. Detritylation was achieved by mild acid hydrolysis with a 1% (v/v) 
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TFA/dichloromethane solution at a reduced temperature of -10 oC. The tetrasaccharide 
triphosphate 96 was then isolatedin a very good yield of 68% overall, showing that the 
synthesis is both efficient and reproducible.  
 
2.6.4 Synthesis of linker containing phosphosaccharide derivatives. 
In order to allow for future conjugation of the synthesised phosphosaccharides to 
protein a suitable linker was required. The linker chosen in this case was 6-
aminohexanol, the amine moiety of which was protected with a benzyloxycarbonyl 
(Cbz) group (Scheme 33). The introduction of the linker was to the non-reducing end of 
the molecule througha phosphodiester bridge, ruling out a simple glycosylation, as used 
earlier for the introduction of the dec-9-enyl linker. The linker had to be converted to a 
more reactive species first before introduction could be realised and an ideal candidate 
for this was a 6-aminohexyl H-phosphonate derivative. This strategy would add the 
linker to the phosphoglycans whilst also introducing an additional phosphate moiety. 
The commercially available Cbz protected 6-amino-hexanol was first converted to the 
H-phosphonate through treatment with phosphorous trichloride followed by aqueous 
work-up to yield the H-phosphonate linker derivative 97 in 88% yield.  
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Scheme 33: Synthesis and condensation of the linker H-phosphonate 97. 
 
The disaccharide phosphate 92 was combined with the H-phosphonate 97 in pyridine 
and condensation was again initiated with pivaloyl chloride.The reaction was then 
cooled to -40 oC after which time a solution of pyridine/water and Et3N was added. The 
oxidation was then initiated with the addition of solid iodine.The linker containing 
disaccharide diphosphate 98 was isolated in a very impressive yield of 88%. 
 
The H-phosphonate linker 97 was again used for the introduction of the linker to 
the trisaccharide diphosphate 94 (Scheme 32). This again provided the required linker 
whilst also introducing a third phosphate moiety to the CPS fragment. 
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Scheme 34: Condensation of linker H-phosphonate. 
 
The trisaccharide diphosphate 94 was combined with the H-phosphonate 97 in pyridine 
before addition of pivaloyl chloride to initiate the condensation.Following coupling, the 
reaction was cooled to -40 oC after which time a solution of pyridine/water and Et3N 
was added. The oxidation was then initiated with the addition of solid iodine.The linker 
containing trisaccharide triphosphate 99 was isolated in a very impressive yield of 88%. 
 
2.6.5  Deprotection of linker containing phosphosaccharide derivatives 98 and 99 
With the successful formation of the disaccharide diphosphate 98 and 
trisaccharide triphosphate 99 it was time to assess the suitability of the planned 
reduction and deprotection strategy. This involved initially the reduction of the azido 
functionality to the required amino group followed by in situ N-acetylation 
(Scheme35). This was carried out on the disaccharide diphosphate 98 using sodium 
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borohydride and nickel chloride hexahydrate as a catalyst in a solution of THF and 
methanol. 
 
 
Scheme 35: Deprotection to provide synthetic target 83. 
 
Following the complete reduction of the azido groups, acetic anhydride was injected to 
undertake N-acetylation. The remaining O-4 benzyl protection and Cbz protection of the 
linker could then be removed through catalytic hydrogenation. This was achieved by 
first treating with IR-120 (Na+) ion exchange resin to convert the phosphate 
triethylammonium salts to the corresponding di-sodium salt which is known to help 
facilitate the hydrogenation and increase the overall efficiency of the reaction.81,115The 
prepared disaccharide diphosphatewas then hydrogenated over palladium hydroxide on 
charcoal (Pd(OH)2/C) in a solution of methanol/THF to provide the first synthetic target 
83 in 96% yield overall. 
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Given that the deprotection of the disaccharide diphosphate 98 proceeded without issue, 
it was possible to continue straight to the deprotection of the trisaccharide triphosphate 
99 with the same reaction conditions (Scheme 36). 
 
OBnO
N3
O
AcO
P
O-
O
OBnO
N3
OMe
AcOO
Et3NH
+
OBnO
N3
O
AcO
P
O-
O
O
Et3NH
+
CbzHN(H2C)6O
P
O-
O
O
Et3NH
+
99
(1) (i) NaBH4, NiCl2 6H2O, MeOH;
(ii) Ac2O, MeOH, 0
oC,
(2) (i) Amberlite IR-120 (Na+)
(ii) H2, Pd(OH)2/C, THF/methanol, 90% overall
OHO
NHAc
O
AcO
P
O-
O
OHO
NHAc
OMe
AcOO
Na+
OHO
NHAc
O
AcO
P
O-
O
O
Na+
H2N(H2C)6O
P
O-
O
O
Na+
84  
Scheme 36: Deprotection to provide synthetic target 84. 
 
The trisaccharide triphosphate 99 was dissolved in a solution of THF and methanol and 
subsequent reduction was performed with the addition of sodium borohydride and 
nickel chloride hexahydrate as a catalyst. Following reduction of the azido groups, 
acetic anhydride was again introduced to accomplish N-acetylation. Conversion of the 
phosphates to the sodium salt form was achieved by treating with IR-120 (Na+) ion 
exchange resin. The remaining benzyl and Cbz protecting groups were then removed 
through catalytic hydrogenolysis over palladium hydroxide on charcoal (Pd(OH)2/C) in 
69 
 
 
 
a solution of methanol/THF to provide the second synthetic target 84in 90% yield 
overall. 
 
2.6.6 Attempted chain elongation of a tetrasaccharide triphosphate derivative 96. 
 
Encouraged by the high yielding success for the synthesis of the tetrasaccharide 
triphosphate 96,a further condensation was attempted to introduce a fourth 
intersaccharidic phosphate (Scheme 37). 
 
 
Scheme 37: Attempted introduction of a fourth intersaccharidic phosphate. 
 
To this end, the tetrasaccharide triphosphate 96 (a monohydroxylic derivative)andthe H-
phosphonate 89 were then combined in pyridine prior to the addition of pivaloyl 
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chloride to begin the condensation. Coupling was again monitored with TLC however 
analysis of progress was somewhat complicated. The monohydroxylic acceptor 96, 
already containing three phosphate moieties, and the pentasaccharide tetraphosphate 
product 100 had identical travel (i.e., Rf values) on the TLC plate. The condensation 
itself was definitely occurring as seen by orange colour produced by the dimethoxytrityl 
group of thepentasaccharide tetraphosphateformed on developing the TLC plate. The 
main problem was estimating how much of the monohydroxylic acceptor 96 had been 
consumed. After 40 minutes of condensation conditions some other minor spots could 
be seen on the TLC plate, probably indicating signs of degradation. At this point it was 
judged best to proceed with the oxidation. The oxidation was again performed at -40 oC, 
initiated with the addition of solid iodine, in a solution of pyridine/water. This gave, 
after purification, an inseparable mixture (~1:1) of the newly formed pentasaccharide 
tetraphosphate 100 and tetrasaccharide triphosphate 96 starting material.  
At this stage it was thought that the best course of action for this inseparable mixture 
was to attempt the condensation again to convert the remaining monohydroxylic 
acceptor 96 to thepentasaccharide tetraphosphate 100. The inseparable mixtureandthe 
H-phosphonate 89 were then combined in pyridine and pivaloyl chloride was added to 
begin the condensation. The progress again was difficult to monitor but the reaction 
conditions were maintained until minor signs of degradation were observed. The 
oxidation was performed at -40 oC, initiated with the addition of solid iodine, in a 
solution of pyridine/water. Unfortunately this additional condensation did not appear to 
improve the situation as again an inseparable mixture (~1:1) of the pentasaccharide 
tetraphosphate 100 and tetrasaccharide triphosphate 96 starting material was isolated 
(see Figure 14).  
 
71 
 
 
 
 
Figure 14: 31P NMR of  inseparable mixture of tetrasaccharide triphosphate 96 andpentasaccharide tetraphosphate 
100. 
 
The mixture of tetraphosphate 100 and triphosphate 96 was then detritylated under mild 
acid hydrolysis conditions, 1% (v/v) TFA/dichloromethane solution at a reduced 
temperature of -10 oC (Scheme 38). The resulting mixture generated five distinct peaks, 
in a ratio of 2:2:1:1:1, with 31P NMR analysis (see Figure 15). 
 
 
Figure 15: :31P NMR of  inseparable mixture of tetrasaccharide triphosphate 96 andpentasaccharide tetraphosphate 
101. 
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Scheme 38: Detritylation of pentasaccharide tetraphosphate 100. 
 
Regrettably the resulting mixture of pentasaccharide tetraphosphate 101 and 
tetrasaccharide triphosphate 96 appeared to be also inseparable on silica gel. 
 
2.6.7 Attempted synthesis of a longer linker containing phosphosaccharide 
derivative 102. 
 
Following the incomplete synthesis of the pentasaccharide tetraphosphate 100 
attention turned to the preparation of the third synthetic target, a linker containing 
tetrasaccharide tetraphosphate 102(Scheme 39). The tetrasaccharide triphosphate 96 
was combined with the H-phosphonate 97 in pyridine before addition of pivaloyl 
chloride to initiate the condensation. 
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Scheme 39: Attempted formation of a linker containing tetrasaccharide tetraphosphate 102.  
 
As mentioned earlier monitoring of the reaction using TLC proved difficult. Following 
coupling, the reaction was cooled to -40 oC after which time a solution of pyridine/water 
and Et3N was added. The oxidation was then initiated with the addition of solid iodine. 
After purification of what was assumed to be the condensation product102,NMR 
analysis showed very low incorporation of the linker H-phosphonate derivative 97 
similar to the attempted preparation of the pentasaccharide tetraphosphate 100. As the 
glycosyl H-phosphonate 89 and the linker H-phosphonate 97had been shown before to 
react readily in previous syntheses this probably indicates a quite low reactivity of the 
6’’’-OH group in the tetrasaccharide triphosphate 96. 
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2.6.8Deprotection of a mixture of phosphosaccharide derivatives 96 and 101. 
Even though the synthesis of the pentasaccharide tetraphosphate 101was 
somewhat unsuccessful and led to an inseparable mixture of pentasaccharide 
tetraphosphate 101 and tetrasaccharide triphosphate 96 it was still worthy of 
deprotection. Given that neither of the phosphoglycans contained the amine linker a 
more straightforward deprotection strategy was utilised (Scheme 40). This involved the 
reduction of the azido functionality to the required amino group and removal of the 
benzyl ethers through catalytic hydrogenation. Again the triethylammonium salts of the 
phosphates were exchanged to the sodium salts by treating with IR-120 (Na+) ion 
exchange resin. The hydrogenation was then performed over palladium hydroxide on 
charcoal (Pd(OH)2/C) in a solution of methanol/THF in the presence of acetic anhydride 
to facilitate in situ N-acetylation in a one pot reaction. This led to a mixture of the fully 
deprotected tetrasaccharide triphosphate 103 andpentasaccharide tetraphosphate 104. 
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Scheme 40: Catalytic hydrogenation of a mixture of 96 and 101. 
 
2.7  CONCLUSIONS 
 
The ultimate aim of this work was to design a synthetic strategy for the 
preparation of (1-6)-linked poly(2-acetamido-2-deoxy-α-D-mannopyranosyl phosphate) 
derivatives containing a 3-O acetate group and a linker moiety. To achieve this four 
different orthogonally protected monosaccharide synthons were prepared (derivatives 
56-59) to attempt to find the optimal protecting group arrangement.  
The initial synthetic strategy utilised synthons 56 and 57, derivative 57 (a thioglycoside) 
being used unsuccessfully as a glycosyl donor in the preliminary glycosylation with 9-
decen-1-ol, while derivative 56 was converted to the glycosyl H-phosphonate 77. The 
required 9-decen-1-yl glycoside 74 was subsequently prepared starting from the tetra-
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acetate derivative 64 via the preparation of the trichloroacetimidate donor 72 followed 
by a glycosylation with 9-decen-1-ol.   
The chemical synthesis of the 9-decenyl linked disaccharide phosphate 79 and the 9-
decenyl linked trisaccharide diphosphate 81 was accomplished through the 
condensation of the DMTr protected H-phosphonate derivative 77 and the 
monohydroxylic derivatives 78 and 80 respectively. Unfortunately however, during the 
reduction required for deprotection the 9-decen-yl linker was reduced to an-decanol 
moiety thus rendering the linker ineffective and so forced a redesigned synthetic 
strategy.  
With the improved synthetic strategy the position of the linker (6-aminohexanol) 
was moved to the non-reducing end of the phosphoglycan chain and a simpler methyl 
mannoside (derivative 87) used as the primary saccharide unit. The O-4 protection of 
the primary saccharide unit 87 was a benzyl ether and so to keep the protecting group 
arrangement consistent this approach concentrated on the monosaccharide synthons 58 
and 59, both of which also contain the O-4 benzyl protection. Both synthons 58 and 59 
were successfully converted to the required H-phosphonate derivatives 87 and 89 
through the use of the phosphonylating agent salicylchlorophosphite and assessed for 
condensation efficiency. 
The chain elongation was successful in the integration of up to 3 intersaccharidic 
phosphates in a phosphoglycan molecule (compounds 95 and 96). Also the introduction 
of a fourth intersaccharidic phosphate was in partial success, but the reaction did not go 
to completion and resulted in an inseparable mixture of pentasaccharide tetraphosphate 
101 and tetrasaccharide triphosphate 96. 
 
Some interesting observations have been made in terms of the condensation 
reaction time required for the preparation of the disaccharide phosphate 92 (coupling the 
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glycosyl H-phosphonate 89 and the monosaccharide derivative 87), trisaccharide 
diphosphate 94 (coupling the glycosyl H-phosphonate 89 and the disaccharide 
monophosphate derivative 92) and the tetrasaccharide triphosphate 95 (coupling the 
glycosyl H-phosphonate 89 and the trisaccharide diphosphate derivative 94).In the first 
condensation with the glycosyl H-phosphonate 89 and the monosaccharide derivative 
87,the condensation was complete (as monitored by TLC) after only 5 minutes after the 
addition of pivaloyl chloride. For the second condensation with the glycosyl H-
phosphonate 89 and the disaccharide monophosphate derivative 92the reaction time 
increased to around 20 minutes after the addition of pivaloyl chloride. With the 
introduction of the third intersaccharidic phosphate, the condensation between the 
glycosyl H-phosphonate 89 and the trisaccharide diphosphate derivative 94the reaction 
time increased further to around 40 minutes after initiation with pivaloyl chloride. These 
observations are in line with the proposed reaction mechanism shown by Nikolaev and 
co-workers in 1992 while investigating the suitability of the H-phosphonate approach in 
the synthesis of oligo(mannosyl phosphate) derivatives.116 An example of this is shown 
in Scheme 41. During the condensation, with a monohydroxylic derivative, which 
already contains a phosphate group, both the hydroxyl and the oxygen of the phosphate 
can act as the nucleophile. Nucleophilic attack from the hydroxyl group leads to the 
required H-phosphonic diester in an irreversible reaction. The latter scenario, 
nucleophilic attack from the phosphate, results in an unstable mixed anhydride [i.e., 
glycosyl H-phosphono(phosphoric) anhydride] being formed in a reversible reaction 
with the equilibrium in favour of the starting materials.92 This goes some way in 
explaining why the presence of a phosphate group slows the reaction time of the 
condensation and the reaction time increases further with two phosphate groups present. 
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Scheme 41: Proposed H-phosphonate reaction mechanism. 
 
Introduction of the linker H-phosphonate 97 into phosphosaccharides 92 and 94was 
achieved without issue to give the linker containing disaccharide diphosphate 98 andthe 
linker containing trisaccharide triphosphate 99. However, the introduction of the linker 
H-phosphonate 97 into the tetrasaccharide triphosphate 96 was unsuccessful due to 
reasons unclear at this time. 
Following deprotection the desired linker containing synthetic targets, the disaccharide 
diphosphate83 and the trisaccharide triphosphate 84 were obtained in high yield 
complete with a linker containing an amine functionality allowing for bioconjugation.  
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2.8  SUITABLE BIOCONJUGATION TECHNIQUES FOR THE PREPARED 
PHOSPHOGLYCANS 
 
2.8.1  Suitable bioconjugation techniques 
Although, due to time constraints, no bioconjugation of the synthesised CPS 
fragments 83 and 84was performed it is still worth mentioning conjugation techniques 
which would be suitable for our structures. These methods were chosen for two reasons. 
The first was simply that they both require an amine functionality in the linker 
andsecondly both have been shown to work well in the preparation of glycoconjugates 
where the polysaccharide used was a phosphoglycan containing fragile intersaccharidic 
phosphodiester linkages. 
The first possible method was used by Verez-Bencomo and co-workers in 2004 
in the preparation of the synthetic conjugate vaccine against Haemophilus influenza 
type b86which is composed of ribosylribitol phosphate repeating units (see Figure 7, 
section 1.1.6). In this approach the desired protein is first treated with bis-succinimidyl 
di(3-thiopropionate) (Scheme 42).117 
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Scheme 42: Protein modification using N-hydroxysuccinimide di(3-thiopropionate). 
 
Following addition treatment with dithiothreitol (DTT) gives the required thiolated 
protein suitable for conjugation. The linker containing phosphoglycans (83 or 84) must 
also be modified with 3-(maleimido)propionic acid N-hydroxysuccinimide ester 
(Scheme 43). 
81 
 
 
 
N
O
O
O
N
O
O
O
3-(Maleimido)propionic acid N-hydroxysuccinimide ester
OHO
NHAc
O
AcO
P
O-
O
OHO
NHAc
OMe
AcOO
Na+
H2N(H2C)6O
P
O-
O
O
Na+
83
+
OHO
NHAc
O
AcO
P
O-
O
OHO
NHAc
OMe
AcOO
Na+
N(H2C)6O
P
O-
O
O
Na+N
O
O
O
H
PROTEIN CARRIER NH
SHO
m
OHO
NHAc
O
AcO
P
O-
O
OHO
NHAc
OMe
AcOO
Na+
N(H2C)6O
P
O-
O
O
Na+N
O
O
O
H
PROTEIN CARRIER NH
SO
m
 
Scheme 43: Phosphoglycan modification and protein conjugation. 
 
The resulting 3-(maleimido)propionamido phosphoglycan derivative can then be 
conjugated to the thiolated protein resulting in a glycoconjugate suitable for antigenicity 
trials.  
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Another suitable method was developed by Pozsgay and Kubler-Kielb in 
2005.118 It is based on the known oxime formation between a protein modified with O-
alkyl hydroxylamine grouping and a phosphoglycan modified with a carbonyl group 
containing spacer. 
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Scheme 44: Protein modification using succinimidyl 3-(bromoacetamido)propionateand O-(3-
thiopropyl)hydroxylamine. 
 
To this end, the chosen protein is first treated with succinimidyl 3-
(bromoacetamido)propionate(Scheme 44). The resulting bromoacylated protein then 
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reacted with O-(3-thiopropyl)hydroxylamine, thus making corresponding 
aminooxylated protein derivative. 
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Scheme 45: AlternativePhosphoglycan modification and protein conjugation. 
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With subsequent treatment of the linker containing phosphoglycan (83 or 84) with 5-
ketohexanoic anhydride the conjugation of the prepared 5-ketohexanoyl phosphoglycan 
derivative to the previously modified aminooxylated protein can be performed (Scheme 
45). This again would hopefully provide glycoconjugates suitable for further testing in 
antigenicity trials. 
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CHAPTER 3 
3.  EXPERIMENTAL 
 
General Procedures  
Melting points were determined on a Griffin melting point apparatus and are 
uncorrected.  Optical rotations were measured with a Perkin-Elmer 141 polarimeter at 
22 oC; [α]D values are given in units of 10
-1 deg cm2 g-1. 1H, 13C and 31P NMR spectra 
were recorded with Bruker AVANCE 500 MHz spectrometer, unless otherwise 
indicated. Chemical shifts (δ in ppm)are given relative to those for Me4Si (for 
1H and 
13C) and external aq. 85% H3PO4 (for 
31P); all J values are given in Hz.  ES mass 
spectra were recorded with a Mariner™ Biospectrometry Workstation and Aglient 
spectrometer. High resolution mass spectra were recorded on a Bruker microTOF. IR 
spectra were recorded with Nicolet 205 FT-IR spectrometer. Thin layer chromatography 
(TLC) was performed on silica gel60 F254 aluminium plates (Merck) with various 
solvent systems as developers, followed by detection under UV light and/or by charring, 
which was carried out with sulphuric acid-water-ethanol (15:85:5) for protected 
compounds or a mixture of orcinol containing sulphuric acid-ethanol-water (10:75:5) 
for final deprotected compounds. Flash columnchromatography (FCC) was performed 
on Kieselgel 60 (0.040-0.063 mm) (Merck), unless otherwise indicated. 
Dichloromethane, acetonitrile, pyridine and toluene were freshly distilled from CaH2.  
Petroleum ether refers to that with boiling fraction 40-60 oC, unless otherwise stated.  
Solutions worked up were concentrated under reduced pressure at < 40 oC.   
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Methyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α-D-mannopyranoside 62 
 
OO
O N3
OMe
Ph
BzO
62  
 
Triflic anhydride (26.3 ml, 159.5 mmol, 1.8 eq.) was added to a cooled (-30 °C) solution 
of the diol 60 (25 g, 88.6 mmol) in a mixture of CH2Cl2 (100 ml) and pyridine (40 ml). 
The solution was stirred at -30 °C for 2 h, after which benzoyl chloride (14.4 ml, 124 
mmol, 1.4 eq.) was added. Cooling was then discontinued and after warming to room 
temperature the reaction mixture was quenched with saturated aq. NaHCO3 before 
extracting with CH2Cl2. The organic extract was then washed successively with water, 1 
M HCl, water, and brine and finally dried (Na2SO4) before concentrating under reduced 
pressure. The residue (crude 2-triflate) was then dissolved in DMF (150 ml) and NaN3 
(37.3 g, 573 mmol, 6.5 eq) was added. The mixture was then heated to 70 °C with 
stirring for 16 h. The reaction mixture was then diluted with EtOAc before washing 
with water, brine and dried (Na2SO4), before concentrating under reduced pressure. 
FCC [toluene-EtOAc, (95:5)] of the residue gave the azido derivative 62 (26.60 g, 73%, 
64.68 mmol,) as an amorphous solid. 
 
υmax (film)/cm-1 (inter alia): 1723 (C=O), 2104 (-N3); 
[α]D +63.1 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 3.37 (3H, s, OCH3), 3.81 (1H, t, J5,6a = J6a,6b = 10.2, H-
6a), 3.91 (1H, ddd, J5,6b 4.6, H-5), 4.15 (1H, t, J3,4 = J4,5 = 10.0, H-4), 4.20 (1H, dd, J2,3 
3.9, H-2), 4.23 (1H, dd, J5,6b 4.6, H-6b), 4.69 (1H, d, J1,2 1.5, H-1), 5.54 (1H, s, PhCH), 
5.67 (1H, dd, J2,3 3.9, H-3) and 7.24-8.05 (10H, m, 2 x Ph); 
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13C NMR (125 MHz; CDCl3): δC 55.25 (OCH3), 62.44 (C-2), 63.92 (C-5), 68.73 (C-6), 
70.47  (C-3), 76.30 (C-4), 100.04 (C-1), 101.89 (PhCH), 126.13-137.04 (Ph) and 165.59 
(C=O). 
 
ES-MS(+): found m/z 434.13 [M+Na]+ (C21H21N3O6requires M, 411.1430). 
High resolution ES-MS(+): found m/z 412.1498 [M+H]+ (C21H22N3O6
+ requires m/z, 
412.1503), 429.1760 [M+NH3+H]
+ (C21H25N4O6
+ requires m/z, 429.1774); (C21H21N3O6 
requires M, 411.1430). 
 
 
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-α-D-mannopyranose 64 
 
 
 
A solution of 4.5 M sodium methoxide in methanol (1.00 ml) was added to a stirring 
solution of compound 62 (3 g, 7.29 mmol) in a mixture of CH2Cl2 (30 ml) and methanol 
(30 ml). The solution was then stirred at room temperature for 1 h after which it was 
deionised with the addition of DOWEX 50WX4-50 (H+) resin. The resin was then 
filtered off and the filtrate was concentrated under reduced pressure. The residue was 
co-evaporated with toluene (3 x 50 ml) and then dissolved in acetic anhydride (30 ml) 
and cooled to 0 °C, before the addition of 2% (v/v) H2SO4 in acetic anhydride (600 µl). 
The solution was maintained at 0 °C with stirring for 4 h, then allowed to warm to room 
temperature and stirred for an additional 1 h. Ice was added to quench the reaction. The 
mixture was allowed to stir for 1 h and then extracted with CH2Cl2. The organic layer 
was washed with water, saturated aq. NaHCO3, and dried (Na2SO4) before 
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concentrating under reduced pressure. FCC [toluene-EtOAc, (9:1)] of the residue gave 
the tetra-acetate derivative 64 (2.21 g, 81%) as an amorphous solid. 
 
υmax (film)/cm
-1 (inter alia): 1724 (C=O), 2102 (-N3); 
[α]D +86.7 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.99, 2.04, 2.06 and 2.10 (12H, 4 x s, 4 x Ac), 3.95 (1H, 
ddd, J5,6a 2.3, H-5), 3.97 (1H, dd, J2,3 3.4, H-2), 4.03 (1H, dd, J6a,6b 12.5, H-6a), 4.19 (1H, 
dd, J5,6b 4.5, H-6b), 5.29-5.36 (2H, m, H-3 and H-4) and 6.05 (1H, d, J1,2 1.9, H-1); 
13C NMR (125 MHz; CDCl3): δC 20.57, 20.67, 20.78 and 20.95 (CH3CO), 60.52 (C-2), 
61.77 (C-6), 65.29 (C-4), 70.58 and 70.76 (C-3 and C-5), 91.38 (C-1) and 168.26, 169.42, 
170.13 and 170.79 (CH3C=O). 
 
ES-MS(+): found m/z 396.10 [M+Na]+ (C14H19N3O9 requires M, 373.1121). 
High resolution ES-MS(+): found m/z 391.1471 [M+NH3+H]
+ (C14H23N4O9
+ requires m/z, 
391.1465), 396.1029 [M+Na]+ (C14H19N3NaO9
+ requires m/z, 396.1019), 769.2146 
[2M+Na]+ (C28H38N6NaO18
+ requires m/z, 769.2140); (C14H19N3O9 requires M, 373.1121). 
 
 
Ethyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-1-thio-α-D-mannopyranoside 65 
 
 
 
Ethanethiol (405 µl, 5.46 mmol, 2 eq.) and BF3
.Et2O (1.38 ml, 10.92 mmol, 4 eq.) were 
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added to a solution of the tetra-acetate 64 (1.02 g, 2.73 mmol) in CH2Cl2 (10 ml) prior 
to the addition of freshly activated 4Å molecular sieves (1 g). The solution was then 
stirred under argon for 16 h before quenching the reaction with the addition of Et3N (2.5 
ml, 17.8 mmol). The reaction mixture was then applied directly onto a SiO2 column and 
flushed with toluene to remove the excess ethanethiol. The product was then eluted 
from the column with toluene-EtOAc (1:1) and corresponding fractions were combined 
and concentrated under reduced pressure. FCC [toluene-EtOAc, (9:1)] of the residue 
gave the thioglycoside derivative 65 (938 mg, 91%). 
 
υmax (film)/cm
-1 (inter alia): 1722 (C=O), 2101 (-N3); 
[α]D +91.4 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.25 (3H, t, J 7.4, CH2CH3), 1.99, 2.03 and 2.04 (9H, 3 x 
s, 3 x Ac), 2.51-2.65 (2H, m, SCH2), 4.02 (1H, dd, J6a,6b 12.3, H-6a), 4.06 (1H, dd, J2,3 
3.6, H-2), 4.22 (1H, dd, J5,6b 4.9, H-6b), 4.29 (1H, ddd, J5,6a 2.3, H-5), 5.23 (1H, dd, J2,3 
3.6, H-3), 5.27 (1H, d, J1,2 1.4, H-1) and 5.28 (1H, t, J3,4 = J4,5 = 9.7, H-4); 
13C NMR (125 MHz; CDCl3): δC 14.70 (CH3CH2), 20.55, 20.67 and 20.73 (CH3CO), 
25.44 (SCH2), 62.12 (C-6), 62.79 (C-2), 66.06 (C-4), 68.70 (C-5), 71.32 (C-3), 82.32 (C-
1) and 169.57, 169.91 and 170.70 (CH3C=O). 
 
ES-MS(+): found m/z 398.10 [M+Na]+ (C14H21N3O7S requires M, 375.1100).  
High resolution ES-MS(+): found m/z 393.1448 [M+NH3+H]
+ (C14H25N4O7S
+ requires 
m/z, 393.1444), 398.1004 [M+Na]+ (C14H21N3NaO7S
+ requires m/z, 398.0998),773.2100 
[2M+Na]+ (C28H42N6NaO14S2
+ requires m/z, 773.2098); (C14H21N3O7S requires M, 
375.1100). 
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Ethyl 3-O-acetyl-2-azido-2-deoxy-4,6-O-isopropylidene-1-thio-α-D-
mannopyranoside 67 
 
 
 
A solution of 4.5 M sodium methoxide in methanol (250 µl) was added to a stirring 
solution of the thioglycoside 65 (567 mg, 1.51 mmol) in a mixture of CH2Cl2 (10 ml) 
and methanol (10 ml). The solution was then stirred at room temperature for 1h before 
deionising with the addition of DOWEX 50WX4-50 (H+) resin. The resin was then 
filtered off and the filtrate was concentrated under reduced pressure. The residue was 
co-evaporated with toluene (3 x 20 ml) and then dissolved in a mixture of DMF (4 ml) 
and dry acetone (0.8 ml). 2,2-Dimethoxypropane (1.2 ml) and p-toluenesulphonic acid 
(15 mg) were then added and the solution was stirred at room temperature for 5 h, prior 
acetic anhydride (1.2 ml) and pyridine (4 ml) were added and stirring was continued for 
another 16 h. Water was added and the mixture was extracted with EtOAc. The organic 
layer was washed successively with 1 M HCl, water and saturated aq. NaHCO3 and 
dried (Na2SO4) before concentrating under reduced pressure. FCC [toluene-EtOAc, 
(19:1)] of the residue gave the derivative 67 (400 mg, 80%). 
 
υmax (film)/cm
-1 (inter alia): 1718 (C=O), 2105 (-N3);  
[α]D +73.6 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.29 (3H, t, J 6.4, SCH2CH3), 1.41, (3H, s, CCH3), 
1.52 (3H, s, CCH3), 2.14 (3H, s, Ac), 2.62 (2H, m, SCH2CH3), 3.79-3.86 (2H, m, H-6
a + 
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H-6b), 4.08 (1H, t, J3,4 = J4,5 = 9.7, H-4), 4.13 (1H, m, H-5), 4.21 (1H, dd, J2,3 3.8, H-2), 
5.19 (1H, dd, J2,3 3.8, H-3) and 5.25 (1H, d, J1,2 1.1, H-1); 
13C NMR (125 MHz; CDCl3): δC 14.74 (CH3CH2), 19.21 (CH3C), 20.74 (CH3CO), 25.36 
(CH3CH2), 29.10 (CH3C), 61.96 (C-6), 63.38 (C-2), 65.29 (C-5), 69.00 (C-4), 70.82 (C-3), 
83.09 (C-1), 100.17 (C(CH3)2) and 170.13 (CH3C=O). 
 
ES-MS(+): found m/z 354.11 [M+Na]+ (C13H21N3O5S requires M, 331.12). 
 
 
Ethyl 3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-1-thio-α-D-
mannopyranoside 56a 
 
 
 
Trifluoroacetic acid (1.5 ml) and water (50 µl) was added to a stirred solution of 
compound 67 (160 mg, 0.48 mmol) in CH2Cl2 (15 ml). The mixture was stirred at room 
temperature for 45 min before concentrating under reduced pressure, followed by co-
evaporation with toluene. The residue was then dissolved in pyridine (1.5 ml) followed 
by the addition of p,p’-dimethoxytrityl chloride (204 mg, 0.60 mmol, 1.25 eq.). The 
solution was stirred for 16 h before water was added and the mixture was diluted with 
CH2Cl2. The organic layer was then washed with water, dried (Na2SO4) and 
concentrated before co-evaporation with toluene. FCC [toluene-EtOAc, (19:1)→(4:1)] 
of the residue gave the DMTr derivative 56a (260 mg, 91%). 
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1H NMR (500 MHz; CDCl3): δH 1.29 (3H, t, J 6.4, CH2CH3), 2.15, (3H, s, Ac), 2.62 
(2H, m, CH2CH3), 2.69 (1H, d, J4, 4-OH 3.45, 4-OH), 3.42 (2H, d, J5,65.10, H-6), 3.79 
(6H, s, 2 x OMe), 3.97 (1H, dt, J3,4 = J4,5 = 9.6, H-4), 4.09 (1H, dd, J1,2 1.4, J2,3 3.6, H-
2), 4.12 (1H, dt, J5,65.10, H-5), 5.16 (1H, dd, J3,4 9.6, H-3) and 5.27 (1H, d, J1,2 1.4, H-
1). 
 
 
Ethyl 3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-triethylsilyl-1-
thio-α-D-mannopyranoside 56b 
 
OTESO
DMTrO N3
SEt
AcO
56b  
 
Triethylsilyl triflate (113 µl, 0.50 mmol, 1.25 eq.) was added to a cooled (0 °C) solution 
of compound 56a (238 mg, 0.40 mmol) in a mixture of pyridine (1.5 ml) and Et3N (0.4 
ml). The solution was stirred at 0 °C for 15 min and diluted with water before extraction 
with CH2Cl2. The organic layer was then washed with saturated aq. NaHCO3, before 
concentrating under reduced pressure. Toluene was evaporated off from the residue. 
FCC [toluene-EtOAc, (19:1)] of the residue gave the derivative 56b (243 mg, 86%). 
 
υmax (film)/cm
-1 (inter alia): 1725 (C=O), 2109 (-N3); 
[α]D +58.7 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 0.33 (6H, q, J 8.0, Si(CH2CH3)3), 0.75 (9H, t, J 8.0, 
Si(CH2CH3)3) 1.21 (3H, t, J 7.4, SCH2CH3), 1.94 (3H, s, Ac), 2.53-2.70 (2H, m, 
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SCH2CH3), 3.02 (1H, dd, J5,6a 7.1, J6a,6b 9.7, H-6
a), 3.15 (1H, dd, J5,6b 1.8, H-6
b), 3.60 
(6H, s, 2 x OMe), 3.69 (1H, t, J3,4 = J4,5 = 9.3, H-4), 3.97 (1H, dd, J1,2 1.4, J2,3 3.8, H-2), 
4.07 (1H, ddd, J4,5 9.3,H-5), 4.89 (1H, dd, J2,3 3.8, J3,4 9.3, H-3), 5.21 (1H, d, J1,2 1.4, H-
1) and 6.61-7.30 (13H, m, Ph, 2 x C6H4); 
13C NMR (125 MHz; CDCl3): δC 4.86 (CH3CH2Si), 6.82 (CH3CH2Si), 14.54 (CH3CH2S), 
20.87 (CH3CO), 24.74 (CH3CH2S), 55.22 (CH3O), 62.57 (C-2), 63.25 (C-6), 66.95 (C-4), 
73.24 (C-5), 74.98 (C-3), 81.05 (C-1), 85.90 (Ar3C), 113.02-158.44 (C6H4, Ph) and 170.08 
(CH3C=O). 
 
ES-MS(+): found m/z 730.30 [M+Na]+ (C37H49N3O7SSi requires M, 707.31). 
 
 
Ethyl 3-O-acetyl-2-azido-2-deoxy-4,6-di-O-triethylsilyl-1-thio-α-D-
mannopyranoside 57 
 
 
 
Trifluoroacetic acid (1.5 ml) and water (50 µl) was added to a stirred solution of 
compound 67 (169 mg, 0.51 mmol) in CH2Cl2 (15 ml). The solution was stirred at room 
temperature for 45 min before concentrating under reduced pressure, followed by co-
evaporation with toluene. The residue was then dissolved in a mixture of pyridine (2 ml) 
and Et3N (0.53 ml), the solution was then cooled (0 °C) prior the addition of triethylsilyl 
triflate (288 µl, 1.28 mmol, 2.5 eq.). The solution was stirred at 0 °C for 15 min, 
quenched with water before extraction with CH2Cl2. The organic layer was then washed 
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with saturated aq. NaHCO3 before concentrating under reduced pressure. Toluene was 
evaporated off from the residue. FCC [toluene-EtOAc, (19:1)] of the residue gave the 
derivative 57 (230 mg, 87%). 
 
υmax (film)/cm
-1 (inter alia): 1726 (C=O), 2102 (-N3); 
[α]D +49.6 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 0.51-0.59 (12H, m, 2 x Si(CH2CH3)3), 0.87-0.91 (18H, 
m, 2 x Si(CH2CH3)3) 1.21 (3H, t, J 7.4, SCH2CH3), 2.08 (3H, s, Ac), 2.47-2.64 (2H, m, 
SCH2CH3), 3.71 (1H, dd, J5,6a 5.1, J6a,6b 11.2, H-6
a), 3.76 (1H, dd, J5,6b2.0,  H-6
b), 3.90 
(1H, ddd, J5,6a 5.1, J5,6b2.0, H-5), 3.95 (1H, t, J3,4 = J4,5 = 9.2, H-4), 4.04 (1H, dd, J2,3 
3.8, H-2), 4.99 (1H, dd, J2,3 3.8, H-3) and 5.2 (1H, d, J1,2 1.3, H-1); 
13C NMR (125 MHz; CDCl3): δC 4.48 (CH3CH2Si), 5.05 (CH3CH2Si), 6.72 (CH3CH2Si), 
6.83 (CH3CH2Si),  14.60 (CH3CH2S), 20.92 (CH3CO), 24.91 (CH3CH2S), 61.94 (C-6), 
62.62 (C-2), 66.62 (C-4), 74.33 (C-5), 76.78 (C-3), 81.45 (C-1) and 170.12 (CH3C=O). 
 
ES-MS(+): found m/z 542.25 [M+Na]+ (C22H45N3O5SSi2 requires M, 519.26). 
 
 
Ethyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio-α-D-mannopyranoside 68 
 
 
 
The thioglycoside 65 (750 mg, 2 mmol) was deacetylated as described for the 
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preparation of compound 67. To a stirred solution of the prepared ethyl 2-azido-2-
deoxy-1-thio-α-D-mannopyranoside (2 mmol) and benzaldehyde dimethylacetal (1.15 
ml, 7.49 mmol, 3.75 eq.) in MeCN (20 ml) activated NaHSO4
.SiO2 (500 mg) was 
added. The reaction mixture was stirred at room temperature for 0.5 h and quenched 
with the addition of Et3N (0.5 ml). The mixture was then filtered through a Celite pad 
and the filtrate was concentrated under reduced pressure. FCC [toluene-EtOAc, (9:1)] of 
the residue gave the benzylidene derivative 68 (572 mg, 85%). 
 
υmax (film)/cm-1 (inter alia): 2105 (-N3); 
[α]D +68.9 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.34 (3H, t, J 7.4, SCH2CH3), 2.61 (1H, d, JH,OH 3.9, 3-
OH), 2.61-2.75 (2H, m, SCH2CH3), 3.86 (1H, m, H-6
a), 3.96 (1H, t,  J3,4 = J4,5 = 9.5,  H-
4), 4.13 (1H, dd, J2,3 3.9, H-2), 4.21-4.30 (3H, m, H-4, H-5 and H-6
b), 5.32 (1H, d, J1,2 
1.1, H-1) 5.61 (1H, s, PhCH) and 7.38-7.59 (5H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 14.86 (CH3CH2S), 25.58 (CH3CH2S), 63.85 (C-5), 65.10 
(C-2), 68.48 (C-6), 69.40 (C-3), 79.28 (C-4), 83.30 (C-1), 102.34 (PhCH) and 126.25, 
128.42, 129.40, 137.00 (Ph). 
 
ES-MS(+): found m/z 360.10 [M+Na]+ (C15H19N3O4S requires M, 337.11). 
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Ethyl 3-O-acetyl-2-azido-4,6-O-benzylidene-2-deoxy-1-thio-α-D-mannopyranoside 
69 
 
 
To a stirred solution of compound 68 (570 mg, 1.69 mmol) in pyridine (10 ml) acetic 
anhydride (5 ml) was added. The reaction mixture was stirred at room temperature for 
1.5 h before concentrating under reduced pressure. The residue was then co-evaporated 
three times with toluene. FCC [toluene-EtOAc, (19:1)] of the residue gave the 
benzylidene derivative 69 (632 mg, 98%). 
 
υmax (film)/cm
-1 (inter alia): 1720 (C=O), 2103 (-N3); 
[α]D +86.7 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.24 (3H, t, J 7.4 SCH2CH3), 2.06 (1H, s, Ac), 2.51-
2.65 (2H, m, SCH2CH3), 3.79 (1H, t, J5,6a = J6a,6b = 10.3, H-6
a), 4.03 (1H, t,  J3,4 = J4,5 = 
9.9,  H-4), 4.16 (1H, dd, J5,6b  4.9, H-6
b), 4.19 (1H, dd, J1, 2 1.1, H-2), 4.27 (1H, ddd, H-
5) and 5.22 (1H, d, H-1) 5.31 (1H, dd, J2, 3 3.8, H-3), 5.50 (1H, s, PhCH) and 7.25-7.42 
(5H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 14.77 (CH3CH2S), 21.20 (CH3CO), 25.46 (CH3CH2S), 
63.39 (C-2), 64.34 (C-5), 68.48 (C-6), 70.41 (C-3), 76.31 (C-4), 83.18 (C-1), 102.02 
(PhCH) and 126.23, 128.33, 129.23, 137.10 (Ph) and 170.00 (CH3C=O). 
 
ES-MS(+): found m/z 402.11 [M+Na]+ (C17H21N3O5S requires M, 379.12). 
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Ethyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-1-thio-α-D-mannopyranoside 70 
 
 
A solution of 1 M BH3 in THF (6.45 ml, 6.45 mmol, 3 eq.) was added to compound 69 
(821 mg, 2.15 mmol) at 0 oC. A solution of 1 M Bu2BOTf in CH2Cl2 (2.15 ml, 2.15 
mmol, 1 eq.) was then added slowly under stirring and the mixture was left to stir at 0 
oC for 1 h. The reaction was then quenched with the addition of Et3N (0.6 ml) and 
methanol (5 ml). The solution was then concentrated under reduced pressure followed 
by co-evaporation with methanol. FCC [toluene-EtOAc, (9:1)] of the residue gave the 
derivative 70 (672 mg, 82%). 
 
υmax (film)/cm
-1 (inter alia): 1719 (C=O), 2107 (-N3); 
[α]D +54.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.22 (3H, t, J 7.4, SCH2CH3), 1.99 (3H, s, Ac), 2.48-
2.62 (2H, m, SCH2CH3), 3.72-3.76 (2H, m, H-6
a,b), 3.92 (1H, t,  J3,4 = J4,5 = 9.5, H-4), 
4.02 (1H, dt, J5,6 3.0, H-5), 4.08 (1H, dd, J1, 2 1.5, H-2), 4.61 and 4.65 (2H, 2 x d, J 11.3, 
PhCH2), 5.19 (1H, d, J1, 2 1.5, H-1) 5.25 (1H, dd, J2, 3 3.8, H-3) and 7.22-7.32 (5H, m, 
Ph); 
13C NMR (125 MHz; CDCl3): δC 14.85 (CH3CH2S), 20.75 (CH3CO), 25.35 (CH3CH2S), 
61.6 (C-6), 63.14 (C-2), 72.23 (C-5), 72.81 (C-4), 73.91 (C-3), 75.11 (PhCH2) 82.20 (C-
1), 127.81, 127.99, 128.56, 136.50 (Ph) and 172.86 (CH3C=O). 
 
ES-MS(+): found m/z 404.13 [M+Na]+ (C17H23N3O5S requires M, 381.14). 
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Ethyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-6-O-(p,p’-dimethoxytrityl)-1-thio-α-
D-mannopyranoside 58 
 
 
 
p,p’-Dimethoxytrityl chloride (413 mg, 1.22 mmol, 1.5 eq.) was added to a solution of 
compound 70 (310 mg, 813 µmol) in pyridine (10 ml), after which DMAP (20 mg) was 
added the mixture left under stirring for 16 h. The reaction mixture was then quenched 
with water and diluted with CH2Cl2. The solution was then washed with water, dried by 
filtration through cotton wool and concentrated before co-evaporation with toluene. 
FCC [toluene-EtOAc, (19:1)→(4:1)] of the residue gave the DMTr derivative 58 (260 
mg, 91%). 
 
υmax (film)/cm
-1 (inter alia): 1722 (C=O), 2101 (-N3); 
[α]D +37.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.26 (3H, t, J 7.4, SCH2CH3), 2.00 (3H, s, Ac), 2.54-
2.70 (2H, m, SCH2CH3), 3.17 (1H, dd, J5,6a  4.6, J6a,6b 10.2, H-6
a), 3.40 (1H, dd,  J5,6b 
1.9,  H-6b), 3.70 (6H, s, 2 x OCH3), 3.93 (1H, t, J3,4 = J4,5 = 9.5, H-4), 4.07 (1H, dd, J1,2 
1.6, H-4), 4.15 (1H, ddd, H-5), 4.19 and 4.40 (2H, 2 x d, J 10.9, PhCH2) 5.20 (1H, dd, 
J2,3 3.8, H-3), 5.33 (1H, d, J1,2 1.6, H-1) and 6.67-7.46 (18H, m, Ph, C6H4); 
13C NMR (125 MHz; CDCl3): δC 14.72 (CH3CH2S), 20.81 (CH3CO), 25.17 (CH3CH2S), 
55.22 (2 x CH3O) 62.15 (C-6), 63.02 (C-2), 71.92 (C-5), 73.46 (C-4), 73.91 (C-3), 74.84 
(PhCH2), 81.74 (C-1), 113.08, 126.72, 127.73, 127.83, 128.26, 130.13, 130.22, 135.88, 
136.16, 137.67, 144.92, 158.44 (Ph, C6H4) and 170.00 (CH3C=O). 
ES-MS(+): found m/z 706.26 [M+Na]+ (C38H41N3O7S requires M, 683.27)  
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Ethyl 3-O-acetyl-2-azido-4-O-benzyl-6-O-(tert-butyldimethylsilyl)-2-deoxy-1-thio-
α-D-mannopyranoside 59 
 
 
 
Tert-butyldimethylsilyl chloride (165 mg, 1.10 mmol, 1.5 eq.) was added to a solution 
of compound 70 (279 mg, 731 µmol) in pyridine (5 ml), after which DMAP (20 mg) 
was added and the mixture left under stirring for 16 h. The reaction mixture was then 
quenched with water and diluted with CH2Cl2. The solution was then washed with 
water, dried by filtration through cotton wool and concentrated before co-evaporation 
with toluene. FCC [toluene-EtOAc, (19:1)→(4:1)] of the residue gave the TBS 
derivative 59 (341 mg, 94%). 
 
υmax (film)/cm
-1 (inter alia): 1718 (C=O), 2107 (-N3); 
[α]D +38.5 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH -0.02, 0.00 (6H, 2 x s, (CH3)2Si), 1.83 (9H, s, Me3CSi), 
1.20 (3H, t, J 7.4, SCH2CH3), 1.96 (3H, s, Ac), 2.46-2.62 (2H, m, SCH2CH3), 3.70 (1H, 
dd, J5,6a  1.8, J6a,6b 11.5, H-6
a), 3.78 (1H, dd,  J5,6b 4.5,  H-6
b), 3.89 (1H, t, J3,4 = J4,5 = 9.5, 
H-4), 3.96 (1H, ddd, H-5), 4.02 (1H, dd, H-2), 4.58 and 4.61 (2H, 2 x d, J 11.4, PhCH2), 
5.19 (1H, dd, J1,2 1.6, H-1), 5.21 (1H, dd, J2,3 3.8, H-3) and 7.05-7.32 (5H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC -5.36, -5.15 (2 x Me2Si) 14.68 (CH3CH2S), 17.77 
(Me3C) 20.81 (CH3CO), 25.05 (CH3CH2S), 25.89 (Me3C) 62.12 (C-6), 62.99 (C-2), 73.04 
(C-5), 73.18 (C-4), 73.85 (C-3), 74.92 (PhCH2), 81.65 (C-1), 127.72, 127.84, 128.47, 
133.40 (Ph) and 170.00 (CH3C=O). 
ES-MS(+): found m/z 518.21 [M+Na]+ (C23H37N3O5SSi requires M, 495.22). 
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Attempted glycosylation of dec-9-en-1-ol using the thioglycosidic donor 57 
 
 
 
A solution of the thioglycoside 57 (160 mg, 308 µmol) in CH2Cl2 was prepared under 
argon. To this dec-9-en-1-ol (71.4 µl, 400 µmol, 1.3 eq) and freshly activated 4Å 
molecular sieves was added. The mixture was cooled to -20 ºC and allowed to stir for 
30 minutes. N-iodosuccinimide (90 mg, 400 µmol, 1.3 eq.) and silver triflate (40 mg, 
156 µmol, 0.5 eq) were added and stirring continued for 4.5 hr. The reaction mixture 
was quenched with addition of triethylamine (250 µl) before diluting with CH2Cl2. The 
solution was filtered through celite topped with cotton wool and the filtrate was washed 
with 10% aq. Na2S2O3. The organic layer was concentrated under reduced pressure. 
TLC analysis showed that an array of products formed. 
 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α,β-D-mannopyranose 71 
 
 
To a stirred solution of the tetra-acetate 64 (510 mg, 1.37 mmol) in THF (1 ml) was 
added solution of 2 M dimethylamine in THF (1.7 ml, 3.35 mmol, 2.5 eq). Stirring was 
continued for 0.5 h. The mixture was then concentrated under reduced pressure. FCC 
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[toluene-EtOAc, (9:1)] of the residue gave the hemiacetal 71 (450mg, 99%). 
 
υmax (film)/cm
-1 (inter alia): 1721 (C=O), 2102 (-N3); 
 
1H NMR (500 MHz; CDCl3): δH (signals of the α-anomer only) 1.992, 2.042 and 2.046 (3 
x s, 3 x Ac), 4.01 (dd, J2,3 3.7, H-2), 4.07 (dd, J5,6a 2.1, J6a,6b 11.8, H-6
a), 4.10-4.18 (m, H-
5, H-6b), 5.22 (d, J1,2 1.8, H-1), 5.28 (t, J3,4 = J4,5 9.8, H-4) and 5.40 (dd,  H-3); (selected 
signals of the  β-anomer) 1.988, 2.038 and 2.059 (3 x s, 3 x Ac),  3.57 (1H, ddd, J5,6a 2.3, 
J5,6b 5.1, J4,5 9.9, H-5), 4.84 (1H, d, J1,2 1.2, H-1), 5.07 (1H, dd, J2,3 3.7, J3,4 9.9, H-3); α:β 
= 4:1. 
 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranosyl trichloroacetimidate 72 
 
 
 
The hemiacetal 71 (276 mg, 833 µmol) was dissolved in dichloromethane (5 ml) under 
an atmosphere of argon. The solution was cooled to 0 ºC before addition of 
trichloroacetonitrile (251 µl, 2.50 mmol, 3 eq.) and DBU (35 µl, 250µmol, 0.3 eq.). 
Stirring was then continued for 1 h at 0 ºC after which the solution was concentrated 
under reduced pressure. FCC [toluene-EtOAc, (9:1)] of the residue gave the 
trichloroacetimidate derivative 72 (270 mg, 68%). 
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1H NMR (500 MHz; CDCl3): δH 2.00, 2.03 and 2.06 (9H, 3 x s, 3 x Ac), 4.06-4.10 (2H, m, 
H-5, H-6a), 4.19 (1H, dd, J5,6a 5.0, J6a,6b 12.9, H-6
b), 4.22 (1H, dd, J2,3 3.3, H-2), 5.34-4.41 
(2H, m, H-3, H-4), 6.23 (1H, d, J1,2 1.9, H-1) and 8.72 (1H, s, NH).  
 
 
Dec-9-enyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-mannopyranoside 73 
 
 
 
A solution of the trichloroacetimidate 72 (270 mg, 568 µmol) and dec-9-en-1-ol (254 
µl, 1.99 mmol, 3.5 eq) in dichloromethane (5 ml) was prepared under argon. Freshly 
activated 4Å molecular sieves (70 mg) were added and the mixture was cooled to 0 ºC 
with stirring. TMSOTf (1 µl, 5.50 µmol, 0.01 eq.) was then added and stirring continued 
for 0.5 h. The reaction was then quenched with triethylamine (250 µl) before diluting 
the mixture with chloroform. The mixture was then filtered through cotton wool and the 
filtrate was then washed successively three times with water. The solvent was then 
removed under reduced pressure. FCC [petroleum ether-EtOAc, (1:0→4:1)] of the 
residue gave the glycoside derivative 73 (248 mg, 93%). 
 
υmax (film)/cm
-1 (inter alia): 2103 (-N3); 
[α]D +81.4 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.20-1.35 (8H, m, 4 x CH2), 1.48-1.56 (4H, m, 2 x CH2), 
1.95-2.00 (2H, m, CH2), 1.98, 2.03 and 2.04 (9H, 3 x s, 3 x Ac), 3.37(1H, dt, 
2
JH,H 9.6, 
3
JH,H 6.6, OHCHCH2), 3.59 (1H, dt, OHCHCH2), 3.85 (1H, ddd, J5,6a 2.3, H-5), 3.94 (1H, 
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dd, J1,2 1.7, H-2), 4.02 (1H, dd, J6a,6b 12.3, H-6
a), 4.18 (1H, dd, J5,6b 4.9, H-6
b), 4.76 (1H, 
d, H-1), 4.86 (1H, br d,3JH,H 10.2, CH=HCH), 4.93 (1H, br d,
3
JH,H 17.1, CH=HCH),  5.25 
(1H, t, J3,4 = J4,5 = 9.9, H-4), 5.32 (1H, dd, J2,3 3.8, H-3) and 5.75 (1H, m, CH=CH2); 
13C NMR (125 MHz; CDCl3): δC 20.61 and 20.78 (CH3CO), 26.07, 38.90, 29.07, 29.25, 
29.30, 29.39, and 33.78 (CCH2C), 61.69 (C-2), 62.24 (C-6), 66.05 (C-4), 68.39 (C-3), 
68.51 (OCH2), 71.17 (C-5), 97.97 (C-1), 114.21 (CH=CH2), 139.17 (CH=CH2) and 
169.62, 169.99 and 171.13 (C=O). 
 
ES-MS(+): found m/z 492.23 [M+Na]+ (C22H35N3O8 requires M, 469.24). 
 
 
Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-4,6-O-isopropylidene-α-D-
mannopyranoside 74 
 
 
 
A solution of 4.5 M sodium methoxide in methanol (250 µl) was added to a stirring 
solution of compound 73 (245 mg, 522 µmol) in a mixture of CH2Cl2 (1 ml) and 
methanol (6 ml). The solution was then stirred at room temperature for 1 h prior the 
addition of DOWEX 50WX4-50 (H+) resin. The resin was then filtered off and the 
filtrate was concentrated under reduced pressure. The residue was co-evaporated with 
toluene (3 x 20 ml) and then dissolved in a mixture of DMF (2 ml) and dry acetone (400 
µl). 2,2-Dimethoxypropane (478 µl, 3.90 mmol) and toluenesulphonic acid (10 mg) 
were then added and the solution was stirred at room temperature for 16 h. Pyridine (2 
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ml) and acetic anhydride (600 µl) were then added and stirring was continued for 2.5 h. 
Water was then added and the mixture was extracted with EtOAc. The organic layer 
was washed successively with 1 M HCl, water, saturated aq. NaHCO3 and dried (by 
filtration though cotton wool) before concentrating under reduced pressure. FCC 
[toluene-EtOAc, (19:1)] of the residue gave the derivative 74 (172 mg, 78%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +72.8 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.20-1.35 (8H, m, 4 x CH2), 1.33 (3H, s, CCH3), 1.45 
(3H, s, CCH3), 1.46-1.55 (4H, m, 2 x CH2), 1.95-2.00 (2H, m, CH2), 2.07 (3H, s, Ac), 
3.30 (1H, dt, 2JH,H 9.6, 
3
JH,H 6.6, OHCHCH2), 3.57 (1H, dt, OHCHCH2), 3.64 (1H, m, H-
5), 3.70-3.78 (2H, m, H-6a,b), 3.98 (1H, t, J3,4 = J4,5 = 9.8, H-4), 4.03 (1H, dd, J1,2 1.4, H-
2), 4.66 (1H, d, H-1), 4.86 (1H, br d,3JH,H 10.2, CH=HCH), 4.93 (1H, br d,
3
JH,H 17.1, 
CH=HCH),  5.20 (1H, dd, J2,3 3.9, H-3) and 5.75 (1H, m, CH=CH2); 
13C NMR (125 MHz; CDCl3): δC (selected signals) 19.22 (CH3C), 20.75 (CH3CO), 26.04, 
28.90, 29.13, 29.28, 33.78 (CCH2C and CH3C), 62.24 (C-2), 64.67 (C-6), 68.25, 68.88, 
70.73 (C-3, C-4, C-5 and OCH2), 98.87 (C-1) and 114.21 (C=CH2). 
 
 
 
 
 
 
 
105 
 
 
 
Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-triethylsilyl-
α-D-mannopyranoside 75 
 
 
 
Trifluoroacetic acid (1 ml) and water (33 µl) were added to a stirring solution of 
compound 74 (165 mg, 391 µmol) in CH2Cl2 (10 ml). The solution was stirred at room 
temperature for 30 min before concentrating under reduced pressure, followed by co-
evaporation with toluene. The residue was then dissolved in pyridine (2 ml) followed by 
the addition of p,p’-dimethoxytrityl chloride (172 mg, 508 µmol, 1.3 eq.) and the 
solution was stirred for 16 h. Triethylamine (500 µl) was then added and the solution 
cooled to 0 ºC followed by the addition TESOTf (114 µl, 508 µmol, 1.3 eq). The 
solution was stirred at 0 °C for 3 h, water (1 ml) was added and stirring was continued 
for a further 1 h. The solution was then diluted with dichloromethane, washed with 
saturated aq. NaHCO3, dried by filtration through cotton wool before concentrating 
under reduced pressure. FCC [petroleum ether-EtOAc, (1:0→4:1)] of the residue gave 
the derivative 75 (245 mg, 78%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +48.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 0.25-0.38 (6H, m, 3 x CH3CH2Si), 0.75 (9H, t, J 8.0, 3 x 
CH3CH2Si), 1.25 (12H, m, 6 x CH2), 1.67 (2H, m, CH2), 2.02 (2H, m, CH2), 2.12 (3H, s, 
Ac), 3.17 (1H, dd, J5,6a 7.3, J6a,6b 9.5, H-6
a), 3.30 (1H, dd, J5,6b 1.4, H-6
b), 3.52(1H, dt, 
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2
JH,H 9.6, 
3
JH,H 6.6, OHCHCH2), 3.78 (6H, 2 x s, 2 x OMe), 3.82 (1H, t, J3,4 = J4,5 = 9.4, H-
4), 3.85-3.93 (2H, m, OHCHCH2 and H-2), 4.05 (1H, dd, J1,2 1.6, H-2), 4.85 (1H, d, H-1), 
4.92 (1H, br d,3JH,H 10.2, CH=HCH), 4.98 (1H, br d,
3
JH,H 17.1, CH=HCH), 5.11 (1H, dd, 
J2,3 3.9, H-3), 5.80 (1H, m, CH=CH2) and 6.78-7.49 (13H, m, Ph, C6H4). 
 
ES-MS(+): found m/z 824.43 [M+Na]+ (C45H63N3O8S requires M, 801.44). 
 
 
Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranoside 78 
 
 
 
The dec-9-enyl glycoside 75 (100 mg, 125 µmol) was dissolved in CH2Cl2 (5 ml) and 
the solution was cooled to 0 ºC under stirring. A mixture of CH2Cl2-TFA (49:1, 5 ml) 
was then prepared and cooled to 0 ºC before adding to the stirring solution. After 1 min 
the reaction was quenched with the addition ofsaturated aq. NaHCO3. The solution was 
then diluted with CH2Cl2, washed with saturated aq. NaHCO3, water, dried by filtration 
though through cotton wool and concentrated under reduce pressure. FCC [petroleum 
ether-EtOAc, (1:0→4:1)] of the residue gave the derivative 78 (60 mg, 96%). 
 
1H NMR (500 MHz; CDCl3): δH 0.25-0.38 (6H, m, 3 x CH3CH2Si), 0.75 (9H, t, J 8.0, 3 x 
CH3CH2Si), 1.25 (12H, m, 6 x CH2), 1.67 (2H, m, CH2), 2.02 (2H, m, CH2), 2.12 (3H, s, 
Ac), 3.17 (1H, dd, J5,6a 7.3, J6a,6b 9.5, H-6
a), 3.30 (1H, dd, J5,6b 1.4, H-6
b), 3.52(1H, dt, 
2
JH,H 9.6, 
3
JH,H 6.6, OHCHCH2), 3.78 (6H, 2 x s, 2 x OMe), 3.82 (1H, t, J3,4 = J4,5 = 9.4, H-
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4), 3.85-3.93 (2H, m, OHCHCH2 and H-2), 4.05 (1H, dd, J1,2 1.6, H-2), 4.85 (1H, d, H-1), 
4.92 (1H, br d,3JH,H 10.2, CH=HCH), 4.98 (1H, br d,
3
JH,H 17.1, CH=HCH), 5.11 (1H, dd, 
J2,3 3.9, H-3) and 5.80 (1H, m, CH=CH2). 
 
 
3-O-Acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-triethylsilyl-α,β-D-
mannopyranose 76 
 
 
 
The thioglycoside 56 (270 mg, 381 µmol) was dissolved in wet dichloromethane (10 
ml) and cooled to -20 ºC with stirring. N-iodosuccinimide (103 mg, 457 µmol, 1.2 eq) 
and silver triflate (5 mg, 19 µmol, 0.05 eq) was then added and stirring was continued at 
-20 ºC for 0.5 h. Two drops of water (~66 µl) was then added and the mixture was 
stirred for another 0.5 h. The reaction was then diluted with dichloromethane and the 
solution was washed successively with 0.5 aq. Na2S2O2, water and dried by filtration 
through cotton wool. The solvent was then removed under reduced pressure. FCC 
[toluene-EtOAc, (19:1)] of the residue gave the hemiacetal derivative 76 (100 mg, 
40%). 
 
1H NMR (500 MHz; CDCl3): δH(signals of the α-anomer only) 0.26-0.39 (m, 3 x 
CH3CH2Si), 0.75 (m,3 x CH3CH2Si) 2.14 (s, Ac), 2.89 (d, J1,OH 3.4, 1-OH) 3.17 (dd, J6a,6b 
9.9, H-6a), 3.38 (dd, J5,6b 1.9, H-6
b), 3.78 (s, 2 x OMe), 3.96 (t, J3,4 = J4,5 = 9.2, H-4), 4.08 
(ddd, J5,6a 6.7, H-5), 4.12 (dd, J1,2 1.9,H-2), 5.19 (dd, J2,3 3.6, H-3), 5.21 (m, H-1) and 
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6.80-7.51 (m, Ph, 2 x C6H4); (selected signals of the  β-anomer) 2.16 (s, Ac), 3.38 (d, J1,OH 
10.0, 1-OH),3.48 (m,H-5),3.92 (t, J3,4 = J4,5 = 9.1, H-4), 4.15 (dd, J2,3 3.6,H-2), 4.84 (dd,H-
3), 4.95 (dd, J1,2 1.3, H-1); α:β = 3.4:1. 
 
 
Triethylammonium 3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-
triethylsilyl-α,β-D-mannopyranosyl hydrogenphosphonate 77 
 
OTESO
DMTrO N3
AcO
3.5:1 ( : )
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O-
H
O
Et3NH
+
 
 
To a stirred solution of imidazole (130 mg, 1.90 mmol, 14 eq) in MeCN (3.5 ml) at 0 ºC 
was added PCl3 (47 µl, 544 µmol, 4 eq) and then triethylamine (284 µl, 2.04 mmol, 15 
eq). The mixture was stirred for 0.5 h. A solution of the hemiacetal 76 (90 mg, 136 
µmol) in MeCN (3.5 ml) was then added dropwise at 0 ºC over 0.5 h. Cooling was then 
ceased and the mixture was allowed to warm to room temperature with stirring for 0.5 h 
before 0.5 M TEAB (triethylammonium hydrogen carbonate) buffer (pH 7) was added 
to quench the reaction. To clear solution chloroform was added, and the organic layer 
was then washed in turn twice with water, twice with 0.5 M TEAB buffer and dried by 
filtration through cotton wool. The solvent was then removed under reduced pressure. 
FCC [CH2Cl2-methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the H-
phosphonate 77 (95 mg, 84%). 
 
1H NMR (500 MHz; CDCl3): δH(signals of the α-anomer only) 0.15-0.30 (m, 
Si(CH2CH3)3), 0.66 (t, J 8.0, Si(CH2CH3)3) 1.27 (t, J 7.3, 3 x NCH2CH3), 2.05 (s, Ac), 
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3.00 (q, 3 x NCH2CH3), 3.08 (dd, J5,6a 3.3, J6a, 6b 9.4, H-6
a), 3.26 (dd, J5,6b 1.7, H-6
b), 3.71 
(s, 2 x OMe), 3.92 (t, J3,4 = J4,5 = 9.4, H-4), 4.01-4.04 (m, H-5), 4.05 (dd, J1,2 2.0, H-2), 
5.13 (dd, J2,3 3.8, H-3), 5.67 (dd, , J1,P 8.7, H-1), 7.09 (d, JP,H 635.6, PH) and 6.69-7.47 (m, 
Ph, C6H4); (selected signals of the  β-anomer) 4.08 (dd, J2,3 3.7,H-2), 4.69 (dd, J3,4 9.3,H-
3), 4.45 (dd, J1,2 1.0, J1,P 8.8, H-1), 7.15 (1H, d, JP,H 641.8, PH); 
31P NMR (202 MHz; CDCl3): δP 0.22 (α-anomer) and 0.59(β-anomer); α:β = 3.2:1 . 
 
 
Triethylammonium 3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-
triethylsilyl-α-D-mannopyranosyl hydrogenphosphonate 77 
 
 
 
The H-phosphonate 77 (85 mg, 102 µmol) was dissolved in a mixture of CH2Cl2 (2.1 
ml) and methanol (0.5 ml). A solution of silver triflate (50 mg, 200 µmol, 2 eq.) in 
toluene (1 ml) was added under stirring. Stirring was then continued for 45 min before 
quenching the reaction with the addition of 0.5 M TEAB buffer, followed by the 
aqueous work-up as described for the preparation of compound 77. FCC [CH2Cl2-
methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the pure α-H-phosphonate 
derivative 77 (46 mg, 37%). 
 
[α]D +29.4 (c 1, CHCl3); 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
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δH 0.15-0.30 (6H, m, Si(CH2CH3)3), 0.66 (9H, t, J 8.0, Si(CH2CH3)3) 1.27 (9H, t, 3 x 
CH3CH2N), 2.05 (3H, s, Ac), 3.00 (6H, q, 3 x CH3CH2N), 3.08 (1H, dd, J5,6a 3.3, J6a, 6b 
9.4, H-6a), 3.26 (1H, dd, J5,6b 1.7, H-6
b), 3.71 (6H, s, 2 x OMe), 3.92 (1H, t, J3,4 = J4,5 = 
9.4, H-4), 4.01-4.04 (1H, m, H-5), 4.05 (1H, dd, J1,2 2.0, H-2), 5.13 (1H, dd, J2,3 3.8, H-
3), 5.67 (1H, dd, J1,P 8.7, H-1), 7.12 (1H, d, JP,H 635.4, PH) and 6.69-7.47 (13H, m, Ph, 
C6H4); 
31P NMR (200 MHz; CDCl3): δP 0.17. 
 
 
Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranoside 6-
[3-O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-triethylsilyl-α-D-
mannopyranosyl phosphate], triethylammonium salt 79 
 
 
 
A mixture of compounds 77 (46 mg, 56 µmol, 1.2 eq.) and 78 (23 mg, 46 µmol) was 
dried by evaporation of pyridine (3 x 3 ml) therefrom. The residue was then dissolved in 
pyridine (1 ml) under argon, prior trimethylacetyl chloride (17 µl, 138 µmol, 2.4 eq) 
was added, and the mixture was stirred for at 20 oC for 40 min. The mixture was cooled 
to -40 ºC before a freshly prepared solution of iodine (24 mg, 92 µmol, 2 eq.) in 
pyridine-water (95:5; 1 ml) was added. The mixture was then allowed to slowly warm 
to room temperature (~1 h) with stirring. Chloroform was then added to the mixture, 
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and the solution was washed successively with cold 0.5 M Na2S2O3, cold 0.5 M TEAB 
buffer, dried by filtration through cotton wool and concentrated. FCC [CH2Cl2-
methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the phosphodiester  derivative79 
(49 mg, 75%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +19.4 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH0.26 (6H, m, 3 x SiCH2CH3), 0.63 (6H, q, J 7.8, 3 x 
SiCH2CH3), 0.71 (9H, t, J 7.8, 3 x SiCH2CH3), 0.93 (9H, t, J 7.9, 3 x SiCH2CH3) 1.10-
1.42 (12H, m, 6 x CH2), 1.29 (9H, t, J 7.5, 3 x CH3CH2N) 1.97-2.03 (2H, m, CH2), 2.10 
and 2.13 (6H, 2 x s, 2 x Ac), 3.03 (6H, m, 3 x CH3CH2N), 3.10-3.18 (2H, m, OHCHCH2 
and H-6a’), 3.33 (1H, m, H-6b’) 3.45-3.52 (1H, m, OHCHCH2), 3.68 (1H, m, H-5), 3.75 
(6H, s, 2 x OMe), 4.00 (1H, dd, J1,2 1.5, H-2), 4.03 (1H, t, J3,4 = J4,5 = 9.3, H-4), 4.04-4.09 
(2H, m, H-5’and H-6a), 4.10 (1H, t, J3’,4’ = J4’,5’ = 9.3, H-4’), 4.20 (1H, m, H-6
b), 4.30 
(1H, dd, J1’,2’ 2.0, H-2’), 4.63 (1H, d, H-1), 4.90 (1H, br d,
3
JH,H 10.2, CH=HCH), 4.96 
(1H, br d,3JH,H 17.1, CH=HCH),  5.11 (1H, dd, J2,33.8, H-3), 5.26 (1H, dd, J2’,3’ 3.6, H-3’), 
5.67 (1H, dd, J1,P 7.9, H-1’), 5.78 (1H, m, CH=CH2) and 6.74-7.49 (13H, m, Ph, 2 x 
C6H4); 
31P NMR (200 MHz; CDCl3): δP -3.13. 
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Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranoside 6-
(3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranosyl phosphate), 
triethylammonium salt 80 
 
 
 
The disaccharide phosphate 79 (52 mg, 65 µmol) was dissolved in CH2Cl2 (5 ml) and 
cooled to 0 ºC with stirring. A mixture of CH2Cl2-TFA (49:1, 5 ml) was then prepared 
and cooled to 0 ºC before adding to the stirring solution. After 1 min the reaction was 
quenched with the addition ofsaturated aq. NaHCO3. The mixture was then diluted with 
CH2Cl2, washed successively with saturated aq. NaHCO3, 0.5 M TEAB buffer, dried by 
filtration through cotton wool and concentrated under reduce pressure. FCC [CH2Cl2-
methanol-Et3N, (90:10:1)] of the residue gave the phosphodiester derivative 80 (31 mg, 
96%). 
 
1H NMR (500 MHz; CDCl3): δH0.52-0.61 (12H, m, 6 x SiCH2CH3), 0.86-0.91 (18H, m, 6 
x SiCH2CH3), 1.17-1.33 (10H, m, 5 x CH2), 1.25 (9H, t, J 7.3, 3 x CH3CH2N), 1.45-1.51 
(2H, m, CH2), 1.94-2.00 (2H, m, CH2), 2.07 and 2.09 (6H, 2 x s, 2 x Ac), 2.99 (6H, q, 3 x 
CH3CH2N), 3.24-3.30 (1H, m, OHCHCH2), 3.56-3.68 (3H, m, H-5, H-6
a’ and 
OHCHCH2), 3.75 (1H, dd, J5’,6b’ 1.7, J6a’,6b’ 10.5, H-6
b’),3.89-4.00 (5H, m, H-2, H-4, H-
4’, H-5’ and H-6a), 4.09-4.13 (2H, m, H-2’ and H-6b), 4.63 (1H, d, J1,2 1.5,  H-1), 4.86 
(1H, br d,3JH,H 10.2, CH=HCH), 4.92 (1H, br d,
3
JH,H 17.1, CH=HCH),  5.07 (1H, dd, 
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J2,33.8, J3,49.3, H-3), 5.17 (1H, dd, J2’,3’ 3.9, J3’,4’ 9.8,  H-3’), 5.48 (1H, dd, J1,2 1.7,  J1,P 
7.1, H-1’) and 5.75 (1H, m, CH=CH2); 
31P NMR (200 MHz; CDCl3): δP -2.58. 
 
 
Dec-9-enyl 3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranoside 6-
{3-O-acetyl-2-azido-2-deoxy-4-O-triethylsilyl-α-D-mannopyranosyl phosphate 6-[3-
O-acetyl-2-azido-2-deoxy-6-O-(p,p’-dimethoxytrityl)-4-O-triethylsilyl-α-D-
mannopyranosyl phosphate]}, bis-triethylammonium salt 81 
 
 
 
A mixture of the H-phosphonate 77 (33mg, 36 µmol, 1.2 eq) and the disaccharide 
phosphate 80 (31 mg, 30 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, prior 
trimethylacetyl chloride (12 µl, 91 µmol, 3 eq.) was added, and the mixture was stirred 
for at 20 oC for 40 min. The mixture was cooled to -40 ºC before a freshly prepared 
solution of iodine (15 mg, 61 µmol, 2 eq) in pyridine-water (95:5; 1 ml) was added. The 
mixture was then allowed to slowly warm to room temperature (~1 h) with stirring. 
Chloroform was then added to the mixture, and the solution was washed successively 
with cold 0.5 M Na2S2O3, cold 0.5 M TEAB buffer, dried by filtration through cotton 
114 
 
 
 
wool and concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→85:15:1)] of the residue 
gave the phosphosaccharide derivative 81 (28 mg, 50%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +10.7 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH0.21 (6H, m, 3 x SiCH2CH3), 0.55 (12H, m, 6 x 
SiCH2CH3), 0.66 (9H, t, J 7.8, 3 x SiCH2CH3), 0.79-0.91 (18H, m, 6 x SiCH2CH3),1.21 
(18H, t, 6 x CH3CH2N), 1.27-1.33 (2H, m, CH2),1.45-1.55 (8H, m, 4 x CH2),1.93-1.98 
(4H, m, 2 x CH2), 2.06 and 2.08 (9H, 2 x s, 3 x Ac), 2.97 (12H, q, 6 x CH3CH2N), 3.06 
(1H, dd, J5’’,6a’’ 4.4, J6a’’,6b’’ 9.8, H-6
a’’), 3.24 (1H, m, OHCHCH2), 3.29-3.33(1H, m, H-
6b’’), 3.59-3.67 (2H, m, OHCHCH2 and H-5), 3.71 (6H, s, 2 x OMe),  3.89-4.02 (8H, m, 
H-2, H-4, H-4’, H-4’’, H-5’, H-5’’, H-6a and H-6a’), 4.05-4.26 (4H, m, H-2’, H-2’’, H-6b 
and H-6b’), 4.62 (1H, br s, H-1), 4.85 (1H, br d,3JH,H 10.2, CH=HCH), 4.92 (1H, br 
d,3JH,H 17.1, CH=HCH),  5.07 (1H, dd, J2,33.8, J3,49.3, H-3), 5.18 (1H, dd, J2’’,3’’ 3.8, 
J3’’,4’’9.3, H-3’’), 5.25 (1H, dd, J2’,3’ 3.5, J3’,4’9.6, H-3’), 5.41 (1H, dd, J1’,2’1.1, J1’,P 7.9, H-
1’), 5.60 (1H, dd, J1’’,2’’1.6, J1’’,P 7.7, H-1’’), 5.74 (1H, m, CH=CH2) and 6.70-7.45 (13H, 
m, Ph, C6H4); 
31P NMR (200 MHz; CDCl3): δP -3.42. 
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Dec-9-enyl 2-acetamido-3-O-acetyl-2-deoxy-α-D-mannopyranoside 6-(2-acetamido-
3-O-acetyl-2-deoxy-α-D-mannopyranosyl phosphate), triethylammonium salt 82 
 
 
 
The disaccharide phosphate 79 (18 mg, 13µmol) was dissolved in a mixture of THF (0.5 
ml) and MeOH (0.5 ml) before the addition of NiCl2
.6H2O (25 mg). The mixture was 
then cooled to 0 ºC with stirring. In portions, NaBH4 (30 mg) was added slowly over the 
course of 1 h, after which time AcO2 (100 µl) was added. The solution was stirred for an 
additional 1 h. The reaction was then diluted with CH2Cl2 and washed with 0.5 M 
TEAB buffer. The organic layer was filtered through silica and concentrated under 
reduced pressure. The residue was then dissolved in CH2Cl2 (3 ml) and cooled to 0 
ºC. 
A further solution of TFA (60 µl) in CH2Cl2 (3 ml) and was prepared and cooled to 0 
ºC. The solutions were combined and stirred for 1.5 min, and the reaction was quenched 
with saturated aq. NaHCO3. The mixture was then diluted with CH2Cl2, washed 
successively with saturated aq. NaHCO3, 0.5 M TEAB buffer, dried by filtration 
through cotton wool and concentrated under reduce pressure. The residue was dissolved 
in THF (0.5 ml) before the addition of Et3N (15 µl) and Et3N
.3HF (15 µl, 92 µmol). The 
reaction was then stirred at ambient temperature for 2 h then quenched with a solution 
of Et3SiOMe before concentrating under reduced pressure. The residue was then 
triturated with ether to remove any silylated products to give the phosphodiester 82 (4 
mg, 40 %) as a white solid. 
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1H NMR (500 MHz; CDCl3): δH0.81 (3H, t, J 6.9, CH3, n-decyl), 1.16-1.32 (25H, m, 8 x 
CH2, n-decyl, 3 x CH3CH2N), 1.95 (12H, s, 2 x OAc, 2 x NAc), 3.10 (6H, q, J 7.5, 3 x 
CH3CH2N), 3.26 (1H, m, OHCHCH2, n-decyl), 3.47-3.63 (3H, m, H-4, H-4’ and 
OHCHCH2, n-decyl), 3.79-4.02 (5H, m, H-5, H-5’, H-6
a, H-6a’, H-6b’),4.33 (1H, m, H-
6b), 4.53 (2H, m, H-2 and H-2’), 4.56 (1H, br, H-1), 5.07 and 5.16 (2H, 2 x d, J2,3 4.3, J3,4 
10.0, J2’,3’ 4.3, J3’,4’ 10.0, H-3 and H-3’), 5.47 (1H, br d, J1’,P 7.3, H-1’); 
31P NMR (200 MHz; CDCl3): δP -1.30. 
 
 
Methyl 2-azido-3-O-benzoyl-4-O-benzyl-2-deoxy-α-D-mannopyranoside 86 
 
 
 
A solution of 1 M BH3 in THF (3 ml, 3 mmol) was added to compound 62 (567 mg, 
1.38 mmol) at 0 °C. A solution of 1 M Bu2BOTf in CH2Cl2 (1.4 ml, 1.4 mmol) was then 
added slowly under stirring and the mixture was left to stir at 0 oC for 1 h. The reaction 
was then quenched with the addition of Et3N (0.6 ml) before dropwise addition of 
methanol (5 ml). The solution was then concentrated under reduced pressure followed 
by co-evaporation with methanol (3 x 30 ml). FCC [toluene-EtOAc, (9:1)] of the 
residue gave the derivative 86 (533 mg, 94%). 
 
υmax (film)/cm-1 (inter alia): 1723 (C=O), 2103 (-N3); 
[α]D +53.1 (c 1, CHCl3); 
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1H NMR (500 MHz; CDCl3): δH 1.85 (1H, m, 6-OH), 3.33 (3H, s,OMe), 3.69 (1H, dt, 
J5,6  3.1, H-5), 3.71-3.82 (2H, m, H-6
a,b), 4.06 (1H, t,  J3,4 = J4,5 = 9.7,  H-4), 4.09 (1H, 
dd, H-2), 4.58 and 4.65 (2H, 2 x d, J 11.0, PhCH2), 4.68 (1H, d, J1, 2 1.5, H-1) 5.63 (1H, 
dd, J2, 3 3.8, H-3) and 7.05-8.07 (10H, m, 2 x Ph); 
13C NMR (125 MHz; CDCl3): δC 55.16 (CH3O), 61.69 (C-6), 62.09 (C-2), 71.89 (C-5), 
72.64 (C-4), 73.85 (C-3), 75.18 (PhCH2), 99.16 (C-1), 127.96, 128.05, 128.45, 128.63, 
129.23, 129.90, 133.54 (Ph) and 165.49 (C=O). 
 
ES-MS(+): found m/z 436.15 [M+Na]+ (C21H23N3O6 requires M, 413.16). 
 
 
Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 87 
 
 
 
A solution of compound 86 (491 mg, 1.19 mmol) in CH2Cl2 (10 ml) and methanol (5 
ml) was prepared with stirring. To this sodium methoxide (solid, ~10 mg) was added. 
The solution was then stirred at room temperature for 2 h and then deionised with the 
addition of DOWEX 50WX4-50 (H+) resin. The resin was filtered off before filtrate was 
concentrated. The residue was co-evaporated with toluene (3 x 30 ml) and dissolved in 
pyridine (10 ml) with stirring prior to the addition of p,p’-dimethoxytrityl chloride (484 
mg, 1.43 mmol, 1.2 eq). The solution was then stirred at ambient temperature for 16 h, 
after which time acetic anhydride (2 ml) was added. The solution was stirred for an 
additional 1 h before quenching with the addition of water. The mixture was diluted 
with CH2Cl2, washed successively with saturated aq. NaHCO3, water and dried by 
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filtration through cotton wool and concentrated. The residuewas dissolved in CH2Cl2 
(10 ml) and cooled to 0 ºC with stirring. A mixture of CH2Cl2-TFA (49:1, 10 ml) was 
then prepared and cooled to 0 ºC before adding to the stirring solution. After 1 min the 
reaction was quenched with the addition ofsaturated aq. NaHCO3. The solution was 
then diluted with CH2Cl2, washed with saturated aq. NaHCO3, dried by filtration 
through cotton wool and concentrated. FCC [toluene-EtOAc, (9:1)] of the residue gave 
the derivative 87 (326 mg, 78%). 
 
υmax (film)/cm
-1 (inter alia): 2106 (-N3); 
[α]D +34.5 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.99 (3H, s, Ac), 3.30 (3H, s,OCH3), 3.62 (1H, ddd, 
J5,6a 3.8, H-5), 3.71 (1H, dd, J5,6a 3.8, J6a, 6b 12.0, H-6
a), 3.77 (1H, dd, J5,6b 2.6, H-6
b), 
3.89 (1H, t,  J3,4 = J4,5 = 9.7,  H-4), 3.98 (1H, dd, H-2), 4.60 and 4.65 (2H, 2 x d, J 11.3, 
PhCH2), 4.61 (1H, d, J1,2 1.7, H-1) 5.31 (1H, dd, J2,3 3.8, H-3) and 7.21-7.31 (5H, m, 
Ph); 
13C NMR (125 MHz; CDCl3): δC 20.76 (CH3CO), 55.10 (CH3O), 61.66 (C-6), 61.75 (C-
2), 71.79 (C-5), 72.61 (C-4), 73.62 (C-3), 75.06 (PhCH2), 99.04 (C-1), 127.76, 127.93, 
128.51 137.89 (Ph) and 170.02 (C=O). 
 
ES-MS(+): found m/z 374.13 [M+Na]+ (C16H21N3O6 requires M, 351.14). 
High resolution ES-MS(+): found m/z 374.1342 [M+Na]+ (C16H21N3NaO6
+ requires m/z  
374.1323). 
 
 
119 
 
 
 
3-O-Acetyl-2-azido-4-O-benzyl-2-deoxy-6-O-(p,p’-dimethoxytrityl)-α,β-D-
mannopyranose 88 
 
 
 
The thioglycoside 58 (1.37 g, 2.00 mmol) was dissolved in dichloromethane (10 ml) 
and cooled to 0 ºC with stirring. Bromine (109 µl, 2.00 mmol, 1 eq.) was then added, 
stirring was continued at 0 ºC for 30 min. The reaction mixture was then diluted with 
acetone-water (9:1; 50 ml) before the addition of silver carbonate (400 mg). Cooling 
was ceased and the mixture was stirred for an additional 16 h at room temperature. The 
suspension was then diluted with toluene, filtered through a Celite pad, and the filtrate 
was dried by filtration through cotton wool and concentrated. FCC [toluene-EtOAc, 
(9:1)] of the residue gave the hemiacetal derivative 88 (1.13 g, 89%). 
 
1H NMR (500 MHz; CDCl3): δH(signals of the α-anomer only) 2.00 (s, Ac), 2.71 (d, J1,OH 
3.4, 1-OH) 3.15 (m, H-6a), 3.42 (dd, J5,6b 1.8, J6a,6b 10.3 H-6
b), 3.70 (s, 2 x OMe), 3.98 
(ddd, J5,6a 3.6, J4,5 = 9.0, H-5), 4.02 (m, H-4), 4.04 (m, H-2), 4.20 and 4.42 (2 x d, J 11.0, 
PhCH2), 5.26 (dd, J1,2 1.9, H-1), 5.33 (dd, J2,3 3.8, J3,4 9.0, H-3) and 6.72-7.46 (m, Ph, 2 x 
C6H4); (signals of the  β-anomer) 2.02 (s, Ac), 3.15 (m, H-6
a), 3.35 (d, J1,OH 10.2, 1-OH), 
3.38 (ddd, J5,6a 3.5, J4,5 9.7, H-5), 3.50 (dd, J5,6b 1.9, J6a,6b 10.3, H-6
b), 3.70 (s, 2 x OMe), 
4.02 (m, H-4), 4.07 (dd, J2,3 3.7,H-2), 4.21 and 4.39 (2 x d, J 10.9, PhCH2), 4.83 (dd, J1,2 
1.5, H-1), 4.97 (dd, J3,4 9.8, H-3) and 6.72-7.46 (m, Ph, 2 x C6H4);α:β = 4.5:1. 
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Triethylammonium 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-6-O-(p,p’-
dimethoxytrityl)-α-D-mannopyranosyl hydrogenphosphonate 89 
 
 
 
The hemiacetal 88 (232 mg, 363 µmol) was dissolved in a mixture of dioxane (10 ml) 
and Et3N (7 ml) and with stirring for 1 h. Salicylchlorophosphite (88 mg, 436 µmol, 1.2 
eq) was then added and the mixture was stirred for 1 h. The reaction was then quenched 
with the addition of saturated aq. NaHCO3 and stirring continued for additional 30 min. 
The mixture was then diluted with chloroform (80 ml) and the solution was washed 
successively with saturated aq. NaHCO3, water, cold 0.5 M TEAB buffer, dried by 
filtration through cotton wool and concentrated. FCC [CH2Cl2-methanol-Et3N, 
(95:5:1→90:10:1)] of the residue gave the H-phosphonate derivative 89 (257 mg, 88%). 
 
υmax (film)/cm
-1 (inter alia): 2103 (-N3); 
[α]D +32.8 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.24 (9H, t, 3 x CH3 CH2NH
+), 1.97 (3H, s, COCH3), 
2.97 (6H, q, 3 x CH3 CH2NH
+), 3.12 (1H, dd, J5,6a 3.6, J6a, 6b 10.3, H-6
a), 3.43 (1H, dd, 
J5,6b 1.7, H-6
b), 3.69 (6H, s, 2 x O-Me), 3.99 (1H, ddd, H-5), 4.06 (1H, dd, J1,2 2.0, H-2), 
4.10 (1H, t, J3,4 =J4,5 9.8, H-4), 4.20 and 4.40 (2H, 2 x d, PhCH2), 5.32 (1H, dd, J2,3 3.7, 
H-3), 5.69 (1H, dd, , J1,P 8.6, H-1), 6.96 (1H, d, JP,H 633.2, PH) and 6.71-7.47 (18H, m, 
Ph, C6H4); 
121 
 
 
 
 
13C NMR (125 MHz; CDCl3): δC 10.19 (CH3CH2N), 20.85 (CH3CO), 45.88 (CH3CH2N) 
55.20 (2 x CH3O) 61.88 (C-6), 62.62 (d,
 3
JC,P 6.5, C-2), 72.54, 72.87 and 73.46 (C-3, C-4 
and C-5), 74.72 (PhCH2), 85.63 (Ar3C), 93.36 (d, 
2
JC,P 3.8, C-1), 113.07-158.35 (Ph, 
C6H4) and 170.18 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP 0.22. 
 
High resolution ES-MS(-): found m/z 702.2251 [M-Et3N-H]
- (C36H37N3O10P
- requires 
m/z  702.2222). 
 
 
Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-(3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate), 
triethylammonium salt 92 
 
 
 
A mixture of the H-phosphonate 89 (300 mg, 376 µmol, 1.2 eq) and compound 87 (110 
mg, 313 µmol) was dried by evaporation of pyridine (3 x 3 ml) therefrom. The residue 
was then dissolved in pyridine (1 ml) under argon, before trimethylacetyl chloride (70 
µl, 564 µmol, 1.8 eq.) was added, and the solution was stirred for at 20 oC for 30 min. 
The solution was cooled to -40 ºC before Et3N (210 µl, 1.50 mmol, 4.8 eq.) and a 
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mixture of pyridine-water (95:5; 1 ml) were added. Iodine (191 mg, 752 µmol, 2.4 eq) 
was then added, the mixture was stirred for 30 min at -40 ºC, prior it was allowed to 
slowly warm to room temperature (~1 h) with stirring. Chloroform was then added to 
the mixture, and the solution was washed successively with cold 0.5 M Na2S2O3, cold 
0.5 M TEAB buffer, dried by filtration through cotton wool and concentrated. The 
residuewas dissolved in CH2Cl2 (5 ml) and cooled to -10 ºC with stirring. A mixture of 
DCM-TFA (49:1, 5 ml) was then prepared and cooled to -10 ºC before adding to the 
stirring solution. After 1 min the reaction was quenched with the addition ofsaturated 
aq. NaHCO3. The solution was then diluted with chloroform and washed successively 
with saturated aq. NaHCO3 and cold 0.5 M TEAB buffer, by filtration through cotton 
wool and concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→90:10:1)] of the residue 
gave the phosphodiester 92 (235 mg, 88%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +23.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.20 (9H, t, J 7.3, 3 x CH3CH2NH
+), 1.94 and 1.96 
(6H, 2 x s, 2 x Ac), 2.92 (6H, q, J 6.8, 3 x CH3CH2NH
+), 3.27 (3H, s,OCH3), 3.57 (1H, 
dd, J5,6a 5.4, J6a,6b 11.8, H-6’
a), 3.70-3.75 (1H, m, H-5), 3.73 (1H, dd, J5,6b 2.5, H-6’b), 
3.78 (1H, t J3,4 = J4,5 = 9.6, H-4’), 3.84 (1H, t J3,4 = J4,5 = 9.7, H-4), 3.94 (1H, dd, J1,2 1.8, 
H-2), 3.97 (1H, ddd, H-5’), 4.11 (1H, dd, J1’,2’ 2.0, H-2’), 4.12-4.15 (2H, m, H-6), 4.56 
(1H, d, J1,2 1.7, H-1), 4.57, 4.59, 4.61 and 4.71 (4H, 4 x d, J 11.3, 2 x PhCH2), 5.27 (1H, 
dd, J2,3 3.8, H-3), 5.41 (1H, dd, J2,3 3.7, H-3’), 5.54 (1H, d, J1,P 7.2, H-1’) and 7.21-7.31 
(10H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 8.81 (CH3CH2N), 20.67 and 20.71 (2 x CH3CO), 45.59 
(CH3CH2N), 55.07 (CH3O), 61.75 (C-6’), 61.82 (C-2), 62.46 (d,
 3
JC,P 8.1, C-2’), 64.38 (br, 
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C-6), 71.07 (d, 3JC,P 12.5, C-5), 73.02, 73.18, 73.30 and 73.59 (C-3, C-3’, C-4, C-4’ and 
C-5’), 74.82 and 74.86 (2 x PhCH2), 94.04 (br, C-1’), 98.71 (C-1), 127.65-138.22 (Ph) 
and 170.02 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -2.69. 
 
High resolution ES-MS(-): found m/z749.2218 [M-Et3N-H]
- (C31H38N6O14P
- requires 
m/z749.2189). 
 
 
3-O-Acetyl-2-azido-4-O-benzyl-6-O-(tert-butyldimethylsilyl)-2-deoxy-α,β-D-
mannopyranose 90 
 
 
 
The thioglycoside 59 (237 mg, 478 µmol) was dissolved in dichloromethane (2 ml) and 
cooled to 0 ºC with stirring. Bromine (26 µl, 502 µmol, 1.05 eq) was then added, 
stirring was continued at 0 ºC for 30 min. The reaction mixture was then diluted with 
acetone-water (9:1; 10 ml) before the addition of silver carbonate (300 mg). Cooling 
was ceased and the mixture was stirred for an additional 16 h at room temperature. The 
suspension was then diluted with toluene, filtered through a Celite pad, and the filtrate 
was dried by filtration through cotton wool and concentrated. FCC [toluene-EtOAc, 
(9:1)] of the residue gave the hemiacetal derivative 90 (205 mg, 95%). 
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1H NMR (500 MHz; CDCl3): δH(signals of the α-anomer only) 0.00, 0.02 (6H, 2 x s, 
(CH3)2Si), 0.85 (9H, s, Me3CSi), 1.99 (3H, s, Ac), 3.72 (1H, dd, J5,6a 1.3, J6a,6b 11.3, H-
6a), 3.80 (1H, dd,  J5,6b 3.5,  H-6
b), 3.83 (1H, ddd, H-5), 3.88 (1H, t, J3,4 = J4,5 = 9.0, H-
4), 3.98 (1H, dd, J2,3 3.7, H-2), 4.60 and 4.63 (2H, 2 x d, J 11.4, PhCH2), 5.14 (1H, dd, 
J1,2 1.9, H-1), 5.36 (1H, dd, J3,4 9.0, H-3) and 7.07-7.30 (5H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC -5.32 (Me2Si), 17.77 (Me3C), 20.81 (CH3CO), 25.94 
(Me3C) 61.92 (C-2), 62.24 (C-6), 72.83 (C-3, C-4 and C-5), 74.92 (PhCH2), 92.77 (C-1), 
127.75, 128.48 and 134.36 (Ph) and 170.00 (CH3C=O). 
 
 
Triethylammonium 3-O-acetyl-2-azido-4-O-benzyl-6-O-(tert-butyldimethylsilyl)-2-
deoxy-α-D-mannopyranosyl hydrogenphosphonate 91 
 
 
 
 
The hemiacetal 90 (200 mg, 443 µmol) was dissolved in a mixture of dioxane (10 ml) 
and Et3N (4.4 ml) and with stirring for 1 h. Salicylchlorophosphite (678 mg, 3.30 mmol, 
7 eq) was then added and the mixture was stirred for 1 h. The reaction was then 
quenched with the addition of saturated aq. NaHCO3 and stirring continued for 
additional 30 min. The mixture was then diluted with chloroform (80 ml) and the 
solution was washed successively with saturated aq. NaHCO3, water, cold 0.5 M TEAB 
buffer, dried by filtration through cotton wool and concentrated. FCC [CH2Cl2-
125 
 
 
 
methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the H-phosphonate derivative 91 
(269 mg, 91%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +34.6 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 0.00, 0.03 (6H, 2 x s, Me2Si), 0.86 (9H, s, Me3CSi), 
1.27 (9H, t, J 7.3, 3 x CH3CH2NH), 1.95 (3H, s, Ac), 3.00 (6H, q, J 6.8, 3 x 
CH3CH2NH), 3.73 (1H, m, H-6a), 3.81-3.87 (2H, m,  H-6b and H-5), 3.98 (1H, t, J3,4 = 
J4,5 = 9.9, H-4), 4.01 (1H, dd, J1,2 2.0, H-2), 4.61 and 4.65 (2H, 2 x d, J 11.4, PhCH2), 
5.35 (1H, dd, J2,3 3.8, H-3), 5.54 (1H, dd, J1,P 8.6, H-1) 6.91 (1H, dd, JP,H 634, PH) and 
7.19-7.30 (5H, m, Ph); 
31P NMR (200 MHz; CDCl3): δP 0.34. 
 
High resolution ES-MS(-): found m/z514.1794 [M-Et3N-H]
- (C21H33N3O8PSi
-requires 
m/z 514.1780). 
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Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-[3-O-
acetyl-2-azido-4-O-benzyl-6-O-(tert-butyldimethylsilyl)-2-deoxy-α-D-
mannopyranosyl phosphate], triethylammonium salt 93 
 
OBnO
TBSO N3
O
AcO
P
O-
O
OBnO
N3
OMe
AcOO
Et3NH
+
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A mixture of the H-phosphonate 91 (269 mg, 436 µmol, 1.2 eq.) and compound 87 (128 
mg, 363 µmol) was dried by evaporation of pyridine (3 x 3 ml) therefrom. The residue 
was then dissolved in pyridine (1 ml) under argon, before trimethylacetyl chloride (107 
µl, 872 µmol, 2.4 eq.) was added, and the solution was stirred for at 20 oC for 30 min. 
The solution was cooled to -40 ºC before a freshly prepared solution of iodine (221 mg, 
872 µmol, 2.4 eq.) in a mixture pyridine-water (95:5; 1 ml) was added. The mixture was 
allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform was then 
added to the mixture, and the solution was washed successively with cold 0.5 M 
Na2S2O3, cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the 
phosphodiester 93 (263 mg, 75%). 
 
υmax (film)/cm
-1 (inter alia): 2104 (-N3); 
[α]D +29.6 (c 1, CHCl3); 
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1H NMR (500 MHz; CDCl3): δH -0.04 and 0.00 (6H, 2 x s, Me2Si), 0.83 (9H, s, 
Me3CSi), 1.27 (9H, t, J 7.3, 3 x CH3CH2NH), 1.91 and 1.92 (6H, 2 x s, 2 x Ac), 2.87 
(6H, q, J 6.8, 3 x CH3CH2NH), 3.25 (3H, s,OCH3), 3.66 (1H, dd, J5,6a 1.4, J6a,6b 11.8, H-
6’a), 3.69-3.72 (1H, m, H-5), 3.73 (1H, dd, J5,6b 2.6, H-6’b), 3.78 (1H, t J3,4 = J4,5 = 9.8, 
H-4), 3.79-3.84 (1H, m, H-5’), 3.92 (1H, dd, J1,2 1.7, H-2), 4.00 (1H, t, J3,4 = J4,5 = 9.8, 
H-4’), 4.11 (1H, dd, J1’,2’ 1.8, H-2’), 4.06-4.16 (2H, m, H-6), 4.53 (1H, d, H-1), 4.55, 
4.57, 4.61 and 4.68 (4H, 4 x d, J 11.3, 2 x PhCH2), 5.25 (1H, dd, J2,3 3.9, H-3), 5.39 
(1H, dd, J2’,3’ 3.8, H-3’), 5.52 (1H, dd, J1,P 7.7, H-1’) and 7.11-7.26 (10H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC -5.06 (Me2Si), 8.81 (CH3CH2N), 17.77 (Me3C), 20.68 
and 20.77 (2 x CH3CO), 25.92 (Me3C), 45.60 (CH3CH2N), 54.96 (CH3O), 61.73 (C-6’), 
61.82 (C-2), 62.44 (d, 3JC,P 6.3, C-2’), 64.42 (d, 
2
JC,P 4.4, C-6), 71.12 (d,
 3
JC,P 8.8, C-5), 
72.42 (C-5’) 73.07, 73.21, 73.43 and 73.65 (C-3, C-3’, C-4 and C-4’), 74.78 and 74.95 (2 
x PhCH2), 94.24 (d, 
2
JC,P 4.3, C-1’), 98.60 (C-1), 127.54-128.44 (Ph) and 170.02 
(CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -2.74. 
 
High resolution ES-MS(-): found m/z863.3069 [M-Et3N-H]
- (C37H52N6O14PSi
-requires 
m/z 863.3054). 
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Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-(3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate), 
triethylammonium salt 92 
 
 
 
The disaccharide phosphate 93 (258 mg, 267 µmol) was dissolved in THF (5 ml) with 
stirring. To this Et3N
.3HF (218 µl, 1.34 mmol, 5 eq) was added and the solution was 
stirred at ambient temperature for 16 h. The solvent was then removed under reduced 
pressure. FCC [CH2Cl2-methanol-Et3N, (95:5:1→90:10:1)] of the residue gave the 
phosphodiester 92 (216 mg, 95%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +23.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.20 (9H, t, J 7.3, 3 x CH3CH2NH), 1.94 and 1.96 (6H, 
2 x s, 2 x Ac), 2.92 (6H, q, J 6.8, 3 x CH3CH2NH), 3.27 (3H, s,OCH3), 3.57 (1H, dd, 
J5,6a 5.4, J6a,6b 11.8, H-6’
a), 3.70-3.75 (1H, m, H-5), 3.73 (1H, dd, J5,6b 2.5, H-6’b), 3.78 
(1H, t J3,4 = J4,5 = 9.6, H-4’), 3.84 (1H, t J3,4 = J4,5 = 9.7, H-4), 3.94 (1H, dd, J1,2 1.8, H-
2), 3.97 (1H, ddd, H-5’), 4.11 (1H, dd, J1’,2’ 2.0, H-2’), 4.12-4.15 (2H, m, H-6), 4.56 
(1H, d, J1,2 1.7, H-1), 4.57, 4.59, 4.61 and 4.71 (4H, 4 x d, J 11.3, 2 x PhCH2), 5.27 (1H, 
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dd, J2,3 3.8, H-3), 5.41 (1H, dd, J2,3 3.7, H-3’), 5.54 (1H, d, J1,P 7.2, H-1’) and 7.21-7.31 
(10H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 8.81 (CH3CH2N), 20.67 and 20.71 (2 x CH3CO), 45.59 
(CH3CH2N), 55.07 (CH3O), 61.75 (C-6’), 61.82 (C-2), 62.46 (d,
 3
JC,P 8.1, C-2’), 64.38 (br, 
C-6), 71.07 (d, 3JC,P 12.5, C-5), 73.02, 73.18, 73.30 and 73.59 (C-3, C-3’, C-4, C-4’ and 
C-5’), 74.82 and 74.86 (2 x PhCH2), 94.04 (br, C-1’), 98.71 (C-1), 127.65-138.22 (Ph) 
and 170.02 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -2.69. 
 
High resolution ES-MS(-): found m/z749.2218 [M-Et3N-H]
- (C31H38N6O14P
- requires 
m/z749.2189). 
 
 
Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-[3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-(3-O-acetyl-
2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate)], bis-
triethylammonium salt 94 
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A mixture of the H-phosphonate 89 (110 mg, 137 µmol, 1.3 eq.) and the disaccharide 
phosphate 92 (90 mg, 106 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (22 µl, 180 µmol, 1.7 eq.) was added, and the solution was 
stirred for at 20 oC for 30 min. The solution was cooled to -40 ºC before Et3N (44 µl, 
360 µmol, 3.4 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (46 
mg, 180 µmol, 1.7 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, 
prior it was allowed to slowly warm to room temperature (~1 h) with stirring. 
Chloroform was then added to the mixture, and the solution was washed successively 
with cold 0.5 M Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through 
cotton wool and concentrated. The residuewas dissolved in CH2Cl2 (5 ml) and cooled to 
-10 ºC with stirring. A mixture of DCM-TFA (49:1, 5 ml) was then prepared and cooled 
to -10 ºC before adding to the stirring solution. After 1 min the reaction was quenched 
with the addition ofsaturated aq. NaHCO3. The solution was then diluted with 
chloroform and washed successively with saturated aq. NaHCO3 and cold 0.5 M TEAB 
buffer, by filtration through cotton wool and concentrated. FCC [CH2Cl2-methanol-
Et3N, (95:5:1→85:15:1)] of the residue gave the phosphosaccharide 94 (130 mg, 74%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +13.8 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.12 (18H, t, J 7.3, 6 x CH3CH2N), 1.92, 1.93 and 1.95 
(9H, 3 x s, 3 x Ac), 2.76 (12H, br, 6 x CH3CH2N), 3.27 (3H, s,OCH3), 3.58 (1H, m, H-6
 
a’’), 3.70-3.85 (5H, m, H-4, H-4’, H-4’’, H-5, and H-6 b’’), 3.89-3.92 (1H, m, H-5’’), 
3.93 (1H, dd, J1,2 1.6, H-2), 4.01-4.23 (7H, m, H-2’, H-2’’, H-5’, H-6
a, H-6b, H-6a’ and 
H-6b’), 4.54-4.61 (5H, m, 2 x PhCH2 and H-1),4.67-4.74 (2H, m, PhCH2), 5.26 (1H, dd, 
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J2,3 3.8, H-3), 5.37 (1H, m, H-3’’), 5.43-5.53 (3H, m, H-1’, H-1’’ and H-3’) and 7.14-
7.27 (15H, m, 3 x Ph); 
13C NMR (125 MHz; CDCl3): δC 9.44 (CH3CH2N), 20.55, 20.67 and 20.78 (3 x CH3CO), 
45.73 (CH3CH2N), 55.16 (CH3O), 61.52 (C-6’’), 61.83 (C-2), 62.52 (2 x d,
3
JC,P 7.3,
3
JC,P 
7.6, C-2’, C-2’’), 64.32 and 64.40 (br and d,2JC,P 5.4, C-6 and C-6’), 71.13 (d,
3
JC,P 8.5, C-
5), 72.41 (d,3JC,P 7.1, C-5’), 72.46, 72.90, 72.99, 73.07, 73.13 and 73.62 (C-3, C-3’, C-3’’, 
C-4, C-4’, C-4’’ and C-5’’), 74.66, 74.80 and 74.92 (3 x PhCH2), 93.98 and 94.26 (2 x br, 
C-1’ and C-1’’), 98.55 (C-1), 126.46-137.46 (Ph), 169.67, 169.76 and 170.02 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -3.18 and -2.77. 
 
High resolution ES-MS(-): found m/z1148.2894 [M-2Et3N-H]
- (C46H56N9O22P2
-requires 
m/z1148.3021). 
 
 
 
 
 
 
 
 
Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-(3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-{3-O-acetyl-
2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-[3-O-acetyl-2-
azido-4-O-benzyl-2-deoxy-6-O-(p,p’-dimethoxytrityl)-α-D-mannopyranosyl 
phosphate]}), tris-triethylammonium salt 95 
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A mixture of the H-phosphonate 89 (93 mg, 116 µmol, 2 eq.) and the trisaccharide 
diphosphate 94 (79 mg, 58 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (19 µl, 151 µmol, 2.6 eq.) was added, and the solution was 
stirred for at 20 oC for 30 min. The solution was cooled to -40 ºC prior Et3N (50 µl, 302 
µmol, 5.2 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (38 mg, 
151 µmol, 2.6 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, before 
it was allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform 
was then added to the mixture, and the solution was washed successively with cold 0.5 
M Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→80:20:1)] of the residue gave the 
phosphosaccharide 95 (91 mg, 73%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +12.8 (c 1, CHCl3); 
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1H NMR (500 MHz; CDCl3): δH 1.05 (27H, t, J 7.3, 9 x CH3CH2N), 1.87, 1.92, 1.93 
and 1.95 (12H, 4 x s, 4 x Ac), 2.65 (18H, br, 9 x CH3CH2N), 3.04 (1H, dd, J5’’’,6a’’’ 2.2, 
J6 a’’’,6b’’’ 10.3, H-6
a’’’), 3.26 (3H, s,OCH3), 3.40 (1H, br d, H-6
b’’’), 3.67 (6H, 2 x s,2 x 
OCH3), 3.71 (1H, br d, H-5), 3.77 (1H, t, J3,4 = J4,5 = 9.6, H-4’), 3.81 (1H, t, J3,4 = J4,5 = 
9.6, H-4), 3.86-4.02 (6H, m, H-2, H-4’’, H-5’- H-5’’’, H-6a), 4.03-4.23 (10H, m, H-2’- 
H-2’’’, H-4’’’, H-6b, H-6a’, H-6b’, H-6a’’, H-6b’’, PhCH2), 4.35 (1H, d, J11.0, PhCH2), 
4.48 (1H, d, J11.0, PhCH2) 4.54-4.77 (7H, m, 3 x PhCH2 and H-1), 5.26 (1H, dd, J2,3 
3.8, J3,4 9.4, H-3), 5.37-5.43 (3H, m, H-1’’, H-3’ and H-3’’’), 5.44-5.49 (2H, m, H-1’ 
and H-3’’), 5.68 (1H, br d, J1’’’,P 6.9, H-1’’’)  and 6.64-7.48 (33H, m, 4 x Ph, C6H4); 
13C NMR (125 MHz; CDCl3): δC 10.32 (CH3CH2N), 20.60, 20.67 and 20.78 (CH3CO), 
45.96 (CH3CH2N), 55.01 (CH3O), 55.16 (CH3O), 61.52 (C-6’’’), 61.83 (C-2), 62.53 (br, 
C-2’, C-2’’ and C2’’’), 64.23 (br, C-6, C-6’ and C-6’’’), 71.06 (d, 3JC,P 7.6, C-5), 72.22 (2 
x d, 3JC,P 7.2,
 3
JC,P 8.1, C-5’ and C-5’’), 72.45 (C-5’’’), 72.87, 73.02 and 73.59 (C-3 - C-
3’’’ and C-4 - C-4’’’), 74.66, 74.82 and 74.91 (PhCH2), 85.58 (Ar3C), 93.97 (br, C-1’ and 
C-1’’), 94.26 (br, C-1’’’), 98.55 (C-1), 113.06-158.37 (Ph, C6H4) and 169.71 and 169.77 
(C=O); 
31P NMR (200 MHz; CDCl3): δP -3.28, -3.18 and -3.06. 
 
High resolution ES-MS(-): found m/z1849.5724 [M-3Et3N-H]
- (C82H92N12O32P3
- 
requires m/z1849.5159), 1871.5583 [M-3Et3N-2H+Na]
- (C82H91N12NaO32P3
- requires 
m/z1871.4978), 1887.5346 [M-3Et3N-2H+K]
- (C82H91KN12O32P3
- requires 
m/z1887.4718), 1893.5346 [M-3Et3N-3H+2Na]
- (C82H90N12Na2O32P3
- requires 
m/z1893.4798).  
 
 
134 
 
 
 
Triethylammonium 6-(N-benzyloxycarbonyl)aminohexyl hydrogenphosphonate 97 
 
 
 
To a solution of 6-(N-benzyloxycarbonyl)aminohexanol (300 mg, 1.20 mmol) in MeCN 
(20 ml) was added PCl3 (794 µl, 9 mmol). The reaction was stirred at ambient 
temperature for 30 min before evaporating to dryness. The residue was dissolved in 
MeCN (10 ml) before the dropwise addition of 0.5 M TEAB buffer (5 ml). The solution 
was allowed to stir for an additional 30 min before removing the solvent under reduced 
pressure to give a white solid. This was then dissolved in CHCl3 (1 ml) before ether (20 
ml) was added. The white precipitate which formed was filtered off. The solvent was 
then removed under reduced pressure to give the H-phosphonate 97 (440 mg, 88%) as 
an amorphous solid. 
 
1H NMR (500 MHz; CDCl3): δH 1.25 (9H, t, J 7.3, 3 x CH3CH2N), 1.26-1.35 (4H, m, 2 
x CH2), 1.42 (2H, m, NCH2CH2), 1.56 (2H, m, OCH2CH2), 2.98 (6H, dq, JCH2,NH 3.6, 3 
x CH3CH2N), 3.11 (2H, m, CH2N), 3.80 (2H, dt, JH,H 6.6, JH,P 7.8, CH2OP), 4.91 (1H, 
br, NH), 5.02 (2H, s, PhCH2O), 6.76 (1H, d, JH,P 624.4, HP), 7.22-7.30 (5H, m, Ph) and 
12.57 (1H, br, Et3NH
+); 
13C NMR (125 MHz; CDCl3): δC 8.53 (CH3CH2N), 25.38, 26.24, 29.85 (3 x CH2), 30.57 
(d, 3JC,P 6.6, CH2CH2OP), 40.91 (CH2CH2N), 45.38 (CH3CH2N), 63.74 (d, 
2
JC,P 4.8, 
CH2OP), 66.52 (PhCH2) and 128.06, 128.14, 128.52 (Ph); 
31P NMR (200 MHz; CDCl3): δP 4.95. 
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High resolution ES-MS(-): found m/z314.1183 [M-Et3N-H]
- (C14H21NO5P
- requires 
m/z314.1163). 
 
 
Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-{3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-[6-
(benzyloxycarbonyl)aminohexyl phosphate]}, bis-triethylammonium salt 98 
 
 
 
A mixture of the H-phosphonate 97 (21 mg, 51 µmol, 1.3 eq.) and the disaccharide 
phosphate 92 (33 mg, 39 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (9 µl, 76 µmol, 1.9 eq.) was added, and the solution was stirred 
for at 20 oC for 30 min. The solution was cooled to -40 ºC prior Et3N (42 µl, 304 µmol, 
7.8 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (40 mg, 152 
µmol, 3.9 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, before it 
was allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform was 
then added to the mixture, and the solution was washed successively with cold 0.5 M 
Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
136 
 
 
 
concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→85:15:1)] of the residue gave the 
phosphosaccharide 98 (43 mg, 88%). 
 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +27.3 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH 1.22 (18H, t, J 7.3, 6 x CH3CH2N), 1.24-1.57 (8H, m, 
4 x CH2), 1.93 and 1.94 (6H, 2 x s, 2 x Ac), 2.94 (12H, q, 6 x CH3CH2N), 3.04-3.13 
(2H, m, NCH2), 3.26 (3H, s,OCH3), 3.70 (1H, br d, H-5), 3.73-3.81 (2H, m, CH2OP), 
3.82 (1H, t, J3,4 = J4,5 = 9.7, H-4), 3.88 (1H, t, J3’,4’ = J4’,5’ = 9.6, H-4’), 3.93 (1H, dd, J1,2 
1.6, H-2), 3.95-4.02 (2H, m,H-5’, H-6a’), 4.06-4.13 (3H, m,H-6a, H-6b and H-6b’), 4.21 
(1H, m, H-2’), 4.55 (1H, d, H-1), 4.57, 4.59, 4.70 and 4.72 (4H, 4 x d, J 11.3, 2 x 
PhCH2), 4.99-5.06 (2H, m, PhCH2OCO), 5.26 (1H, dd, J2,3 3.8, H-3), 5.36 (1H, m, NH), 
5.44-5.50 (2H, m, H-1’ and H-3’) and 7.15-7.7.29 (15H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 8.57 (CH3CH2N), 20.66 and 20.67 (CH3CO), 25.27 
(CH2), 26.21 (CH2), 29.77 (CH2), 30.59 (d,
 3
JC,P 7.1,CH2CH2OP), 40.85 (CH2N), 45.50 
(CH3CH2N), 55.00 (CH3O), 61.77 (C-2), 61.42 (d, 
3
JC,P 6.3, C-2’), 63.36 (d, 
2
JC,P 6.4, 
CH2OP), 64.18 (d, 
2
JC,P 5.1, C-6’), 65.15 (d, 
2
JC,P 5.7, C-6), 66.31 (PhCH2OCO), 71.02 (d, 
3
JC,P 8.9, C-5), 72.29 (d, 
3
JC,P 8.0, C-5’), 73.00, 73.02, 73.04 and 73.55 (C-3, C-3’, C-4, C-
4’), 74.75 and 74.90 (PhCH2), 93.89 (d, 
2
JC,P 4.8, C-1’), 98.50 (C-1), 127.46-138.31 (Ph), 
156.51 (HNC=O) and 169.77 and 170.04 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -3.10 (P) and 0.23 (P’). 
 
High resolution ES-MS(-): found m/z1062.3274 [M-2Et3N-H]
- (C45H58N7O19P2
-requires 
m/z1062.3268). 
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Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-(3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-{3-O-acetyl-
2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-[6-
(benzyloxycarbonyl)aminohexyl phosphate]}), tris-triethylammonium salt 99 
 
 
 
A mixture of the H-phosphonate 97 (25 mg, 58 µmol, 1.2 eq.) and the trisaccharide 
diphosphate 94 (66 mg, 49 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (9 µl, 76 µmol, 1.55 eq.) was added, and the solution was 
stirred for at 20 oC for 30 min. The solution was cooled to -40 ºC prior Et3N (21 µl, 147 
µmol, 3 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (19 mg, 74 
µmol, 1.5 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, before it 
was allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform was 
then added to the mixture, and the solution was washed successively with cold 0.5 M 
Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→80:20:1)] of the residue gave the 
phosphosaccharide 99 (43 mg, 88%). 
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υmax (film)/cm
-1 (inter alia): 2103 (-N3); 
 
1H NMR (500 MHz; CDCl3): δH 1.21 (27H, t, J7.3, 9 x CH3CH2N), 1.22-1.29 (4H, m, 2 
x CH2), 1.33-1.41 (2H, m, NCH2CH2), 1.46-1.54 (2H, m, POCH2CH2), 1.93 and 1.94 
(9H, 2 x s, 3 x Ac), 2.95 (18H, q, 9 x CH3CH2N), 3.03-3.10 (2H, m, NCH2), 3.26 (3H, 
s,OCH3), 3.70-4.16 (14H, m, H-4, H-4’, H-4’’, H-5, H-5’, H-5’’, H-6
a, H-6b, H-6a’, H-
6b’, H-6a’’, H-6b’’ and CH2OP), 3.92 (1H, dd, J1,2 1.6, H-2), 3.94 (1H, dd, J1’,2’ 2.0, H-2’), 
4.20 (1H, br, H-2’’), 4.55 (1H, d, H-1), 4.57, 4.59, 4.71 and 4.74 (6H, 4 x d, J11.3, 3 x 
PhCH2), 4.99-5.06 (2H, m, PhCH2OCO), 5.23 (1H, m, NH), 5.26 (1H, dd, J2,3 3.8, H-3), 
5.39-5.50 (4H, m, H-1’, H-1’’, H-3’ and H-3’’) and 7.13-7.29 (20H, m, Ph); 
13C NMR (125 MHz; CDCl3): δC 8.55 (CH3CH2N), 20.64 and 20.70 (CH3CO), 25.29 
(CH2), 26.25 (CH2), 29.79 (CH2), 30.63 (br,CH2CH2OP), 40.92 (CH2N), 45.51 
(CH3CH2N), 55.05 (CH3O), 61.81 (C-2), 62.49 (d, 
3
JC,P 7.3, C-2’ and C-2’’), 63.65 (d, 
2
JC,P 3.6, CH2OP), 64.24 (d, 
2
JC,P 3.6), 64.36 (d, 
2
JC,P 4.8) (C-6’ and C-6’’), 65.34 (d, 
2
JC,P 
4.8, C-6), 66.40 (PhCH2OCO), 70.99 (d, 
3
JC,P 7.7, C-5), 72.08 (d, 
3
JC,P 8.5), 72.21 (d, 
3
JC,P 
7.4) (C-5’ and C-5’’), 72.84, 73.04, 73.19 and 73.61 (C-3, C-3’, C-3’’, C-4, C-4’ and C-
4’’), 74.85 and 74.95 (PhCH2), 94.00 (d, 
2
JC,P 3.8, C-1’ and C-1’’), 98.53 (C-1), 127.59-
138.45 (Ph), 156.50 (HNC=O) and 169.80 and 170.06 (CH3C=O); 
31P NMR (200 MHz; CDCl3): δP -3.03 (P and P’) and 0.51 (P”). 
 
High resolution ES-MS(-): found m/z1461.4125 [M-3Et3N-H]
- (C60H76N10O27P3
-
requires m/z1461.4100). 
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Methyl 2-acetamido-3-O-acetyl-2-deoxy-α-D-mannopyranoside 6-[2-acetamido-3-
O-acetyl-2-deoxy-α-D-mannopyranosyl phosphate 6-(6-aminohexyl phosphate)], 
bis-sodium salt 83 
 
OHO
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O-
O
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O
O
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A solution of the phosphosaccharide 98 (100mg, 79 µmol) in a mixture of THF (100 µl) 
and MeOH (2 ml) was prepared and cooled to 0 ºC, after which NiCl2.6H2O (20 mg) 
was added. Over the course of 1 h, NaBH4 (4 x 15 mg) was added while stirring at 0 ºC. 
After this time Ac2O (500 µl) was added and the solution stirred for an additional 30 
min while warming to ambient temperature. The solution was then evaporated to 
dryness, the residue was taken in CHCl3 and the solution was washed with 0.5 M TEAB 
buffer. The organic layer was then dried by filtration through cotton wool before 
removing solvent under reduced pressure. The residue was then dissolved in MeOH (5 
ml) and treated with IR-120 (Na+) resin while stirring for 5 h. The resin was then 
filtered off and the solution evaporated to dryness. The residue was then dissolved in a 
mixture of THF (0.5 ml) and MeOH (4 ml) with the addition of AcOH (15 µl). The 
solution was then hydrogenated over Pd(OH)2/C (70 mg) at ambient temperature for 3 
h. The mixture was then filtered through a Celite pad, the filtrate was concentrated and 
the residue was freeze-dried (from an aqueous solution) to give the phosphosaccharide 
83 (50 mg, 96%) as a white solid. 
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1H NMR (500 MHz; D2O): δH 1.29 (4H, m, 2 x CH2), 1.54 (4H, m, CH2CH2OP and 
CH2CH2N), 1.91, 1.94 and 1.95 (12H, 3 x s, 4 x Ac), 2.87 (2H, t, J 7.4, NCH2), 3.29 
(3H, s,OCH3), 3.70-3.82 (4H, m, H-4, H-5 and CH2OP), 3.88 (1H, t, J3,4 = J4,5 = 10.0, H-
4’), 3.93-4.01 (2H, m,H-5’, H-6a’), 4.03-4.12 (3H, m,H-6a, H-6b and H-6b’), 4.37 (1H, br 
d, H-2), 4.45 (1H, br d, H-2’), 4.59 (1H, br, H-1), 4.91 (1H, dd, J2,3 4.4, J3,4 8.6, H-3), 
5.06 (1H, dd, J2,3 4.3, J3,4 10.0, H-3) and 5.33 (1H, br d, J1,P 7.4, H-1’); 
13C NMR (125 MHz; D2O): δC 20.27 (CH3COO), 21.62 (CH3CON), 24.38 (CH2), 25.10 
(CH2), 26.53 (CH2), 29.40 (d,
 3
JC,P 7.1,CH2CH2OP), 39.33 (CH2N), 49.85 (C-2), 50.66 (d, 
3
JC,P 7.3, C-2’), 54.82 (CH3O), 63.22 and 63.63 (C-4 and C-4’), 63.72 (br, C-6), 64.44 (d, 
2
JC,P 4.1, C-6’), 66.22 (d, 
2
JC,P 5.0, CH2OP), 70.88 (d, 
3
JC,P 6.9, C-5), 71.73 and 72.31 (C-
3 and C-3’), 72.15 (d, 3JC,P 12.3, C-5’), 94.87 (d, 
2
JC,P 3.7, C-1’), 99.39 (C-1), 173.37 
(CH3COO) and 174.40 (CH3CON); 
31P NMR (200 MHz; D2O): δP -2.52 (P) and 0.80 (P’). 
 
High resolution ES-MS(-): found m/z780.2301 [M - 2Na + H]- (C27H48N3O19P2
-requires 
m/z780.2363). 
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Methyl 2-acetamido-3-O-acetyl-2-deoxy-α-D-mannopyranoside 6-{2-acetamido-3-
O-acetyl-2-deoxy-α-D-mannopyranosyl phosphate 6-[2-acetamido-3-O-acetyl-2-
deoxy-α-D-mannopyranosyl phosphate 6-(6-aminohexyl phosphate)]}, tris-sodium 
salt 84 
 
 
 
A solution of the phosphosaccharide 99 (40 mg, 22.6 µmol) in a mixture of THF (100 
µl) and MeOH (2 ml) was prepared and cooled to 0 ºC, after which NiCl2
.
6H2O (20 mg) 
was added. Over the course of 1 h, NaBH4 (4 x 15 mg) was added while stirring at 0 ºC. 
After this time Ac2O (500 µl) was added and the solution stirred for an additional 30 
min while warming to ambient temperature. The solution was then evaporated to 
dryness, the residue was taken in CHCl3 and the solution was washed with 0.5 M TEAB 
buffer. The organic layer was then dried by filtration through cotton wool before 
removing solvent under reduced pressure. The residue was then dissolved in MeOH (5 
ml) and treated with IR-120 (Na+) resin while stirring for 5 h. The resin was then 
filtered off and the solution evaporated to dryness. The residue was then dissolved in a 
mixture of THF (0.5 ml) and MeOH (3 ml) with the addition of AcOH (10 µl). The 
solution was then hydrogenated over Pd(OH)2/C (30 mg) at ambient temperature for 3 
h. The mixture was then filtered through a Celite pad, the filtrate was concentrated and 
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the residue was freeze-dried (from an aqueous solution) to give the phosphosaccharide 
84 (24 mg, 90%) as a white solid. 
1H NMR (500 MHz; D2O): δH 1.30 (4H, m, 2 x CH2), 1.55 (4H, m, CH2CH2OP and 
CH2CH2N), 1.92 (9H, m, 3 x Ac), 1.94 (3H, s, Ac), 1.96 (6H, s, 2 x Ac), 2.88 (2H, t, J 
7.4, NCH2), 3.30 (3H, s,OCH3), 3.74-3.92 (6H, m, H-4, H-4’, H-4’’, H-5 and CH2OP), 
3.92-4.16 (8H, m, H-5’, H-5’’, H-6a, H-6b, H-6a’, H-6b’, H-6a’’, H-6b’’), 4.38 (1H, dd, J1,2 
1.2, J2,3 4.3, H-2), 4.44 (1H, dd, J1,2 1.6, J2,3 4.0, H-2’’), 4.46 (1H, dd, J1,2 1.6, J2,3 4.0, H-
2’), 4.60 (1H, d, J1,2 1.2, H-1), 4.91 (1H, dd, J2,3 4.5, J3,4 9.5, H-3), 5.03-5.09 (2H, m, H-
3’ and H-3’’) and 5.28-5.35 (2H, m, H-1’ and H-1’’); 
13C NMR (125 MHz; D2O): δC 20.28 (CH3COO), 21.64 (CH3CON), 24.39 (CH2), 25.09 
(CH2), 26.53 (CH2), 29.41 (d,
 3
JC,P 6.7,CH2CH2OP), 39.35 (CH2N), 49.87 (C-2), 50.62 (d, 
3
JC,P 8.7) and 50.73 (d, 
3
JC,P 6.5) (C-2’ and C-2’’), 54.83 (CH3O), 63.24 (br, C-4, C-4’ and 
C-4’’), 63.73 (br, C-6 and C-6’), 64.43 (br, C-6’’), 66.17 (br, CH2OP), 70.92 (br), 71.55 
(br) and 72.15 (br) (C-5, C-5’ and C-5’’), 71.72 and 72.35 (2C) (C-3, C-3’ and C-3’’), 
94.82 (2C, d, 2JC,P 4.6, C-1’ and C-1’’), 99.39 (C-1), 173.36 (CH3COO) and 174.42 
(CH3CON); 
31P NMR (200 MHz; D2O): δP -2.54, -2.33 (P and P’) and 0.81 (P’’). 
 
High resolution ES-MS(-): found m/z 552.1499 [M - 3Na + H]2- (C37H63N4O28P3
2-
requires m/z552.14265), 1063.2770 [M - CH3CO - 3Na + 3H]
- (C35H62N4O27P3
-requires 
m/z1063.2820), 1085.2603 [M - CH3CO - 2Na + 2H]
- (C35H61N4NaO27P3
-requires 
m/z1085.2639), 1105.2905 [M - 3Na + 2H]- (C37H64N4O28P3
-requires m/z1105.2925), 
1127.2760 [M - 2Na + H]- (C37H63N4NaO28P3
-requires m/z1127.2745). 
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Methyl 3-O-acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranoside 6-{3-O-
acetyl-2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-[3-O-acetyl-
2-azido-4-O-benzyl-2-deoxy-α-D-mannopyranosyl phosphate 6-(3-O-acetyl-2-
azido-4-O-benzyl-2-deoxy-6-O-α-D-mannopyranosyl phosphate)]}, tris-
triethylammonium salt 96 
 
 
 
The tetrasaccharide triphosphate 95 (84 mg, 39 µmol) was dissolved in CH2Cl2 (5 ml) 
and cooled to -10 ºC with stirring. A mixture of CH2Cl2-TFA (49:1, 5 ml) was then 
prepared and cooled to -10 ºC before adding to the stirring solution. After 1 min the 
reaction was quenched with the addition of saturated aq. NaHCO3. The mixture was 
then diluted with CHCl3 (60 ml), and the solution was washed successively with 
saturated aq. NaHCO3 and 0.5 M TEAB buffer, dried by filtration through cotton wool 
and concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→80:20:1)] of the residue gave 
the phosphosaccharide 96 (66 mg, 91%). 
 
υmax (film)/cm
-1 (inter alia): 2103 (-N3); 
[α]D +15.3 (c 1, CHCl3); 
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1H NMR (500 MHz; CDCl3): δH 1.18 (27H, t, J 7.3, 9 x CH3CH2N), 1.98, 1.99 and 2.01 
(12H, 3 x s, 4 x Ac), 2.84 (18H, br, 9 x CH3CH2N), 3.33 (3H, s,OCH3), 3.68 (1H, dd, 
J5,6a’’’ 4.7, J6a’’’,6b’’’ 11.9, H-6
a’’’), 3.78-3.83 (1H, m,H-5 and H-6b’’’), 3.87 (2H, t, J3,4 = 
J4,5 = 9.6, , J3’’’,4’’’ = J4’’’,5’’’ = 9.6, H-4 and H-4’’’), 3.94-4.04 (5H, m, H-2, H-4’, H-4’’, 
H-5’, H-5’’’), 4.08 (1H, br d, J4’’,5’’ 9.1, H-5’’), 4.13-4.23 (8H, m, H-2’, H-2’’’, H-6
a, H-
6b, H-6a’, H-6b’, H-6a’’, H-6b’’), 4.29 (1H, br, H-2’’), 4.61-4.68 (6H, m, PhCH2 and H-
1) 4.76-4.84 (3H, m, PhCH2), 5.33 (1H, dd, J2,3 3.8, J3,4 9.4, H-3), 5.43 (1H, dd, J2’’’,3’’’ 
3.8, J3’’’,4’’’ 9.4, H-3’’’), 5.48 (1H, dd, J2’,3’ 3.8, J3’,4’ 9.4, H-3’),5.50-5.59 (4H, m, H-1’, 
H-1’’, H-1’’’ and H-3’’) and 7.18-7.48 (20H, m, 4 x Ph); 
13C NMR (125 MHz; CDCl3): δC 8.62 (CH3CH2N), 20.59, 20.64, 20.66 and 20.71 
(CH3CO), 45.50 (CH3CH2N), 54.98 (CH3O), 61.02 (C-6’’’), 61.75 (C-2), 62.34 (d,
 3
JC,P 
7.6), 62.41 (d, 3JC,P 8.6), 62.59 (d,
 3
JC,P 7.6) (C-2’, C-2’’ and C-2’’’), 63.51 (d,
 2
JC,P 4.1), 
64.08 (d, 2JC,P 4.1), 64.51 (d,
 2
JC,P 5.1) (C-6’, C-6’’ and C-6’’’), 70.99 (d,
 3
JC,P 9.1, C-5), 
71.99 (d, 3JC,P 9.9), 72.07
 3
JC,P 9.6,) (C-5’ and C-5’’), 72.70, 72.80, 73.00, 73.07 (2C), 
73.13, 73.26, 73.41 and 73.55 (C-3, C-3’, C-3’’, C-3’’’, C-4, C-4’, C-4’’, C-4’’’ and C-
5’’’), 74.75, 74.77 and 74.91 (PhCH2), 93.86 (d,
 2
JC,P 3.5), 93.94  (2C, d,
 2
JC,P 3.6) (C-1’, 
C-1’’ and C-1’’’), 98.43 (C-1), 127.46-138.47 (Ph) and 169.69, 169.74, 169.91 and 
170.03 (C=O); 
31P NMR (200 MHz; CDCl3): δP -3.25, -3.19 (P and P’) and -2.74 (P’’). 
 
High resolution ES-MS(-): found m/z1547.2569 [M-3Et3N-H]
- (C61H74N12O30P3
-
requires m/z1547.3852), 1569.2299 [M-3Et3N-2H+Na]
- (C61H73N12NaO30P3
-requires 
m/z1569.3672), 1585.2056 [M-3Et3N-2H+K]
- (C61H73KN12O30P3
-requires 
m/z1585.3411). 
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Attempted condensation of the H-phosphonate 89 and the phosphosaccharide 96 
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A mixture of the H-phosphonate 89 (45 mg, 56 µmol, 1.5 eq.) and the tetrasaccharide 
triphosphate 96 (66 mg, 36 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (10 µl, 84 µmol, 2.3 eq.) was added, and the solution was 
stirred for at 20 oC for 40 min. The solution was cooled to -40 ºC prior Et3N (31 µl, 224 
µmol, 6.2 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (28 mg, 
112 µmol, 3.1 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, before 
it was allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform 
was then added to the mixture, and the solution was washed successively with cold 0.5 
M Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
concentrated.  
FCC [CH2Cl2-methanol-Et3N, (95:5:1→80:20:1)] of the residue gave the product(43 
mg)which was identified (using 1H and 31P NMR data) as ~1:1 inseparable mixture of 
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the pentasaccharide tetraphosphate 100 and the starting material 96. The mixture was 
then used in a condensation attempt with the H-phosphonate 89 in a similar conditions, 
but no further progress was observed, indicating, probably quite low reactivity of the 
6”’-OH group in compound 96. The ~1:1 inseparable mixture of the pentasaccharide 
tetraphosphate 100 and the starting material 96 was then detritylated with 1% TFA in 
CH2Cl2 in the conditions identical to the preparation of compound 96. This produced a 
~1:1 mixture (39 mg) of the pentasaccharide tetraphosphate 101 and the starting 
material 96. Regrettably, this mixture appeared to be also inseparable on silica. 
 
For the mixture 96 and 100 
1H NMR (500 MHz; CDCl3): δH (selected signals) 1.94, 1.95, 1.99, 2.01, 2.03 (5 x s, in 
a ratio of ~1:1:2:3:1, Ac groups of 96 and 100), 3.32 and 3.33 (2 x s, in a ratio of 1:1, 
anomeric OMe groups of 96 and 100), 3.73 (s, C6H4OMe of 100), 5.33 (2 x dd, J2,33.8, 
J3,49.4, H-3 of 96 and H-3 of 100), 5.68 (dd, J1’’’,2’’’1.2, J1’’’,P7.1, H-1’’’of 96), 5.75 (dd, 
J1’’’’,2’’’’1.4, J1’’’’,P7.7, H-1’’’’of 100) (integration ratio of signals at 5.33, 5.68 and 5.75 
is ~2:1:1), 5.43-5.56 (m, H-1’, H-1’’, H-3’, H-3’’ and H-3”’ of 96 and H-1’, H-1’’, H-
1’”, H-3’, H-3’’, H-3’’’ and H-3’”’ of 100) and 6.70-7.53 (m, Ph groups of 96 and Ph 
and C6H4 of 100); 
31P NMR (200 MHz; CDCl3): δP -3.30, -3.19, -3.17, -3.11 (P and P’ of 96 and P, P’, P’’ 
and P’’’ of 100) and -2.86 (P’’ of 96); a ratio of 96 :100 = ~1:1. 
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For the mixture 96 and 101 
υmax (film)/cm
-1 (inter alia): 2101 (-N3); 
[α]D +11.7 (c 1, CHCl3); 
 
1H NMR (500 MHz; CDCl3): δH (selected signals) 1.982, 1.988, 1.991, 1.999, 2.001 and 
2.008 (6 x s, in a ratio of ~ 1:2:1:1:1:2, Ac groups of 96 and 101), 3.32 and 3.33 (2 x s, 
in a ratio of 1:1, anomeric OMe groups of 96 and 101), 5.33 (dd, J2,33.8, J3,49.5, H-3 of 
96 and H-3 of 101), 5.43 (dd, J2’’’,3’’’3.7, J3’’’,4’’’9.3, H-3’’’ of 96 and J2’’’’,3’’’’3.7, 
J3’’’’,4’’’’9.3, H-3’’’’ of 101), 5.47-5.59 (m, H-1’, H-1’’, H-1’’’, H-3’, H-3’’ of 96 and H-
1’, H-1’’, H-1’”, H-1’’’’, H-3’, H-3’’ and H-3’’’ of 101) and 7.19-7.34 (m, Ph groups of 
96 and 101); 
31P NMR (200 MHz; CDCl3): δP -3.39, -3.29, -3.19 (P, P’ and P’’ of 101), -3.26, -3.19 
(P and P’ of 96), -2.75 (P’’’ of 101) and -2.74 (P’’ of 96); a ratio of 96 :101 = ~1:1. 
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Attempted condensation of the H-phosphonate 97 and the phosphosaccharide 96 
 
 
 
A mixture of the H-phosphonate 97 (7.4 mg, 17.8 µmol, 1.2 eq.) and the tetrasaccharide 
triphosphate 96 (30 mg, 16.2 µmol) was dried by evaporation of pyridine (3 x 3 ml) 
therefrom. The residue was then dissolved in pyridine (1 ml) under argon, before 
trimethylacetyl chloride (2.6 µl, 21.3 µmol, 1.5 eq.) was added, and the solution was 
stirred for at 20 oC for 30 min. The solution was cooled to -40 ºC prior Et3N (10 µl, 71.3 
µmol, 3 eq.) and a mixture of pyridine-water (95:5; 1 ml) were added. Iodine (9 mg, 
35.6 µmol, 1.5 eq.) was then added, the mixture was stirred for 30 min at -40 ºC, before 
it was allowed to slowly warm to room temperature (~1 h) with stirring. Chloroform 
was then added to the mixture, and the solution was washed successively with cold 0.5 
M Na2S2O3 and cold 0.5 M TEAB buffer, dried by filtration through cotton wool and 
concentrated. FCC [CH2Cl2-methanol-Et3N, (95:5:1→80:20:1)] of the residue gave the 
starting material phosphosaccharide 96. 
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Hydrogenation and N-acetylation of the mixture 96 + 101 
 
 
 
A solution of 96 + 101 (39 mg) in MeOH (5ml) was treated with IR-120 (Na+) resin 
while stirring for 16 h. The resin was then filtered off and the solution evaporated to 
dryness. The residue was then dissolved in THF (0.5 ml) and MeOH (3 ml) with the 
addition of Ac2O (200 µl) and AcOH (20 µl). The solution was then hydrogenated over 
Pd(OH)2/C (50 mg) at ambient temperature for 16 h. The mixture was then filtered 
through a Celite pad and the filtrate concentrated under reduced pressure to give a 
mixture of the oligomers 103 and 104 (~1:1, 24 mg) as an amorphous solid. 
 
1H NMR (500 MHz; D2O): δH (selected signals) 1.99-2.06 (m, 8 x Ac groups of 103 and 
10 x Ac groups of 104), 3.31 and 3.38 (2 x s, anomeric OMe groups of 103 and 104), 
3.81-4.27 (m, H-4, H-4’, H-4’’, H-4’’’, H-5, H-5’, H-5’’, H-5’’’, H-6a, H-6b, H-6a’, H-
6b’, H-6a’’, H-6b’’, H-6a’’’ and H-6b’’’ of 103 and H-4, H-4’, H-4’’, H-4’’’, H-4’’’’, H-
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5, H-5’, H-5’’, H-5’’’, H-5’’’’, H-6a, H-6b, H-6a’, H-6b’, H-6a’’, H-6b’’, H-6a’’’, H-6b’’’, 
H-6a’’’’ and H-6b’’’’ of 104), 4.44-4.48 (m, H-2 of 103 and H-2 of 104) 4.50-4.57 (m, 
H-2’, H-2’’, H-2’’’ of 103 and H-2’, H-2’’, H-2’’’ and H-2’’’’ of 104), 4.69 (m, H-1 of 
103 and H-1 of 104), 4.98-5.03 (m, H-3 of 103 and H-3 of 104) 5.11-5.18 (m, H-3’, H-
3’’, H-3’’’ of 103 and H-3’, H-3’’, H-3’’’ and H-3’’’’ of 104), 5.37-5.44 (m, H-1’, H-
1’’ and H-1’’’ of 103 and H-1’, H-1’’, H-1’’’ and H-1’’’’ of 104); 
13C NMR (125 MHz; D2O): δC 20.38 (CH3COO), 21.75 (CH3CON), 49.96 (C-2 of 103 
and C-2 of 104), 50.71 (br, C-2’, C-2’’ and C-2’’’ of 103 andC-2’, C-2’’, C-2’’’ and C-
2’’’’ of 104), 54.93 (CH3O of 103 and CH3O of 104), 59.99 (C-6’’’ of 103 and C-6’’’’ of 
104), 63.39, 63.75, 63.85, 64.27 and 64.56 (C-4, C-4’, C-4’’, C-4’’’, C-6, C-6’ and C-6’’ 
of 103 andC-4, C-4’, C-4’’, C-4’’’, C-4’’’’, C-6, C-6’, C-6’’ and C-6’’’ of 104), 71.02 (d, 
3
JC,P 8.0, C-5 of 103 and C-5 of 104), 71.89, 71.93, 71.98, 72.15, 72.21, 72.27 and 72.43 
(C-3, C-3’, C-3’’, C-3’’’, C-5’ and C-5’’ of 103 andC-3, C-3’, C-3’’, C-3’’’, C-3’’’’, C-5’, 
C-5’’and C-5’’’ of 104), 73.36 (C-5’’’ of 103 and C-5’’’’ of 104), 94.90 (br, C-1’, C-1’’ 
and C-1’’’ of 103 andC-1’, C-1’’, C-1’’’ and C-1’’’’ of 104), 99.48 (C-1 of 103 and C-1 
of 104), 173.46 (CH3COO) and 174.50 (CH3CON); 
31P NMR (200 MHz; D2O): δP -2.42 (br, P, P’ and P’’ of 103 and P, P’, P’’ and P’’’ of 
104). 
 
High resolution ES-MS(-). Signals corresponding to the tetrasaccharide triphosphate 
103: 
foundm/z 416.4192 [M – 3Na]3- (C41H64N4O34P3
3-requires m/z416.4210), 625.1355 [M - 
3Na + H]2- (C41H65N4O34P3
2-requires m/z625.1352), 636.1260 [M - 2Na]2- 
(C41H64N4NaO34P3
2-requires m/z636.12615), 1273.2712 [M - 2Na + H]-
(C41H65N4NaO34P3
-requires m/z1273.2596), 1295.2566 [M - Na]- (C41H64N4Na2O34P3
-
requires m/z1295.2416). 
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Signals corresponding to the pentasaccharide tetraphosphate 104: 
foundm/z 393.1652 [M – 4Na]4- (C51H79N5O43P4
4-requires m/z393.3280), 524.7719 [M - 
4Na + H]3- (C51H80N5O43P4
3-requires m/z524.7731), 798.6538 [M - 3Na + H]2- 
(C51H80N5NaO43P4
2-requires m/z798.6543), 809.6487 [M - 2Na]- (C51H79N5Na2O43P4
2-
requires m/z809.6453), 1642.3367 [M - Na]- (C51H79N5Na3O43P4
-requires 
m/z1642.2798). 
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